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E-mail address: jean-pascal.lefaucheur@hmn.aphp rTMS can produce significant clinical improvement in various neurological and psychiatric disorders.
 Updated guidelines on the therapeutic use of rTMS are presented, including 2014–2018 publications.
 Higher evidence of efficacy is present in the areas of depression, pain, and postacute motor stroke.
a b s t r a c t
A group of European experts reappraised the guidelines on the therapeutic efficacy of repetitive transcra-
nial magnetic stimulation (rTMS) previously published in 2014 [Lefaucheur et al., Clin Neurophysiol
2014;125:2150–206]. These updated recommendations take into account all rTMS publications, includ-
ing data prior to 2014, as well as currently reviewed literature until the end of 2018. Level A evidence
(definite efficacy) was reached for: high-frequency (HF) rTMS of the primary motor cortex (M1) contralat-
eral to the painful side for neuropathic pain; HF-rTMS of the left dorsolateral prefrontal cortex (DLPFC)
using a figure-of-8 or a H1-coil for depression; low-frequency (LF) rTMS of contralesional M1 for hand
motor recovery in the post-acute stage of stroke. Level B evidence (probable efficacy) was reached for:
HF-rTMS of the left M1 or DLPFC for improving quality of life or pain, respectively, in fibromyalgia;
HF-rTMS of bilateral M1 regions or the left DLPFC for improving motor impairment or depression, respec-
tively, in Parkinson’s disease; HF-rTMS of ipsilesional M1 for promoting motor recovery at the post-acute
stage of stroke; intermittent theta burst stimulation targeted to the leg motor cortex for lower limb spas-
ticity in multiple sclerosis; HF-rTMS of the right DLPFC in posttraumatic stress disorder; LF-rTMS of the
right inferior frontal gyrus in chronic post-stroke non-fluent aphasia; LF-rTMS of the right DLPFC in
depression; and bihemispheric stimulation of the DLPFC combining right-sided LF-rTMS (or continuous
theta burst stimulation) and left-sided HF-rTMS (or intermittent theta burst stimulation) in depression.
Level A/B evidence is not reached concerning efficacy of rTMS in any other condition. The current recom-
mendations are based on the differences reached in therapeutic efficacy of real vs. sham rTMS protocols,
replicated in a sufficient number of independent studies. This does not mean that the benefit produced by
rTMS inevitably reaches a level of clinical relevance.
 2019 International Federation of Clinical Neurophysiology. Published by Elsevier B.V. This is an open
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In November 2014, a consensus paper was issued in Clinical
Neurophysiology (Lefaucheur et al., 2014), reporting guidelines
established by a group of European experts on the therapeutic
use of repetitive transcranial magnetic stimulation (rTMS), based
on evidence published until March 2014. In the light of the many
articles published in this domain during the last four years, it
appeared necessary to update these recommendations.
The same methodology was used as for the initial article, with
bibliographic research and critical reading by at least two experts
for each clinical indication. First, studies were classified into four
classes. A Class I study was defined as a randomized, sham-
controlled clinical trial including 25 or more patients receiving real
stimulation therapy, with clearly reported primary outcome,
exclusion/inclusion criteria, randomization/blinding procedure,
and statistical analyses, and taking into account study bias, due
to the heterogeneity of baseline characteristics among treatment
groups, possible carry-over effects (for crossover studies), or
dropouts for example. A Class II study was a randomized,
placebo-controlled trial of between 10 and 25 patients receiving
real stimulation therapy with the same high levels of methodolog-ical quality as a Class I study or a study with a larger sample but
not filling all the aforementioned criteria of high methodological
quality. Class III studies were all other controlled trials with lower
methodological quality, but only studies with at least 10 patients
receiving real stimulation therapy were taken into account in mak-
ing these recommendations. Class IV studies were uncontrolled
studies or case series.
A level of evidence of rTMS efficacy or inefficacy was deter-
mined for each indication, taking care that the results were
obtained with the same method of stimulation applied in patients
with the same clinical profile. A Level A (‘‘definitely effective or
ineffective”) required at least two Class I studies or one Class I
study and at least two Class II studies. Level B (‘‘probably effective
or ineffective”) required at least two Class II studies or the combi-
nation of one Class I or II study and at least two Class III studies.
Level C (‘‘possibly effective or ineffective”) required at least two
Class III studies or any combination of two studies of different
Classes I, II or III. The evaluation was based on the overall result
of the difference between all studies showing beneficial results
and those showing non-significant or detrimental results. No rec-
ommendation was made if there were less than two studies of dif-
ferent Classes I, II or III replicating concordant beneficial results in
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this grading, when a given research group published several stud-
ies with the same methodology for the same clinical indication,
only one study from this group was considered (the one of the best
class). Trials performed in healthy subjects or using single-session
protocols were not considered in this work to focus on the poten-
tial therapeutic impact of repeated rTMS sessions in the short or
long term.
This article presents tables summarizing the data reported for
each indication in which at least two comparable studies (with
the same methodology) of Class I to III were published by indepen-
dent groups from March 2014 to the end of December 2018. This
period of literature search is subsequent to that our previous work.
For information, table data corresponding to papers published
before March 2014 and reviewed in our previous article (Lefau-
cheur et al., 2014) are available as e-only supplementary material
to the present article (e-Table 1). The recommendations proposed
in this article refer not only to the 2014–2018 period but also take
into account all previous data analyzed in the 2014 article. Thus,
for all the sections, the current guidelines are based on the whole
literature database since the beginning of rTMS publications.
2. Pain
A PubMed search (keywords: (rTMS OR theta burst stimulation)
AND pain) identified 165 papers in the 2014–2018 period, includ-
ing 17 original sham-controlled studies with at least 10 patients
receiving real stimulation for several daily sessions.
2.1. Motor cortex stimulation in neuropathic pain
In our previous work (Lefaucheur et al., 2014), a Level A of def-
inite analgesic effect was stated for the use of HF rTMS of the pri-
mary motor cortex (M1) applied contralaterally to the pain side in
patients with neuropathic pain. During the 2014–2018 period, four
sham-controlled Class II studies with limited sample size were
published, all confirming the beneficial effect of this procedure
(Table 1).
In one study, a total of 40 patients with postherpetic neuralgia
were randomly assigned to receive 10 sessions of real (n = 20) orTable 1
HF-rTMS of M1 contralateral to pain region in neuropathic pain.
Articles Number of
patients
Target, coil type Control
condition
Khedr et al. (2015) 30 patients with
malignant
neuropathic pain
(real: 15; sham:
15)
Hand M1 contralateral to
pain, F8c (anteroposterior
orientation)
Tilted coil
Ma et al. (2015) 40 patients with
postherpetic
neuralgia (real:
20; sham: 20)
Homotopic M1
contralateral to pain
region, F8c
(anteroposterior
orientation)
Tilted coil
Attal et al., 2016 32 patients with
neuropathic
lumbar radicular
pain (real: 21;
sham: 11)
Hand M1 contralateral to
pain, F8c (anteroposterior
orientation)
Sham coil
Nurmikko et al.
(2016)
27 patients with
neuropathic pain
of various origins
(crossover)
Homotopic M1
contralateral to pain
region or an adjacent
motor region, F8c
(perpendicular to central
sulcus)
Occipital
stimulationsham (n = 20) rTMS of M1 over two weeks (Ma et al., 2015). The
pattern of stimulation was relatively unusual, consisting of 300
trains of 5 seconds with an intertrain interval of 3 seconds for a
total of 1500 pulses delivered at 80% of the resting motor threshold
(RMT) in a session of 40 minutes. The real rTMS group had greater
pain reduction than the sham group with an average pain reduc-
tion of 45–50% persisting at 3 months after the last rTMS session.
Half of the patients who received real rTMS were considered
responders (>50% pain intensity score reduction). Analgesic effects
were associated with an improvement in quality of life scores.
Another sham-controlled parallel-arm study assessed the effi-
cacy of 10 daily sessions of 20 Hz-rTMS of M1 performed over
two weeks in 30 patients (15 real, 15 sham) suffering from neuro-
pathic pain in the context of malignancy (Khedr et al., 2015). The
pattern of stimulation was more usual, consisting of 10 trains of
10 seconds with an intertrain interval of 30 seconds for a total of
2000 pulses delivered in a session of 6–7 minutes. The figure-of-
8 coil was placed over the M1 representation of the hand on the
hemisphere contralateral to the painful side, with coil orientation
parallel to the interhemispheric midsagittal line, as recommended
(André-Obadia et al., 2008; Lefaucheur, 2016). The group of
patients treated with real rTMS had greater improvement in pain
intensity scores than the sham group, with an average pain reduc-
tion of 35–40% two weeks after the last session, but the beneficial
effect disapppeared by one month. More than 80% of the patients
were considered responders (>30% pain intensity score reduction).
A short-lasting difference between real and sham stimulation was
also observed in terms of depression and neuropathic symptom
score improvement. The short duration of the rTMS sessions in this
study (6–7 minutes) could explain the rather modest analgesic
effects, regardless of the number of pulses per session, as suggested
in another study (Hodaj et al., 2015).
In a third study, the targeting was based on cortical maps pro-
vided by motor evoked potential (MEP) recording to TMS per-
formed with a navigation system integrating magnetic resonance
imaging (MRI) of the brain (Nurmikko et al., 2016). The trial
enrolled 27 patients with unilateral neuropathic pain of various
causes and locations who completed the study with the compar-
isons of three target sites: (i) the motor hotspot (i.e. the cortical
site of the ‘‘affected hemisphere” where MEPs of maximal ampli-Stimulation
frequency
and
intensity
Number of
pulses/
session and
number of
sessions
Significant clinical effects of real versus
sham condition
Class
of
the
study
20 Hz, 80%
RMT
2000 pulses,
10 sessions
Reduction of pain score at the end of
rTMS protocol (49% on VRS and 37% on
VAS), up to 2 weeks after the last session
(46% on VRS and 36% on VAS); 87–80%
responders (>30% pain relief)
II
10 Hz, 80%
RMT
1500 pulses,
10 sessions
Reduction of pain score (17% on VAS), up
to 3 months after the last session; 50%
responders (>50% pain relief)
II
10 Hz, 80%
RMT
3000 pulses,
3 sessions
Reduction of pain score at the end of
rTMS protocol (#60% on VAS), up to
5 days after the last session (#25% on
VAS); 43% responders (>30% pain relief)
II
10 Hz, 90%
RMT
2000 pulses,
5 sessions
Reduction of pain score compared to
control condition one week after the last
session (9–11% on VAS); 30% responders
(>30% pain relief)
II
478 J.-P. Lefaucheur et al. / Clinical Neurophysiology 131 (2020) 474–528tude were obtained in the pain region); (ii) a cortical site where
MEPs were found in TMS maps of the ‘‘affected” hemisphere but
not at an equivalent location in the contralateral ‘‘unaffected”
hemisphere; (iii) the occipital fissure serving as ‘‘active” control
condition. The pattern of 10 Hz-rTMS consisted of 20 trains of 10
seconds with an intertrain interval of 50 seconds for a total of
2000 pulses delivered in a session of 20 minutes. Five daily ses-
sions were performed in a crossover design. Real rTMS produced
greater pain reduction, regardless of the type of motor cortical tar-
get compared to the control procedure, which was a real stimula-
tion delivered over the occipital fissure. The analgesic effect was
very small (less than 15% on average) but maintained at least
two weeks, and 30% of the patients were considered responders
(>30% pain intensity score reduction).
Finally, a fourth sham-controlled Class II study with parallel
arm design compared the efficacy of 3 daily sessions of 10 Hz rTMS
of M1 to anodal transcranial direct-current stimulation (tDCS) of
the same site in a series of 32 patients with lower limb neuropathic
pain due to lumbosacral radiculopathy (21 real, 11 sham) (Attal
et al., 2016). In this study, the motor cortical area corresponding
to the hand on the painful site was stimulated, although patients
had lower limb pain. The pattern of stimulation consisted of 30
trains of 10 seconds with an intertrain interval of 20 seconds for
a total of 3000 pulses delivered in a session of 15 minutes. Real
rTMS was superior to real tDCS and sham condition by decreasing
the intensity of pain by 60% at the end of the stimulation protocol,
with a significant pain relief lasting up to 5 days. Unfortunately,
the protocol of stimulation was quite short (3-session protocol)
and longer lasting effects were not assessed. Also, the mean per-
centage of pain relief was smaller than in previous studies, but
all patients had lower limb neuropathic pain, which is a condition
that may be less favorable than face or upper limb neuropathic
pain for the efficacy of motor cortex rTMS (Lefaucheur et al.,
2004). Nevertheless, this study showed that the rate of responders
was greater after real rTMS (>30% pain intensity score reduction in
43% of patients and > 50% pain intensity score reduction in 30% of
patients) than after real tDCS or sham procedure.
In summary, in the light of these recent studies, our recommen-
dation on the level of evidence regarding the analgesic efficacy of
HF-rTMS of M1 contralateral to neuropathic pain side did not
change (Level A). Some lessons could possibly be drawn from these
four studies, suggesting that the analgesic effect is favored by
longer session duration and serial treatment (i.e. greater number
of sessions).
However, it is still unclear whether targeting the somatotopic
area of the motor cortex corresponding to the painful region or
only the hand area in all cases is of critical importance to produce
analgesic effects. While there is a consensus to stimulate the motor
cortex contralateral to the side of pain (or the left cortex in case of
bilateral or diffuse pain), the exact location of the optimal target to
be stimulated within M1 is not yet defined. Overall, two strategies
are possible: either to stimulate the motor cortical representation
of the painful region or to stimulate the hand motor area whatever
pain location. Then, in each case, two additional possibilities are
offered: either to target the motor hotspot (defined as the cortical
site where MEPs of maximal amplitude are obtained in a muscle of
a given body region) or to target the motor cortical representation
of the same body region using a navigation system integrating
individual morphological or functional MRI data.
Two studies partially addressed these questions by evaluating
the analgesic effects of a single rTMS session performed under neu-
ronavigation guidance. The first study (André-Obadia et al., 2018a)
compared the value of HF-rTMS delivered to the hand or face
motor hotspot in 32 patients suffering of upper limb (n = 20) or
facial (n = 12) pain. This study showed that real rTMS was more
efficacious on pain when delivered over the hand motor area thanthe face area whether pain was located at the hand or the face.
Thus, the hand motor hotspot, which is easy to determine, could
be the target of choice for neuropathic pain treatment, regardless
of the location of pain. In this case, the use of a navigation system
could simply consist of registering the target location to facilitate
the repositioning of the coil at the same place with the same orien-
tation according to the different sessions of an rTMS therapy pro-
cedure (Lefaucheur, 2010). However, a second study (Ayache
et al., 2016) showed that anatomical targeting using MRI-guided
navigation may provide a better target than the motor hotspot.
This study included 66 patients with neuropathic pain of various
causes and locations and compared the value of a navigated proce-
dure targeting the anatomical representation of the painful zone to
a non-navigated procedure targeting the hand motor hotspot.
Indeed, for a given muscle territory (e.g., hand muscles), the
anatomical cortical representation (e.g., ‘‘hand knob”) may differ
from the functional localization (e.g., ‘‘hand motor hotspot”)
(Ahdab et al., 2016). Navigation improved HF-rTMS efficacy com-
pared to hand motor hotspot targeting, at least in patients with
focal upper or lower limb pain.
Although the level of evidence is high in favor of the analgesic
efficacy of HF-rTMS of M1, this does not necessarily mean that the
procedure is clinically relevant and deserves to be applied in routine
practice. Mainly, one of the major limitations of published sham-
controlled studies is the fact that they are based on small number
of sessions (5–10) and short duration of follow-up (less than
3 weeks). To address this issue, it is interesting to look at the results
provided by open-label naturalistic studies that usually report
results obtained over a prolonged period of time in real life setting.
For example, in an open-label study of 18 patients with central
poststroke pain (Kobayashi et al., 2015), a session of HF-rTMS
delivered over the motor cortex of the affected hemisphere was
repeated once a week for 12 weeks (3 months). The rTMS sessions
produced an average pain relief of 61%. Regarding individual
results, pain relief was higher than 40% in 11 of the 18 patients
(61%). A sustainable pain relief was observed in 6 patients who
continued the intervention for one year. Notably, the clinical ben-
efit was better in patients without severe dysesthesia.
Another group published two papers on their experience of
using HF-rTMS delivered to M1 (motor hand spot) over the long
term to treat patients with central neuropathic pain of various ori-
gins and locations (Pommier et al., 2016; Quesada et al., 2018). In
each rTMS session (26-min duration with 1600 stimulations), a
figure-of-8 coil was positioned over the defined cortical target by
a robotized arm under navigation guidance. The first phase of the
protocol consisted of a series of four sessions performed within
two months. Then, in ‘responders’ (defined as a percentage of pain
relief > 10%), the sessions were continued and repeated with inter-
vals adapted to the duration of the analgesic effect for each individ-
ual. In their first paper (Pommier et al., 2016), these authors report
a cumulative effect of repeated sessions in 31 ‘responders’ (among
the 40 patients initially enrolled), leading to a mean pain relief of
41% for a duration of more than two weeks. In their second paper
(Quesada et al., 2018), results are presented for 71 patients and
confirmed the cumulative effect of rTMS sessions in the long term.
After the first four sessions, the percentage of pain relief was 28%
and the duration of pain relief was 11 days. After 12 months of
treatment (15 sessions on average), the percentage of pain relief
increased to 48% and the duration of pain relief to 20 days. No
adverse events occurred, including no seizure. There was also a
decrease in medication consumption, although not significant.
A kind of cumulative impact of the repetition of rTMS sessions
on pain relief was also observed in a naturalistic study based on
a 6-month navigated rTMS protocol (including follow-up), per-
formed in patients with various types of facial pain or headache
disorders, including cluster headache (Hodaj et al., 2015). Facial
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10 Hz-rTMS of M1, as also shown by Lawson McLean et al.
(2018). In this open-label study, 48 patients with various chronic
neuropathic pain conditions (31 patients with facial pain) received
9 HF-rTMS sessions. The overall rate of responders was 58%, but
significantly better in patients with facial pain (71%) than limb
pain (less than 44%). A shorter pain history (less than five years)
was the other predictor of good outcome. At 6-week follow-up
after 9 rTMS sessions, 42% of patients still reported a significant
level of pain relief.
The analgesic effects of rTMS in patients with chronic neuro-
pathic pain were obtained using HF-rTMS, whatever the frequency
(5, 10, or 20 Hz) (Jin et al., 2015), but not using LF-rTMS
(Lefaucheur et al., 2001; André-Obadia et al., 2006; Saitoh et al.,
2007). Regarding patterned rTMS paradigms, such as theta burst
stimulation (intermittent (iTBS) or continuous (cTBS) protocols),
published data only concerned experimental or acute provoked
pain (Antal and Paulus, 2010; Torta et al., 2013; Moisset et al.,
2015; Annak et al., 2019) or TBS used as a priming protocol for
HF-rTMS (Lefaucheur et al., 2012a; Gaertner et al., 2018), except
one study showing a mild relief of orofacial pain after iTBS of M1
(Kohútová et al., 2017).
Finally, a few words should be added regarding the mechanisms
of analgesic action of rTMS delivered to M1. Some recent results
highlighted a significant release of endogenous opioids within a
bihemispheric brain network involved in the perception and mod-
ulation of pain, which was produced by a single session of 10 Hz-
rTMS of M1 in a positron emission tomography (PET) study based
on 10 healthy subjects (Lamusuo et al., 2017). This was consistent
with previous observations made in chronic pain patients treated
by invasive epidural motor cortex stimulation (Maarrawi et al.,
2007, 2013). However, the mechanisms of action of M1 stimulation
in pain are surely more complex and multiple, involving various
pain modulatory systems concerned in emotion, attention, and/or
sensory discrimination processing, related to various neural path-
ways connecting different brain regions, thalamic nuclei, and/or
the spine, and also with various neurotransmitter systems beyond
endogenous opioids, such as glutamate, GABA, and/or dopamine
for example (Lefaucheur, 2016, Moisset and Lefaucheur, 2019;
Moisset et al., 2016; Nguyen et al., 2011). All of these factors can
contribute to the development of long-term synaptic plasticity that
provides significant pain relief beyond the time of stimulation.
2.2. Other cortical targets in neuropathic pain
A few studies addressed motor cortex rTMS therapy of neuro-
pathic pain with a significantly different targeting approach from
the usual procedure, in which a figure-of-8 coil is focally posi-
tioned over an anatomically- or functionally-defined motor cortical
target. These studies investigated the analgesic effect of repeated
daily sessions of HF-rTMS using either various types of figure-of-
8 coils applied over the vertex in patients with lower limb pain
due to spinal cord injury (Yılmaz et al., 2014; Hodaj et al., 2018)
or a H-coil (Onesti et al., 2013; Shimizu et al., 2017). In these
two latter studies, a H10 coil provided a large, bilateral stimulation
of the motor cortex strip, diffusing deep in the medial longitudinal
fissure. The study of Onesti et al. (2013) included 23 patients, all
suffering from lower limb pain due to diabetic polyneuropathy.
This was a crossover study based on a 5-day 20 Hz-rTMS protocol
(1500 pulses per session). Real rTMS produced greater pain reduc-
tion than sham stimulation, lasting for three weeks. However,
these results were not reproduced to date. A second study
(Shimizu et al., 2017) enrolled 18 patients with neuropathic pain
affecting the lower limb, but of various peripheral or central ori-
gins. This study had a cross-over design, with a short wash-out
period of 17 days between series of 5 Hz-rTMS sessions deliveredfor 5 days (500 pulses per session) using an active or sham
H-coil, or an active figure-of-8 coil, which had no proper sham-
controlled condition. A reduction in pain intensity was observed
immediately and 1 hour after rTMS using active H-coil but not
figure-of-8 coil, compared to sham H-coil condition. This result
had no clinical relevance, since no significant analgesic effect was
observed in the 16-day period follow-up period after rTMS ses-
sions, whatever the condition.
In the small sham-controlled study of Yilmaz et al. (2014) per-
formed in 16 patients with chronic pain secondary to spinal cord
injury (SCI), 10 sessions rTMS delivered over the vertex at
suprathreshold intensity did not show superior analgesic efficacy
when applied in real condition (9 patients) versus sham condition
(7 patients). This result was consistent with two previous negative
rTMS studies on SCI pain (Defrin et al., 2007; Kang et al., 2009a),
but also based on very small series of patients: 6 patients who
received real stimulation (plus 5 patients in a sham rTMS group)
in Defrin et al. (2007) and 11 patients in the sham-controlled cross-
over study of Kang et al. (2009a). In addition, there were significant
differences in the stimulation protocol between these studies, such
as targeting the vertex at 110–115% of RMT (Defrin et al., 2007,
Yilmaz et al., 2014) or unilateral hand M1 representation at 80%
of RMT (Kang et al., 2009a). Thus, these studies may suggest that
rTMS is not effective in SCI pain in contrast to other neuropathic
pain conditions, but this conclusion deserves confirmation in larger
replication studies.
One group also applied navigated HF-rTMS over the parieto-
opercular cortex overlying the right secondary somatosensory area
(S2) in patients with chronic neuropathic pain located in the orofa-
cial region (Lindholm et al., 2015, 2016). The stimulation of this
target produced significantly better analgesia than the stimulation
of the primary sensorimotor cortex or sham rTMS. However, these
studies were based on the short term effects of single rTMS ses-
sions (up to 1 month after a single rTMS session given 1 month
apart for the three stimulation conditions). The value of the right
S2 target in patients with pain is consistent with a previous study
in healthy subjects that showed some changes in the thresholds for
the detection of thermal pain produced by such a protocol
(Valmunen et al., 2009). Nevertheless, the long-term results pro-
vided by repeated HF-rTMS sessions over S2 are awaited.
Because of the implication of the insula, especially its posterior
part, in the experience of pain (Mazzola et al., 2009; Isnard et al.,
2011), insular cortex stimulation with a double-cone coil was pro-
posed as a method for producing pain modulation (Ciampi de
Andrade et al., 2012). In two experimental studies, a double-cone
coil was used to deliver a cTBS train over the insular cortex
(Lenoir et al., 2018) or a brief TMS train over the anterior part of
the middle cingulate cortex (D’Agata et al., 2015), both protocols
resulting in a reduction of the perception of acute cutaneous pain
elicited by laser or electrical stimulation. However, insular cortex
stimulation with a double-cone coil recently failed to be effective
in chronic central neuropathic pain, as well as cingulate cortex
stimulation using a H6-coil (Galhardoni et al., 2019).
One study assessed the value of 10 daily sessions of HF-rTMS
delivered to the premotor cortex/dorsolateral prefrontal cortex
(PMC/DLPFC) in patients with central poststroke pain (de Oliveira
et al., 2014). This study was negative and was terminated after
the evaluation of 21 patients because of a significant lack of effi-
cacy in the real rTMS arm. In another study, HF-rTMS of the left
PMC/DLPFC was applied in 12 patients with chronic neuropathic
pain related to cervical or thoracic spinal cord injury (10 sessions
of 1250 pulses/session over 2 weeks) (Nardone et al., 2017). Daily
pain scores significantly decreased during rTMS sessions in the 6
patients who received real rTMS, but not in the 6 patients who
received sham rTMS. However, pain relief did not last beyond the
period of stimulation. Finally, it should be noted that no studies
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DLPFC targeting method, which requires the application of a rele-
vant neuronavigation approach (Mylius et al., 2013; Pommier
et al., 2017).
From all these results, no convincing alternative to focal stimu-
lation using a figure-of-8 coil over M1 contralateral to pain side is
currently relevant in rTMS therapy of neuropathic pain.
2.3. Fibromyalgia and other dysfunctional chronic pain syndromes
In our previous work, no recommendation was made for the use
of rTMS to treat fibromyalgia, because two different targets had
been evaluated (left M1 and left DLPFC) and most studies came
from the same group of researchers for a given target, without
results reproduced by independent teams in this indication.
Regarding the left M1 target, one additional study was pub-
lished during the 2014–2018 period. This Class II study with a
parallel-arm design (Boyer et al., 2014) enrolled 38 patients with
fibromyalgia (19 real, 19 sham) who received HF-rTMS delivered
to the left M1 in 14 sessions over 10 weeks. At week 11, the
improvement in quality of life, especially in the mental, emotional,
and social dimensions, was greater in the real arm than in the
sham arm. Conversely, no significant difference was observed
between real and sham rTMS concerning changes in pain intensity
scores. The fact that rTMS of M1 may be beneficial for pain patients
on their daily functioning and quality of life without any pain relief
was also reported in neuropathic pain (Hodaj et al., 2018). Various
Class II studies of another group (Passard et al., 2007; Mhalla et al.,
2011) previously reported a significant improvement of quality of
life in patients with fibromyalgia treated by HF-rTMS of M1, com-
paring real versus sham conditions. Thus, considering these con-
cordant Class II studies, a recommendation can be made for a
probable efficacy of HF-rTMS of the left M1 (Level B) in improving
quality of life of patients with fibromyalgia (without any conclu-
sion for the proper analgesic effect).
The beneficial impact of HF-rTMS of M1 was also reported by
one group in a chronic myofascial pain syndrome close to
fibromyalgia. In a first study, these authors randomized 24 women
with this clinical condition to receive 10 sessions of 10 Hz-rTMS of
the left M1 (12 real and 12 sham) (Dall’Agnol et al., 2014). Pain
decreased more after real stimulation than sham, with daily pain
score reduction by 30% and analgesic use reduction by 45%. In
addition, the analgesic effect was associated with an increase in
corticospinal excitability, descending inhibitory controls (condi-
tioned pain modulation assessment), and brain-derived neu-
rotrophic factor levels. In a second study performed in 46
patients (23 real and 23 sham), the same group confirmed the ben-
eficial effect of 10 Hz-rTMS of the left M1 and did not find any
additional effect of performing transcutaneous repetitive magnetic
stimulation of muscles (Medeiros et al., 2016).
Regarding the value of HF-rTMS delivered to the left DLPFC in
fibromyalgia, a recent Class II study showed evidence of an impact
on fatigue (Fitzgibbon et al., 2018). This parallel-arm study
enrolled 26 patients with fibromyalgia (14 real, 12 sham) and a
greater improvement in physical and general fatigue scores was
observed after a total of 20 rTMS sessions over four weeks at one
month follow-up in the real versus sham condition. Regarding
the analgesic effects, the difference between real and sham rTMS
was observed in terms of responders (>30% pain relief). A previous
Class II study also showed an analgesic efficacy of HF-rTMS of the
left DLPFC (29% difference in pain relief between real and sham
conditions on average), but did not report the resulting changes
in fatigue or sleep quality (Short et al., 2011). Thus, considering
two concordant Class II studies, a Level B recommendation can
be made for a probable analgesic efficacy of HF-rTMS of the left
DLPFC in patients with fibromyalgia. In addition, in both studies,rTMS was well tolerated, with few minor side effects (e.g., discom-
fort, neck pain, or dizziness during stimulation), not significantly
different between real and sham conditions.
Thus, from our literature data analysis, it appears that in
fibromyalgia, HF-rTMS of the left DLPFC is more efficacious on pain,
while HF-rTMS of the left M1 is more efficacious on the quality of
life. An opposite conclusion was expected, as illustrated by the
meta-analysis of Hou et al. (2016), in which the pooled mean effect
size of rTMS studies in fibromyalgia revealed significant favourable
effects with subtle evidence for a better analgesic efficacy of M1
stimulation and a better antidepressant efficacy of DLPFC
stimulation.
Finally, three studies should be mentioned, addressing the
treatment of various pain syndromes that may share with
fibromyalgia at least some common mechanisms of central sensiti-
zation. First, in 20 patients (12 real, 8 sham) with burning mouth
syndrome, 10 Hz-rTMS of the left DLPFC was found to induce anal-
gesic effects (Umezaki et al., 2016). At 2 months after the begin-
ning of treatment, the pain intensity decreased by 67%, and 75%
of the patients reported > 50% pain decrease, without any change
in mood or the affective aspect of pain. Second, 21 patients with
irritable bowel syndrome were enrolled in a crossover study and
received 5 daily sessions of rTMS of the left M1 (Melchior et al.,
2014). Real and sham stimulations did not differ in the resulting
changes in ongoing pain, pain threshold to rectal distension by a
barostat balloon, and rectal compliance. However, pain tolerance
assessed by the maximum tolerated volume of rectal distension
was improved by real, but not by sham rTMS and this effect was
greater in the subgroup of patients with the most marked rectal
hypersensitivity. Finally, one class II crossover study addressed
the value of 10 daily sessions of real or sham stimulation over
the whole motor cortex using an H10-coil in 13 patients (7 real
and 6 sham) with bladder pain syndrome (Cervigni et al., 2018).
Compared to sham, real stimulation improved pain and urinary
symptoms and quality of life of the patients. The efficacy of LF-
rTMS delivered over the DLPFC of both hemispheres using a
figure-of-8 coil was also found to relieve most symptoms of blad-
der pain syndrome in one illustrative clinical case (Nizard et al.,
2018). However, all these results cannot lead to any recommenda-
tion to date.
2.4. Other pain conditions
In the complex regional pain syndrome (CRPS) of type I, a Level
C recommendation in favor of a possible analgesic effect of HF-
rTMS of M1 was stated in our previous guidelines (Lefaucheur
et al., 2014). An additional study was recently published on a par-
ticular type of CRPS, i.e. shoulder pain occurring in post-stroke
hemiplegic patients (Choi and Chang, 2018). In this study, the
motor cortex of the stroke-affected hemisphere was stimulated
over 10 sessions in 24 patients at chronic stroke stage. A significant
pain relief (of 25–30%) was observed in the real but not the sham
group up to 4 weeks beyond the time of stimulation. In contrast,
rTMS did not change motor function and motricity index in the
affected upper limb. These new results did not change our previous
recommendation, which remains at Level C.
Phantom limb pain is a particular neuropathic pain condition.
One rTMS study was reported in this domain targeting M1 con-
tralateral to the amputated limb (Malavera et al., 2016). In this
large sham-controlled study of 54 patients (27 real and 27 sham),
HF-rTMS was delivered 20 minutes per session, during 10 days.
Real rTMS induced a greater reduction in pain intensity than sham
stimulation, up to two weeks after the last session with a mean
between-group difference of 30%. This effect was lost at one month
follow-up. The percentage of responders (>30% pain intensity
reduction) was 70% in the real group and 41% in the sham group.
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delivered at 20 Hz over the right M1 (2,000 pulses per session) in
53 patients with low back pain (41 real and 12 sham), plus 26
patients who received physical therapy as a control group
(Ambriz-Tututi et al., 2016). The analgesic effect was found signif-
icantly better in the real rTMS group than both sham stimulation
and physical therapy groups. The beneficial effect of real rTMS
lasted up to 9 months using maintenance sessions, first every
two weeks, then every two months.
The main two rTMS targets in the pain domain, i.e. M1 and
DLPFC, were also investigated in migraine and headache disorders.
Since a first open-label study performed in 51 migraineurs
(Misra et al., 2012), one group repeatedly report sham-controlled
data in favor of the beneficial effect in migraine of series of 3 HF-
rTMS sessions delivered to the left M1 with a protocol similar to
that is classically used in neuropathic pain (Misra et al., 2013;
Kalita et al., 2016). In addition, the clinical improvement was asso-
ciated with an increase in beta-endorphin plasma level (Misra
et al., 2017). However, to our knowledge, no other group has
reported the efficacy of repeated rTMS sessions delivered to the left
M1 in migraine. Regarding the DLPFC target, no new data have
been published since the two conflicting studies already discussed
in our previous work (Brighina et al., 2004; Conforto et al., 2014).
One group assessed the value of 4 sessions of 10 Hz-rTMS deliv-
ered to the left M1 (Leung et al., 2016) or the left DLPFC (Leung
et al., 2018) in chronic headache secondary to mild traumatic brain
injury. In a first series of 24 patients, these authors showed a
greater reduction in persistent headache intensity one week after
real vs. sham M1 stimulation with a higher rate of responders
(>50% pain intensity reduction) and a trend towards a lasting effi-
cacy for four weeks (Leung et al., 2016). In a second series of 29
patients (Leung et al., 2018), a greater reduction in persistent head-
ache intensity was found one and four weeks after real vs. sham
DLPFC stimulation (23–25% versus 1–2% of pain relief) together
with a higher rate of responders (>50% pain decrease) and a tran-
sient benefit on depression scores.
In another series of 12 patients (Choi et al., 2018), the intensity
of chronic diffuse pain secondary to mild traumatic brain injury
was significantly reduced during and up to 4 weeks after 10 ses-
sions of 10 Hz-rTMS applied to M1 of the affected hemisphere
(1000 pulses/session) in the 6 patients who received real rTMS
compared to the 6 patients who received sham rTMS.
Obviously, data are too sparse in chronic pain syndromes other
than neuropathic pain or fibromyalgia to make any recommenda-
tion on the value of HF-rTMS delivered to the left M1 or the left
DLPFC.
Finally, in postoperative acute pain, only one sham-controlled
study has been published in the 2014–2018 period. In this large-
sample study (Borckardt et al., 2014), 108 patients who underwent
gastric bypass surgery were randomly assigned to receive 2 ses-Table 2
HF-rTMS of bilateral M1 regions in Parkinson’s disease (motor symptoms).
Articles Number
of
patients
Target, coil type Control
condition
S
fr
a
in
Kim et al. (2015) 17
(crossover)
Bilateral M1, lateralized to
the dominant hemisphere
(leg representation), DCc
Tilted coil 1
R
Brys et al. (2016) 29 (real:
14; sham:
15)
Bilateral M1 (hand
representation), F8c
Realistic
sham coil
1
Makkos et al. (2016) 44 (real:
23; sham:
21)
Bilateral M1 (hand
representation), F8c
Tilted coil 5
Rsions of real or sham 5 Hz-rTMS delivered over the left DLPFC,
one session immediately following surgery and the other 4 h later.
Both affective and sensory dimensions of pain were reduced in the
patients who received 2 real rTMS sessions, but patient-controlled
opioid intake was not significantly modified.3. Movement disorders
3.1. Parkinson’s disease: Motor symptoms
A PubMed search (keywords: (rTMS OR theta burst stimulation)
AND Parkinson’s disease) identified 93 papers, including only 5
original sham-controlled studies with at least 10 patients receiving
real stimulation for several daily sessions.
As stated in our previous work (Lefaucheur et al., 2014) and in
recent meta-analyses (Chou et al., 2015; Zanjani et al., 2015; Yang
et al., 2018), published data suggest an efficacy of HF-rTMS on
parkinsonian motor symptoms, especially if delivered bilaterally
over motor cortical regions. Additional data were provided by
three recent sham-controlled studies (Table 2). First, in a random-
ized crossover Class II study (Kim et al., 2015), 17 parkinsonian
patients were included and the leg area of M1 was targeted with
a double-cone coil (lateralized to the dominant hemisphere). Com-
pared to a figure-of-8 coil, a double-cone coil induces a much less
focal and more deeply penetrating electric field (Deng et al., 2014).
After 5 daily sessions of 10 Hz-rTMS, the number of steps required
to complete the standing start 180 turn test and the freezing of
gait questionnaire (primary outcome measure) significantly
improved in the real as compared to the sham condition, with a
benefit lasting for at least one week after the last rTMS session.
In addition, the global motor performance assessed by the unified
Parkinson’s disease rating scale (UPDRS) part III score (secondary
outcome measure) improved by 26%. The same group later pub-
lished a pilot study including 8 patients with various atypical
parkinsonism (vascular parkinsonism, progressive supranuclear
palsy, or multiple system atrophy) and using exactly the same
study design (Chang et al., 2016). In this study, HF-rTMS was deliv-
ered over the leg representation of M1 for 5 consecutive days and
also improved freezing-of-gait.
Thus, using a large double-cone coil, but not a focal figure-of-8
coil (Rektorova et al., 2007), repeated sessions of HF-rTMS applied
to M1 leg area may help to improve freezing-of-gait of various
origins. Further research is needed to reach a sufficient level of
evidence to make specific recommendation.
Finally, Chang et al. (2017) assessed the additional value of
combining anodal tDCS over the left DLPFC (right supraorbital
cathode) with HF-rTMS of M1 (16 patients receiving dual active
rTMS and tDCS versus 16 patients receiving real rTMS and
sham tDCS). The dual stimulation yielded a significantly bettertimulation
equency
nd
tensity
Number of
pulses/session
and number of
sessions
Significant clinical effects of real
versus sham condition
Class
of the
study
0 Hz, 90%
MT
1000 pulses, 5
sessions
Improvement of UPDRS-III motor
score (26%) and freezing of gait,
one week after rTMS protocol
II
0 Hz, NR 2000 pulses, 10
sessions
Improvement of UPDRS-III motor
score (15%), one month after rTMS
protocol
II
Hz, 90%
MT
2  300 pulses, 10
sessions
Improvement of UPDRS-III motor
score (23%), one month after rTMS
protocol
II
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freezing, motor and ambulatory functions compared to rTMS of M1
alone.
Two other studies showed that rTMS of bilateral M1 regions,
targeted over the motor hotspots of hand representation, was
an effective treatment of parkinsonian motor symptoms (Brys
et al., 2016; Makkos et al., 2016). In the sham-controlled,
parallel-group study of Makkos et al. (2016), the primary end-
point was the change in mood, while motor performance was a
secondary endpoint. The patients improved on both aspects after
10 sessions of real rTMS over two weeks (23 patients in the real
rTMS arm). The study of Brys et al. (2016) enrolled a large sam-
ple of 50 patients with Parkinson’s disease also with comorbid
major depression (according to DSM-IV criteria), but only 14
patients were analyzed in the real M1 rTMS group (Class II
study). In this multicenter, double-blind, sham-controlled,
parallel-group study, a ‘‘realistic” sham procedure was applied
(Rossi et al., 2007), combining the use of a sham coil and electric
stimulation of the scalp at the level of the coil with electrodes
connected to a constant current stimulator. For each M1 target
(defined as the hand motor hotspot), the rTMS protocol consisted
of 50 trains of 4 seconds with an intertrain interval of 11 seconds
for a total of 1000 pulses delivered in a session of 12.5 minutes.
Parkinsonian patients in the ‘‘on-drug” state received 10 daily
sessions over two weeks, the left and right M1 being sequentially
stimulated during each session. At one month after the last rTMS
session, the motor symptoms, especially bradykinesia and rigid-
ity, as assessed by the UPDRS-III score, significantly improved
after real versus sham stimulation (reduction by 15% (4.9 points)
compared to baseline). This effect was considered as a minimal
clinical change and was not observed when the left DLPFC was
stimulated in addition to the both M1 regions. Before 2014, pre-
vious Class II studies of HF-rTMS delivered to bilateral M1
regions (upper and/or lower limb representation) had shown a
significant improvement on UPDRS-III score of 19% (González-
García et al., 2011; Maruo et al., 2013) or ranging between 15
and 49% depending on stimulation frequency (5–20 Hz) (Khedr
et al., 2003,2006). Conversely, other studies performed in PD
patients did not show any beneficial motor effect of a series of
8 sessions over two weeks using iTBS of M1 and DLPFC regions
(Benninger et al., 2011) or 50-Hz rTMS of both motor cortices
(Benninger et al., 2012). Overall, the balance is now leaning
towards a probable efficacy of HF-rTMS delivered to a large
motor cortical region in patients with Parkinson’s disease and
the level of evidence increased to Level B. However, as reviewed
by Benninger and Hallett (2015), these effects are rather modest
and probably not relevant for routine clinical application.
One study reassessed the value of LF-rTMS of M1 (Flamez et al.,
2016). In this study, 1 Hz-rTMS was sequentially applied over the
left and right M1 in the same session during a levodopa challenge
test in 9 late-stage PD patients, but failed to change motor or exec-
utive functions. In a sham-controlled crossover part of the study
including 6 patients, a 5-day ‘‘accelerated” rTMS protocol with
two sessions performed each day, also did not produce significant
clinical change.
In a large cohort of 132 PD patients (Li et al., 2015), one study
compared the therapeutic value of LF- vs. HF-rTMS delivered to
M1 to that of the administration of istradefylline, an analog of
caffeine, which is a selective antagonist of the adenosine A2A recep-
tor, able to reduce the duration of wearing-off periods. After
12 weeks of treatment, motor improvement assessed by the
UPDRS-III score was similar in all patient groups, receiving either
istradefylline with sham rTMS or placebo drugwith LF- or HF-rTMS.
Regarding premotor cortex stimulation, most rTMS studies per-
formed in Parkinson’s disease targeted the medial part of thisregion, i.e. the supplementary motor area (SMA) using a figure-
of-8 coil over the interhemispheric midline to stimulate both
hemispheres simultaneously. A large, multicenter trial showed
that a prolonged protocol of weekly sessions of LF- (but not HF-)
rTMS of SMA could significantly improve global motor perfor-
mance assessed on UPDRS-III score (6.8 point reduction) (Shirota
et al., 2013). Conversely, a recent Class III study on 17 patients (9
real, 8 sham) (Sayin et al., 2014) did not find any beneficial effect
of LF rTMS of bilateral SMA applied for 10 days on global motor
performance. Thus, the value of the SMA target, especially stimu-
lated at LF, to impact on motor symptoms remained to be further
investigated in PD patients.
One crossover study (Yokoe et al., 2018) compared four condi-
tions of bihemispheric HF-rTMS (10 Hz, 100% of RMT, 3 daily ses-
sions of 1000 pulses in total per session for the both
hemispheres using a figure-of-8 coil) in a series of 19 PD patients.
These conditions were a real stimulation over the M1 hand area,
the SMA (defined as 3 cm anterior to the motor hotspot), or the
DLPFC (defined as 5.5 cm anterior to the motor hotspot), or a sham
stimulation (using a ‘‘realistic” procedure with superficial electrical
stimulation). The 3-day treatments for each condition were spaced
at least 4 days apart. The main finding of this study was that the
UPDRS-III score improved after bilateral HF-rTMS of the M1 and
SMA, but not of the DLPFC compared with the sham condition.
The changes tended to be better with the stimulation of M1, espe-
cially regarding akinesia and lower limb functions. In contrast, no
significant changes were observed in either the depression or apa-
thy scores.
In this regard, in the aforementioned multicenter sham-
controlled study (Brys et al., 2016), one group of 12 parkinsonian
patients received a treatment consisting of 10 daily sessions of
10 Hz-rTMS over the left DLPFC (defined as located only 5 cm in
front of the hand motor hotspot). No motor improvement was
observed in this group, as well as in the group treated by both
M1 and DLPFC stimulation, as previously discussed.
In summary, only the M1 target, at least if stimulated bilaterally
using HF-rTMS, can be recommended for the treatment of motor
parkinsonian symptoms for the moment. Beyond stimulating lar-
ger cortical areas, the development of accelerated (intensified) pro-
tocols with a greater number of sessions (including even more
sessions per day) could be a way to optimize the efficacy of rTMS
that should be tested in future studies (Rektorová and
Anderková, 2017). Alternatively, noninvasive TMS of M1 could be
combined with invasive deep brain stimulation to promote asso-
ciative plasticity in the brain circuits of motor control, as demon-
strated in PD patients by Udupa et al. (2016).
3.2. Parkinson’s disease: levodopa-induced dyskinesia
As reported in Lefaucheur et al. (2014), the first report of rTMS
effects on levodopa-induced dyskinesias (LIDs) was published by
Koch et al. (2005). In this pilot study of 8 PD patients, LIDs were
reduced following a single session of 1 Hz-rTMS delivered bilater-
ally over the SMAs. The same group replicated this result in 10 PD
patients (Brusa et al., 2006), without finding any enhancement of
the effect or prolonged benefit after 5 sessions. More recently,
Sayin et al. (2014) observed a reduction of LIDs for only 24 hours
after 10 days of 1 Hz-rTMS sessions bilaterally applied over the
SMAs.
Regarding the M1 target, following a pilot open study of 6 PD
patients (Wagle-Shukla et al., 2007), Filipovic´ et al. (2009) reported
a significant reduction of LIDs after repeated daily sessions of 1 Hz-
rTMS of M1 contralateral to the most affected side in a cross-over
study of 10 PD patients. Overall the benefit was of short duration.
More recently, no change in LIDs was observed after a session of
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levodopa challenge test in 9 PD patients (Flamez et al., 2016). Thus,
neither the SMA nor the M1 region appears to be relevant targets
for the application of LF-rTMS to impact on LIDs in daily life of
PD patients.
Alternative targets are the left DLPFC, using HF-rTMS
(Rektorova et al., 2008), the right inferior frontal cortex, using cTBS
(Cerasa et al., 2015), and especially the lateral cerebellum, also
using cTBS (Koch et al., 2009; Kishore et al., 2014). However, these
preliminary results, sometimes obtained with a single session,
remain to be further investigated in this clinical context.
3.3. Parkinson’s disease: Depression
One aforementioned study (Brys et al., 2016) reported the
absence of beneficial effects of HF-rTMS of the left DLPFC on mood
in a group of 12 PD patients. In this study, a non-significant average
reduction of 1.4 point on the Hamilton Depression Rating Scale
(HDRS) score was observed after real rTMS of the DLPFC, whereas
this reduction was significant in all the other groups, by 6.6, 6.1,
and 4.4 points on average in the real M1, sham, and real M1
+ DLPFC groups, respectively. However, at the same time, another
randomized sham-controlled study showed that real HF-rTMS of
the left DLPFC performed in 10 PD patients with major depressive
disorder (versus sham stimulation performed in 8 patients) was
able to improve depression scores on the Montgomery-Asberg
Depression Rating Scale (MADRS) and the HDRS with a beneficial
effect persisting for 6 weeks after 10 sessions of real stimulation
(Shin et al., 2016). In contrast, no motor change was observed on
the UPDRS-III score.
These two studies with opposite results canceled each other,
and we propose not to change the level of evidence regarding the
antidepressant efficacy of HF-rTMS of the left DLPFC in PD patients,
which was B (probable efficacy) in our previous work (Lefaucheur
et al., 2014), based on several ‘‘positive” Class II studies (Fregni
et al., 2004; Pal et al., 2010).
The study of Brys et al. (2016) further showed that real M1
stimulation performed better than DLPFC stimulation to induce
antidepressant effects in parkinsonian patients (HDRS score reduc-
tion by 40%), although not significantly better than sham stimula-
tion. Makkos et al. (2016) also reported an improvement of
depression scores, by 59% on the MADRS and 50% on the Beck
depression inventory (BDI) after HF-rTMS of bilateral M1. How-
ever, it is too early to draw conclusions about the value of this
‘‘motor” procedure for treating depression in PD patients.
3.4. Dystonia
A PubMed search (keywords: (rTMS OR theta burst stimulation)
AND dystonia) identified 30 papers, but no original sham-
controlled studies with at least 10 patients receiving real stimula-
tion for several daily sessions.
In our previous work (Lefaucheur et al., 2014), no sufficient evi-
dence has been found to establish a recommendation for the use of
any rTMS protocol in dystonia. In most studies, the dorsolateral
part of the premotor cortex (dPMC) contralateral to the most
affected side was the investigated rTMS target. Clinical improve-
ment of writing abilities and reduction of dystonic symptoms
was reported in patients with focal hand dystonia (writer’s cramp)
following LF-rTMS of the dPMC in 3 sham-controlled studies
(Murase et al., 2005; Borich et al., 2009; Kimberley et al., 2013).
However, these studies were based on a single rTMS session
(Murase et al., 2005) or included less than 10 patients in the group
receiving real stimulation (Murase et al., 2005; Borich et al., 2009).
The study by Kimberley et al. (2013) consisted of a series of 5 daily
sessions performed in 12 patients who received real rTMS, but thesham group only included 5 patients. Overall, improvement was
small and of short duration.
Instead of using LF-rTMS, one group assessed the value of cTBS
as an ‘‘excitability-decreasing” protocol applied to the dPMC in a
sham-controlled study of 18 patients with focal hand dystonia (9
real, 9 sham) (Huang et al., 2012). One daily session of cTBS was
delivered to the dPMC over 5 consecutive days. At the end of the
protocol, the real, but not sham stimulation was able to restore
the abnormal PMd-M1 interactions assessed by MEP recordings.
However, the clinical benefit on writing abilities was only
marginal.
Thus, the dPMC target has not proved its interest in dystonia.
At present, more recent studies aimed at investigating the value
of cerebellar rTMS in this clinical condition. A sham-controlled
Class III study with parallel-arm design (Koch et al., 2014)
enrolled 18 patients (9 real, 9 sham) who underwent 10 sessions
(over two weeks) of cTBS delivered to both cerebellar hemi-
spheres. As LF-rTMS, cTBS protocol is considered as ‘‘inhibitory”,
although the cortical plasticity changes induced by this type of
rTMS protocol (like the others) have shown a great interindivid-
ual variability (Hamada et al., 2013; Hordacre et al., 2017). A
small, but significant improvement in cervical dystonia in the
Toronto Western spasmodic torticollis rating scale (TWSTRS),
but not in the Burke-Fahn-Marsden dystonia rating scale
(BFMDRS) was observed in the real cTBS group (Koch et al.,
2014). This effect was very short-lasting (a couple of days) and
was no more observed two weeks after the last session. Some
neurophysiological changes induced by the cTBS protocol were
also reported in this study. Further evidence of the value of cere-
bellar stimulation in dystonia is still needed.
3.5. Essential tremor
A PubMed search (keywords: (rTMS OR theta burst stimulation)
AND essential tremor) identified 9 papers, but no original sham-
controlled studies with at least 10 patients receiving real stimula-
tion for several daily sessions.
In this clinical context, the current state of evidence of rTMS
efficacy has been recently reviewed and mostly concerned LF-
rTMS of the cerebellum (Kang and Cauraugh, 2017; Shih and
Pascual-Leone, 2017). As for dystonia, the value of cTBS was also
investigated. A crossover study of real versus sham cTBS delivered
to the right cerebellar hemisphere, but only as a single session, did
not show any change in tremor variables, on either clinical or kine-
matic analysis (Bologna et al., 2015b). The same group applied the
same cTBS protocol in patients with Parkinson’s disease and also
found no effect on parkinsonian resting tremor (Bologna et al.,
2015a).
Two other studies investigated the effect of a single session of
cTBS for alleviating essential tremor, but considering left M1 or
premotor cortical targets (Hellriegel et al., 2012; Chuang et al.,
2014). In the study of Hellriegel et al. (2012), the clinical severity
of tremor did not change, despite a reduction in the total power of
the tremor signal measured by accelerometry. In the study of
Chuang et al. (2014), only a slight reduction of tremor amplitude
was observed just after real but not sham stimulation of M1 or
premotor cortex. Finally, a pilot study with parallel-arm design,
investigated the value of 15 daily sessions (over 3 weeks) of LF-
rTMS of the pre-SMA, another premotor target, in a series of 10
patients with essential tremor (5 real, 5 sham) (Badran et al.,
2016). A significant reduction of tremor scores was observed after
both real and sham rTMS (by 26% and 19%, respectively), but the
clinical benefit was maintained at 4- and 8-week follow up only
in the real rTMS arm. Overall, however, data from the literature
remain inconclusive for the use of rTMS in the treatment of essen-
tial tremor.
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syndrome
The potential effects of LF-rTMS of the SMA in Tourette’s syn-
drome were first reported in open-label case reports by
Mantovani et al. (2006). A two-centre, sham-controlled, parallel-
arm study reassessed the value of 1 Hz-rTMS of the SMA in this
context (Landeros-Weisenberger et al., 2015). Twenty patients
with severe Tourette’s syndrome underwent 15 daily rTMS ses-
sions over 3 weeks (9 real, 11 sham). This study did not show
any significant reduction in tic severity after real versus sham
stimulation. Thus, still no formal recommendation can be made
in this indication.
The SMA target was also investigated in the treatment of rest-
less leg syndrome (RLS), but using HF-rTMS protocol. In a class IV
open-label study, Lin et al. (2015a) applied 15 Hz-rTMS to the
motor cortical leg representation of both hemispheres in 14
patients with RLS, for 14 sessions over 18 days. The international
RLS rating scale (IRLS-RS) score decreased by 53% at the end of
the rTMS protocol and remained significantly reduced over two
months after the intervention. Anxiety scores and the quality of
sleep concomitantly improved. However, this study was not
sham-controlled, contrary to that of Altunrende et al. (2014), in
which 5 Hz-rTMS was applied over the SMA, a target rather close
to motor representation of the legs. This sham-controlled,
parallel-arm study enrolled 19 patients (11 real, 8 sham) who
underwent 10 rTMS sessions, each spaced 3 days apart. A signifi-
cant reduction of the IRLS-RS score was found in the real but not
the sham group, up to 78% decrease at the completion of the 10
sessions. In 5 patients who have been not improved by sham rTMS,
IRLS-RS scores further decreased after switching to real rTMS.
However, no additional follow-up was available, so it is impossible
to determine whether this intervention has a clinical relevance or
not.4. Stroke
A PubMed search (keywords: (rTMS OR theta burst stimulation)
AND motor stroke) identified 213 papers, including 25 original
placebo/sham-controlled studies with at least 10 patients who
received real rTMS for several daily sessions over the contrale-
sional and/or ipsilesional hemisphere. Among these studies, 13
studies concerned limb motor rehabilitation at the postacute stage
with LF-rTMS of the contralesional M1 and/or HF-rTMS of the
ipsilesional M1, 2 studies concerned limb motor rehabilitation at
the postacute stage with contralesional cTBS or ipsilesional iTBS,
5 studies concerned limb motor rehabilitation at the chronic stage,
2 studies concerned LF-rTMS or iTBS of the cerebellum, and 4 stud-
ies concerned swallowing function rehabilitation. Studies investi-
gating children, central post-stroke pain, depression (e.g., Gu and
Chang, 2017), and neuropsychological impairments were excluded
from this analysis.
Based on the concept of stroke-induced dysbalanced interhemi-
spheric interactions (Murase et al., 2004; Hummel and Cohen,
2006; Hummel et al., 2008; Volz et al., 2015), ‘‘excitatory” HF-
rTMS and iTBS protocols are meant to be applied over the lesioned
hemisphere, but ‘‘inhibitory” LF-rTMS and cTBS over the contrale-
sional hemisphere. In our work, we separately considered the
results obtained by using motor cortex rTMS during the postacute
(subacute) stage of stroke (here defined as between one week and
six months after stroke onset) and the chronic stage of stroke (here
defined as more than six months after stroke onset). The defini-
tions of postacute and chronic stages are based on the fact that
after 6 months, spontaneous recovery is very unlikely to take place
for the motor system. We are, however, aware that there is anongoing debate about the different phases post-stroke and that
other authors have used different definitions about the periods
covered by ‘‘acute”, ‘‘post/subacute” or ‘‘chronic” post-stroke
phase. Furthermore, our definition of ‘‘postacute phase” does not
imply that this phase is homogeneous in terms of plasticity and
recovery. Only one study (Watanabe et al., 2018) enrolled patients
in the hyperacute phase of stroke (here defined as being within one
week post-stroke), because of obvious difficulties in applying the
technique during this phase. In the study of Watanabe et al.
(2018), all the patients started an rTMS protocol within 7 days
post-stroke: 8 patients received real iTBS over the affected motor
cortex hand area, 7 patients received real 1 Hz-rTMS over the unaf-
fected motor cortex hand area, and 6 patients received sham iTBS.
The protocol consisted of one daily session for 10 days with 600
pulses per session for ipsilesional iTBS and 1200 pulses per session
for contralesional LF-rTMS. Both real conditions improved finger
motor function tests evaluated at 12 weeks after stroke onset,
compared to the sham condition.
4.1. Contralesional LF-rTMS or cTBS at postacute (subacute) stage of
limb motor stroke
In the postacute stage after stroke, most studies concerned LF-
rTMS protocols delivered to the ‘‘unaffected”, contralesional motor
cortex. During the 2014–2018 period of this review, 11 sham-
controlled studies were published with protocols based on 5 to
30 daily sessions of LF-rTMS (Wang et al., 2014b; Blesneag et al.,
2015; Lin et al., 2015b: Lüdemann-Podubecká et al., 2015;
Matsuura et al., 2015; Zheng et al., 2015; Du et al., 2016a; Li
et al., 2016b; Meng and Song, 2017; Huang et al., 2018b; Long
et al., 2018) (Table 3).
One of these studies was not reported in Table 3, since only 8
patients were enrolled in either real or sham group (Blesneag
et al., 2015). This study aimed at assessing the changes in motor
cortex excitability (TMS motor mapping) between baseline
(10 days post-stroke) and one to three months after 10 daily LF-
rTMS sessions (45 and 90 days post-stroke). At 45 days after stroke,
patients of the real rTMS group showed a better motor recovery on
the Fugl-Meyer assessment test of the upper limb (FMA-UL) test
and a reduced imbalance between contralesional and ipsilesional
hemispheric excitability.
Eight studies aimed at assessing clinical changes produced by a
contralesional LF-rTMS protocol on upper limb motor function
(Wang et al., 2014b; Lüdemann-Podubecká et al., 2015; Matsuura
et al., 2015; Zheng et al., 2015; Du et al., 2016a; Li et al., 2016b;
Meng and Song, 2017; Long et al., 2018). In one study
(Lüdemann-Podubecká et al., 2015), the impact of rTMS differed
according to the location of stroke in the dominant or non-
dominant hemisphere: contralesional LF-rTMS was only beneficial
for hand dexterity in patients with stroke in the dominant
hemisphere.
Clinical improvement was associated with various changes in
neurophysiological measures. For example, the movement-
related electroencephalographic (EEG) potentials recorded during
self-paced wrist extension of the affected limb were found to be
enhanced over the frontocentral electrodes in the ipsilesional
hemisphere after contralesional LF-rTMS (Matsuura et al., 2015).
In another study (Du et al., 2016a), TMS features of motor cortex
excitability were found to be reduced in the contralesional hemi-
sphere (increased RMT and MEP of reduced amplitude and pro-
longed latency). This study also showed that both clinical
improvement and neurophysiological changes were more marked
after contralesional LF-rTMS than ipsilesional HF-rTMS performed
in another group of patients. Conversely, Li et al. (2016b) compared
real contralesional LF-rTMS (42 patients) to either real (43
patients) or sham (42 patients) ipsilesional HF-rTMS and found
Table 3
LF-rTMS of contralesional M1 in motor stroke at the postacute stage.
Articles Number of patients Target,
coil
type
Control
condition
Stimulation
frequency
and
intensity
Number of pulses/
session and
number of
sessions
Significant clinical effects of real versus
sham condition
Class
of
the
study
Lüdemann-Podubecká
et al. (2015)
40 patients at 0.5–
4 months post-stroke
(real: 20; sham: 20)
Hand
M1, F8c
0% RMT 1 Hz, 100%
RMT
900 pulses, 15
sessions (followed
by 30-min session
of physical motor
therapy)
Improved dexterity of the affected hand in
patients with stroke of the dominant
hemisphere, but not of the non-dominant
hemisphere, lasting at least 6 months after
the last session
II
Matsuura et al. (2015) 20 patients at 4–21 days
post-stroke (real: 10;
sham: 10)
Hand
M1, F8c
Sham coil 1 Hz, 100%
RMT
1200 pulses, 5
sessions
Improved motor function of the affected
hand (FMA-UL and Pegboard test scores),
one day after rTMS protocol (no follow-
up)
II
Zheng et al. (2015) 108 patients at an
average of 19 days post-
stroke (real: 55; sham:
53)
Hand
M1, F8c
Sham coil 1 Hz, 90%
RMT
1800 pulses, 24
sessions (followed
by virtual reality
therapy)
Improved motor function of the affected
hand (FMA-UL, WMFT, and mBI), at the
end of the 4-week rTMS protocol
I
Du et al. (2016a) 35 patients at 3–30 days
post-stroke (real: 16;
sham: 19)
Hand
M1, F8c
Tilted coil 1 Hz, 110–
120% RMT
1200 pulses, 5
sessions (followed
by 60-min session
of physical motor
therapy)
Improved motor function of the affected
limbs (FMA-UL/LL and MRC scores), more
marked than after ipsilesional HF-rTMS,
and lasting at least 3 months after the last
session
II
Meng and Song (2017) 20 patients at unknown
postacute stage (real:
10; sham: 10)
Hand
M1, F8c
Coil away
from the
head
1 Hz, 90%
RMT
1800 pulses, 14
sessions (40-
minute physical
motor therapy
twice a day)
Improved motor function of the affected
hand (FMA-UL, NIHSS, and BI scores) at
the end of the 14-day rTMS protocol
III
Long et al. (2018) 62 patients at an
average of 19–20 days
post-stroke (real LF
only: 21; real LF + HF:
21; sham: 20)
Hand
M1, Cc
Tilted coil 1 Hz (or 1 Hz
followed by
10 Hz), 90%
RMT
1000 pulses (or
1000 pulses
followed by 1000
pulses at 10 Hz), 15
sessions
Improved upper limb motor function
(FMA-UL andWMFT score) up to 3 months
after the last session, with bihemispheric
LF + HF protocol more beneficial than
contralesional LF-rTMS protocol alone
II
Li et al., 2016b 84 patients at an
average of 1.6–
1.9 months post-stroke
(real: 42; sham: 42)
Hand
M1, Cc
Sham coil 1 Hz, 80%
RMT
1000 pulses, 10
sessions (followed
by 40-min session
of occupational
therapy)
Improved motor function of the affected
hand (FMA-UL), at the end of the 2-week
rTMS protocol, with no difference
between contralesional LF-rTMS and
ipsilesional HF-rTMS protocols
II
Lin et al. (2015b) 31 patients at an
average of 34–41 days
post-stroke (real: 16;
sham: 15)
Leg M1,
F8c
Sham coil 1 Hz, 130%
RMT
900 pulses, 15
sessions (followed
by 45-min session
of physical motor
therapy)
Improvement of leg mobility, posture, and
gait at the end of the 3-week rTMS
protocol
II
Huang et al. (2018b) 38 patients at 10–
90 days post-stroke
(real: 18: sham: 20)
Thigh
M1,
DCc
Sham coil 1 Hz, 120%
AMT
900 pulses, 15
sessions (followed
by 45-min session
of physical motor
therapy)
No effect on walking abilities (timed up
and go test), balance, motor function, and
activity of daily living at the end of the 3-
week rTMS protocol
II
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affected hand compared to sham rTMS, but without any difference
between the two real interventions.
The most recent study compared a contralesional LF-rTMS pro-
tocol performed alone or combined to a protocol of ipsilesional HF-
rTMS for 15 consecutive days (Long et al., 2018). Both protocols
were effective in improving upper limb motor function assessed
by the Fugl-Meyer assessment test of the upper limb (FMA-UL)
and the Wolf motor function test (WMFT) up to 3 months after
the last session, but the bihemispheric dual protocol was more
beneficial than the contralesional LF-rTMS protocol performed
alone.
Another study assessed a sequential protocol of 10 daily ses-
sions of contralesional LF-rTMS (900 pulses per session) followed
by 10 daily sessions of ipsilesional iTBS (600 pulses per session),
or the reverse, performed in patients at 2–6 months after stroke
(Wang et al., 2014b). In this study, 32 patients received real stim-
ulation (LF-rTMS prior to iTBS in 17 patients and the reverse in 15
patients), whereas 16 patients received sham stimulation. Motor
improvement (assessed on FMA-UL and WMFT) was significantly
greater in the real condition, especially in patients receiving LF-
rTMS prior to iTBS, with a significant benefit persisting for at least
3 months.One study also combined contralesional LF-rTMS (real or sham,
55 vs. 53 patients) and virtual reality (VR) training for 6 days per
week over 4 weeks (24 sessions) (Zheng et al., 2015). At the end
of rTMS protocol, FMA-UL and WMFT scores, as well as the modi-
fied Barthel index (mBI) were significantly increased in the real
compared to the control group.
Finally, two studies aimed at improving lower limb motor func-
tion in patients at postacute stage using contralesional LF-rTMS
(Lin et al., 2015b; Huang et al., 2018b). One study (Lin et al.,
2015b) showed a greater improvement in the postural assessment
scale for stroke patients (PASS), the balance subscale of the
performance-oriented mobility assessment (POMA), and mBI after
real versus sham stimulation. Conversely, the other study (Huang
et al., 2018b) did not show any effects on walking abilities follow-
ing real rTMS (vs. sham condition). Compared to the previous one,
a non-focal coil was used (double-cone coil vs. figure-of-8 coil) and
stimulation intensity was lower (120% of active motor threshold
(AMT) vs. 130% of RMT) in this study.
Taken together the beneficial results reported in at least one
Class I study and four Class II studies (Table 3), plus three addi-
tional studies published before 2014 (Khedr et al., 2009a;
Conforto et al., 2012; Sasaki et al., 2013), it appears that LF-rTMS
applied to the contralesional motor cortex during the postacute
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486 J.-P. Lefaucheur et al. / Clinical Neurophysiology 131 (2020) 474–528stage after stroke has a definite efficacy for promoting rehabilita-
tion and improving residual motor functions at least for the hand
(Level A). These beneficial effects were mostly observed when
rTMS was used as a priming method before performing 30–60 min-
utes of physical therapy training and may persist up to 6 months
after the intervention (Lüdemann-Podubecká et al., 2015).
Only one study assessed the impact of repeated cTBS sessions
over the contralesional motor cortex (Nicolo et al., 2018). In this
study, 41 patients with upper limb paresis persisting at several
weeks after stroke were assigned to received 3 sessions per week
over 3 weeks (9 sessions) of real cTBS (14 patients), cathodal tran-
scranial direct current stimulation (tDCS) (14 patients), or sham
cTBS or tDCS (13 patients). Cortical stimulation was combined with
30 minutes of active functional motor practice but did not produce
any significant clinical changes assessed on FMA-UL, Box and Block
and 9-Hole Peg test scores, or Jamar dynamometer. Only subtle
changes in transcallosal functional connectivity were evidenced
after cTBS on high-density EEG.
4.2. Ipsilesional HF-rTMS or iTBS at postacute (subacute) stage of limb
motor stroke
In the 2014–2018 period, 5 sham-controlled studies aimed at
assessing clinical changes produced by an ipsilesional HF-rTMS
protocol on upper limb motor function (Du et al., 2016a; Hosomi
et al., 2016; Li et al., 2016b; Guan et al., 2017; Sasaki et al., 2017)
(Table 4). As aforementioned, ipsilesional HF-rTMS protocol was
compared to contralesional LF-rTMS protocol in two of these stud-
ies, showing an equal efficacy of both protocols in one study (Li
et al., 2016b) and a superiority of the contralesional LF-rTMS pro-
tocol in the other study (Du et al., 2016a). However, in this latter
study, HF-rTMS was performed at only 3 Hz. Hosomi et al. (2016)
applied a 5 Hz-rTMS protocol over the lesioned motor cortex and
showed significant improvement of various aspects of the paretic
hand motor function at the end of a series of 10 daily sessions in
the real but not sham condition. These beneficial effects were still
present two weeks beyond the last rTMS session. Guan et al. (2017)
also performed a 10-day protocol of 5 Hz-rTMS applied to the ‘‘af-
fected” motor cortex, but in patients at an earlier post-stroke stage
(4.6 days after stroke onset on average versus 45 days in Hosomi
et al., 2016). During rTMS therapy up to one month after stroke
onset, motor improvement was significantly greater in the real
vs. sham condition. The difference was no more significant at
3 months post-stroke or thereafter, except for the FMA-UL score
that remained improved one year after real HF-rTMS.
Finally, one study showed the value of ipsilesional HF-rTMS tar-
geted with a large double-cone coil over the motor cortical area of
leg representation for enhancing lower limb motor functions
(Sasaki et al., 2017).
Taken together the beneficial results reported in at least three
Class II studies (Table 4), plus four additional studies published
before 2014 (Khedr et al., 2005, 2009a, 2010; Chang et al., 2010),
the current level of evidence is in favor of a probable beneficial
impact of ipsilesional HF rTMS of M1 in the postacute phase of
stroke for promoting motor function recovery, at least for the
upper limb (Level B). However, two studies gave evidence for a
superiority of the contralesional LF-rTMS protocol in terms of effi-
cacy (Khedr et al., 2009a; Du et al., 2016a).
Only one study assessed the impact of repeated iTBS sessions
over the ipsilesional motor cortex (Volz et al., 2016). In this study,
26 patients with upper limb paresis due to a first stroke occurred
1–16 days before, received 5 daily sessions of real or sham iTBS
(13 patients for each condition) at 70% of RMT with 600 TMS pulses
delivered per session a few minutes prior to standard physiother-
apy performed for 45 minutes. The real stimulation produced sig-
nificantly stronger recovery of grip strength of the paretic hand
J.-P. Lefaucheur et al. / Clinical Neurophysiology 131 (2020) 474–528 487compared to control stimulation, with lasting benefit for at least
3 months. Clinical improvement was associated with stronger net-
work connectivity of ipsilesional M1 at functional magnetic reso-
nance imaging (fMRI).
In another study cited above (Wang et al., 2014b), an ipsilesional
iTBS protocol was combined with a contralesional LF-rTMS in a
sequence of 10 daily sessions of each protocol performed succes-
sively. A greater efficacy was found when contralesional LF-rTMS
was first applied, prior to ipsilesional iTBS. In fact, bihemispheric
dual stimulation was rarely performed, e.g. a protocol combining
contralesional LF-rTMS and ipsilesional HF-rTMS for 15 consecutive
days (Long et al., 2018) and therefore no recommendation is
allowed for such a strategy in the objective of promoting motor
function recovery in the postacute stage of stroke.
4.3. Contralesional LF-rTMS at the chronic stage of limb motor stroke
In patients at the chronic stage of stroke (more than 6 months
post-stroke), 3 studies addressed the use of contralesional LF-
rTMS (Rastgoo et al., 2016; Forogh et al., 2017; Harvey et al.,
2018). In series of 15–20 patients, two sham-controlled studies
(7–10 patients in both real and sham groups) showed that focal
stimulation (using a figure-of-8 coil) over the leg motor cortical
representation of the ‘‘unaffected” hemisphere for 5 daily sessions
could reduce spasticity (assessed on modified Ashworth scale) and
improve lower limb motor function (assessed on FMA-LL) (Rastgoo
et al., 2016), with clinical benefits lasting 1 to 3 weeks post-
intervention and up to 3 months regarding the impact on balance
(measured on Berg balance scale) and static postural stability
(Forogh et al., 2017). However, these results on motor recovery
and posture remain to be replicated.
An important study on hand motor recovery following 1 Hz-
rTMS over contralesional M1 was published in the framework of
the NICHE trial (Harvey et al. 2018). Remarkable features of this
industry-initiated clinical trial were the high number of partici-
pants (199 patients) and a multicenter design using a 2:1 random-
ization strategy (real: 132 patients, sham: 67 patients). Inclusion
criteria were patients within 3–12 months post-stroke and with
some remaining hand motor function. The protocol consisted of
18 sessions of 1 Hz-rTMS over 6 weeks (900 pulses per session at
110% of RMT), each rTMS session being followed by arm training.
The results, obtained in 169 participants who completed all ses-
sions, showed that real rTMS was not superior to sham rTMS, for
none of the studied motor parameters (Action Research Arm Test
(ARAT), FMA-UL, WMFT). Hence, this study does not support the
concept of LF-rTMS of contralesional motor cortex as a beneficial
add-on therapy in chronic motor stroke, which was based on sev-Table 5
iTBS of ipsilesional M1 in motor stroke at the chronic stage.
Articles Number of
patients
Target,
coil
type
Control
condition
Stimulation
frequency
and
intensity
Nu
an
Lai et al. (2015) 72 patients at an
average of 9.7–
11.4 months post-
stroke (real: 55;
sham: 17)
Hand
M1, F8c
Sham coil iTBS, 80%
AMT
60
Lin et al. (2019) 20 patients at an
average of 12–
12.8 months post-
stroke (real: 10;
sham: 10)
Thigh
M1, F8c
Sham coil iTBS, 100%
AMT
12
(fo
of
[2
5eral Class II-III studies showing improvement of manual motor
abilities for 2–12 weeks following rTMS protocols based on 5 to
10 daily sessions (Fregni et al., 2006; Emara et al., 2009, 2010;
Avenanti et al., 2012). These recent results significantly weaken
our recommendations from Level B (probable effect) to Level C
(possible effect) concerning LF-rTMS over contralesional M1 to
promote post-stroke recovery of hand motor function in chronic
stroke patients. Furthermore, this statement cannot be extended
to lower limb rehabilitation or spasticity to date.
4.4. Ipsilesional HF-rTMS or iTBS at the chronic stage of limb motor
stroke
In the 2014–2018 period, only one sham-controlled study of 30
patients at the chronic stage post-stroke (4 years post-stroke on
average) was based on an ipsilesional HF-rTMS protocol with a
real-sham crossover design (Choi et al., 2016). In this study, rTMS
was targeted over the thoracic paraspinal muscle representation
with a figure-of-8 coil for 10 daily sessions over two weeks and
resulted in significant improvement of balance (measured by com-
puterized dynamic posturography) after real vs. sham stimulation.
In contrast, three sham-controlled studies with repeated daily
sessions of ipsilesional iTBS were performed in patients at the
chronic stage (Lai et al., 2015; Ackerley et al., 2016; Lin et al.,
2019) (Table 5). In the first study (Lai et al., 2015), ipsilesional iTBS
was able to improve paretic hand motor function (assessed by the
WMFT and a finger tapping task) at the end of the 10-day protocol
(no follow-up). This motor improvement was positively correlated
to the presence and amplitude of MEPs and preserved grip strength
in the paretic hand at baseline. In a second study (Ackerley et al.,
2016), real or sham ipsilesional iTBS was delivered immediately
before a 45-minute session of physical therapy, as a priming proce-
dure. The real stimulation improved paretic upper limb function
(measured by the ARAT) at the end of the 10-day protocol, with
a significantly lasting effect at one month post-intervention (but
not at three months). This functional improvement was correlated
to a reduction of interhemispheric asymmetry of cortical excitabil-
ity (measured on the slope of the MEP recruitment curve) and to an
increase in ipsilesional premotor cortex activation during paretic
hand grip assessed by fMRI. However, this well-conducted study
remains of Class III because of its small sample size (9 patients in
both real and sham iTBS groups) and therefore has not been
reported in Table 5.
The last controlled study used an ipsilesional iTBS protocol to
improve lower limb function (Lin et al., 2019). Despite a broad
assessment (FMA-LL, National Institutes of Health Stroke Scale
(NIHSS), modified Rankin scale, Barthel index, Brunnstorm recov-mber of pulses/session
d number of sessions
Significant clinical effects of real versus
sham condition
Class
of
the
study
0 pulses, 10 sessions Improved motor function of the affected
hand (WMFT, finger tapping task) at the
end of the 2-week rTMS protocol (no
follow-up), with better improvement in
patients (n = 21) with present MEP in the
paretic hand at baseline than in patients
(n = 34) with absent MEP, especially if
hand grip strength was also null
II
00 pulses, 10 sessions
llowed by 45-min session
physical motor therapy)
sessions/week over
weeks]
Marginal improvement of the affected
lower limb (FMA-LL, computerized
dynamic posturography), at the end of the
5-week rTMS protocol
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10-meter walking test (10MWT), and computerized dynamic pos-
turography) and a prolonged stimulation protocol over 5 weeks,
only marginal improvement was observed in the real iTBS condi-
tion, not significantly different from the sham condition.
Thus, in patients at the chronic stage of motor stroke, the func-
tional benefits provided by ipsilesional stimulation protocols (HF-
rTMS or iTBS) were reported by too few studies, also including pre-
viously discussed results published by Emara et al. (2009, 2010), to
obtain a sufficient level of evidence to make a recommendation.
4.5. Ipsilesional cTBS at the chronic stage of limb motor stroke
In the 2014–2018 period of literature search, we found one
small study in which cTBS was delivered on the motor cortex of
the lesioned hemisphere of chronic stroke patients with severe def-
icit in order to improve the response to robot-assisted motor reha-
bilitation (Di Lazzaro et al., 2016). The choice of employing cTBS on
the affected hemisphere was based on the results of studies in nor-
mal subjects showing that rTMS protocols suppressing cortical
excitability strongly facilitate motor learning capacities via an
increase in ‘‘homeostatic” plasticity (Jung and Ziemann, 2009). In
a small previous study of stroke patients with moderate deficits,
an enhanced response to physical therapy was observed after
ipsilesional cTBS (Di Lazzaro et al., 2013). In a subsequent study
of the same research group (Di Lazzaro et al., 2016), 20 chronic
stroke patients wtih severe impairment of upper limb motor per-
formances were randomized to robot-assisted therapy associated
with real or sham ipsilesional cTBS, delivered for 10 working days.
All patients who completed the study (8 real, 9 sham) obtained a
small motor improvement (about 5% on the FMA-UL), but the dif-
ference between real and sham cTBS groups was not significant.
Thus, this study did not replicate findings obtained in patients with
moderate upper limb deficits. The authors suggested that a possi-
ble explanation for the discrepancy is that the affected and unaf-
fected hemispheres might play a different role in mild vs. severe
strokes, so that the hemisphere mainly responsible for motor
recovery in severe stroke is the unaffected one (Di Pino et al.,
2014). Thus, a different approach might be needed in patients with
severe brain damage. Because there are only two small studies
with conflicting results, the level of evidence is not sufficient to
make a recommendation and further studies are needed in order
to evaluate whether subgroups of patients might respond to a
homeostatic modulation of brain plasticity.
4.6. Cerebellar target
Beyond M1, which is the main target considered for rTMS ther-
apy in stroke, recent electrophysiological and imaging evidence
underlined that a large motor network includes other key brain
areas during the process of post-stroke functional recovery
(Grefkes and Fink, 2014; Koch and Hummel, 2017). The cerebellum
is one of these alternative targets to M1 for promoting motor reha-
bilitation by rTMS in the context of stroke (Wessel and Hummel,
2018). First, Kim et al. (2014a) applied LF-rTMS to the cerebellum
in a series of 26 ataxic patients in the subacute stage of a posterior
circulation stroke (15 days post-stroke on average). In this sham-
controlled protocol of 5 daily sessions (20 patients for the real con-
dition vs. 6 patients for the sham condition), a figure-of-8 coil was
used, centered 2 cm below the inion and 2 cm lateral to the mid-
line, ipsilateral to the ataxic side, with the handle pointing superi-
orly. The main result was an improvement of walking ability,
measured on time and number of steps in the 10MWT, only at
1 month after real rTMS compared to sham condition. Balance,
measured on BBS, improved in both conditions, although more sig-
nificantly in the real rTMS group.More recently, Koch et al. (2019) applied iTBS over the contrale-
sional lateral cerebellum coupled with physiotherapy (90-minute
session of motor and balance therapy) for 3 weeks and also showed
an improvement of balance and gait functions (measured on BBS
and step width at a walking test) in a series of 34 patients (17
patients in both real and sham conditions) at the chronic stage of
middle cerebral artery stroke (6–78 months post-stroke).
These approaches appeared to be rather opposite, since LF-rTMS
is usually considered as an ‘‘inhibitory” protocol and iTBS as an
‘‘excitatory” protocol. In fact, such opposition is rather speculative.
Thus, these two studies pave the way of future research based on
cerebellar stimulation for promoting stroke rehabilitation but are
insufficient to provide a level of evidence or make a
recommendation.
It is worth mentioning that the clinical impact of motor cortex
rTMS is still limited and heterogeneous in stroke patients. These
limited effects might be due to the fact that rTMS is not applied
in a personalized medicine fashion, tailored to the phase of recov-
ery or individual characteristics of the patient. Understanding
biomarkers for targeting stratification will provide elements for
precision medicine in order to achieve maximized treatment
effects for stroke recovery in each individual patient (Grefkes and
Fink, 2014; Morishita and Hummel, 2017; Raffin and Hummel,
2018). In addition, the number and size of most trials is rather
small. Larger, multicenter randomized controlled clinical trials
are still missing to achieve highest evidence level (Grefkes and
Fink, 2016), especially for novel targets (such as the premotor cor-
tex or the cerebellum) (Koch and Hummel, 2017; Wessel and
Hummel, 2018), which are going to be evaluated.
4.7. Swallowing and dysphagia
Swallowing dysfunction is a very common symptom, but usu-
ally returns to normal over the first weeks after stroke in many
patients. Although a minority of patients suffer from persistent
dysphagia at 6 months after stroke (Mann et al., 1999), this condi-
tion has an important impact on clinical outcome, as dysphagia is a
frequent cause of severe adverse events, like aspiration pneumonia
which can have lethal consequence. Therefore, accelerating recov-
ery from dysphagia may strongly reduce stroke-related complica-
tions. Several studies have investigated the value of rTMS to
enhance swallowing function recovery after stroke on the same
concept of interhemispheric rivalry as for limb motor functions,
although the control of swallowing is more bilaterally imple-
mented in the brain.
In the 2014–2018 period, 4 sham-controlled studies were pub-
lished in this field of research, 3 concerning the post-acute stage of
stroke (Du et al., 2016b; Park et al., 2017; Zhang et al., 2019) and
one the chronic stage (Cheng et al., 2017).
In two studies (Du et al., 2016b; Park et al., 2017), ipsilesional
HF-rTMS was applied to the motor cortex representing the swal-
lowing muscles (hot spot of the mylohyoid muscle) in patients in
the postacute phase of poststroke dysphagia. In Du et al. (2016b),
13 patients (1.2 week post-stroke on average) received 3 Hz-
rTMS for 5 days over one week, while in Park et al. (2017), 11
patients (4.2 weeks post-stroke on average) received 10 Hz-rTMS
for 10 days over 2 weeks. Swallowing function improved after real
rTMS when compared with sham rTMS in the first study, but not in
the second one (Table 6).
Before 2014, three studies reported beneficial rTMS effects for
dysphagia rehabilitation in the post-acute stage (one week to
two months post-stroke on average): in two studies from the same
group (Khedr et al., 2009b; Khedr and Abo-Elfetoh, 2010) 3 Hz-
rTMS was applied over the oesophageal representation of the
affected motor cortex (300 pulses/session at 120–130% of hand
RMT for 5 consecutive days), whereas in the third study (Park
Table 6
HF-rTMS of ipsilesional M1 in post-stroke dysphagia.
Articles Number of patients Target,
coil type
Control
condition
Stimulation
frequency
and
intensity
Number of pulses/
session and
number of
sessions
Significant clinical effects of real versus
sham condition
Class
of
the
study
Postacute stage
Du et al. (2016b) 25 patients at 4–
26 days post-stroke
(real: 13; sham: 12)
Mylohyoid
M1, F8c
Tilted coil 3 Hz, 90%
RMT
1200 pulses, 5
sessions
Improved swallowing function at the end of
the rTMS protocol, lasting at least 3 months
beyond the last session
II
Park et al. (2017) 22 patients at an
average of 4.2 to
6.6 weeks post-
stroke (real: 11;
sham: 11)
Mylohyoid
M1, F8c
Tilted coil 10 Hz, 90%
RMT
500 pulses, 10
session
No effect on swallowing function II
Zhang et al. (2019) 31 patients at an
average of 21 to
26 days post-stroke
(real: 15; sham: 16)
Mylohyoid
M1, F8c
Tilted coil 10 Hz, 110%
RMT
900 pulses, 10
session combined
with digastic
muscle electrical
stimulation
Improved swallowing function at the end of
the rTMS protocol, lasting at least 1 month
beyond the last session
III
Chronic stage
Cheng et al. (2017) 14 patients at 19–
77 months post-
stroke (real: 10;
sham: 4)
Tongue
M1, F8c
Sham coil 5 Hz, 90%
RMT
3000 pulses, 10
sessions
No effect on swallowing function, video-
fluoroscopic assessment, tongue strength, or
swallowing-related quality of life at any
time point (up to 2 to 12 months post-rTMS)
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ryngeal motor cortex (500 pulses/session at 90% of hand RMT for
10 days over 2 weeks). Because of this discrepancy (ipsilesional
vs. contralesional), no recommendation can be made for the use
of HF-rTMS in the context of swallowing dysfunction at the post-
acute phase of stroke.
In Park et al. (2017), an additional group of 11 patients received
bilateral 10 Hz-rTMS over both M1 regions projecting to mylohy-
oid muscles (500 pulses for 10 minutes over the ipsilesional cortex,
followed by 500 pulses for 10 minutes over the contralesional
cortex). In contrast to unilateral ispilesional stimulation, bilateral
HF-rTMS significantly improved clinical and videofluoroscopic
swallowing function at the end of the protocol and also 3 weeks
after. This is in line with the aforementioned bilateral cortical con-
trol of swallowing. However, this study remains to be replicated.
In Du et al. (2016b), an additional group of 13 patients received
contralesional 1 Hz-rTMS protocol, which produced similar
improvement as ipsilesional 3 Hz-rTMS. Both protocols increased
cortical excitability of the affected hemisphere (increased ampli-
tude and decreased latency of mylohyoid MEPs).
In another study (Lim et al., 2014), LF-rTMS was applied 5 days/
week for 2 weeks over the pharyngeal hotspot of the contralesional
motor cortex in a series of 14 patients in the subacute stage of
stroke (30 days post-stroke on average). This study was not sham
controlled, the other experimental groups being 18 patients
treated by 30-minute daily sessions of neuromuscular electrical
stimulation (NMES) of the digastric and hyoid muscles and 15
patients with only conventional dysphagia rehabilitation therapy.
Both rTMS and NMES improved dysphagia on a functional scale.
A final study on post-stroke swallowing rehabilitation in the
postacute stage combined rTMS and NMES performed during the
same sessions 5 days/week for 2 weeks (Zhang et al., 2019). In four
groups of 13–16 patients in the subacute stage of stroke
(21–26 days post-stroke on average), NMES was combined to con-
tralesional 1 Hz-rTMS, ipsilesional 10 Hz-rTMS, both protocols
(bilateral rTMS), or sham stimulation (tilted coil). All real rTMS
protocols enhanced swallowing function recovery compared with
NMES delivered alone, especially bilateral rTMS protocol.
In the chronic phase of stroke, Cheng et al. (2017) found that
HF-rTMS delivered to the lesioned hemisphere did not provide
any benefit. As post-stroke swallowing dysfunction usually rapidlyrecover, rTMS should probably be applied early in the history of the
disease to achieve more relevant therapeutic effects.
In summary, given the heterogeneity of results and protocols, it
is still not possible to conclude that rTMS may be a beneficial ther-
apeutic modality for patients with persisting dysphagia in the
postacute or chronic stage of stroke.
4.8. Aphasia
A PubMed search (keywords: (rTMS OR theta burst stimulation)
AND aphasia) identified 53 papers, including 6 original sham-
controlled studies with at least 10 patients receiving real stimula-
tion for several daily sessions.
Before 2014, mostly case reports have been published in this
field of research, or studies based on small samples (Barwood
et al., 2011a,b; Medina et al., 2012). In our previous work
(Lefaucheur et al., 2014), we identified only few studies based on
a sufficiently large sample of patients, reporting the effects of
repeated daily LF-rTMS delivered over the right inferior frontal
gyrus (IFG) followed by 45-min speech and language therapy
(Waldowski et al., 2012; Heiss et al., 2013; Thiel et al., 2013;
Seniów et al., 2013). These studies mixed patients at the postacute
stage with either nonfluent Broca’s or fluent Wernicke’s aphasia
and originated from two research groups. One group used vertex
stimulation as control and reported significant improvement in
several language functions following real rTMS with no change fol-
lowing sham stimulation (Heiss et al., 2013; Thiel et al., 2013). In
contrast, the other group used sham coil as control and did not find
any difference in the degree of speech improvement between real
and sham conditions (Waldowski et al., 2012; Seniów et al., 2013).
Therefore, no conclusion regarding the efficacy of LF rTMS of the
right IFG in patients with non-selected type of poststroke aphasia
in the postacute phase could be drawn.
In the 2014–2018, only one additional study performed in the
postacute phase with a similar design was identified (Rubi-
Fessen et al., 2015). In this study, a series of 30 stroke patients in
the postacute phase (17–94 days post-stroke) with non-selected
type of aphasia (one-third nonfluent type) underwent a 10-day
protocol of LF-rTMS delivered over the right IFG (15 real, 15 sham
consisting of active vertex stimulation). Similarly to previous stud-
ies, each rTMS session (1200 pulses/session) was immediately
Table 7
LF-rTMS of right IFG in post-stroke nonfluent aphasia at chronic stage.
Articles Number of
patients
Target,
coil
type
Control
condition
Stimulation
frequency
and
intensity
Number of pulses/session
and number of sessions
Significant clinical effects of real
versus sham condition
Class
of
the
study
Tsai et al. (2014) 53 patients at
18 months post-
stroke on
average (real:
31; sham: 22)
Right
IFG
(BA45),
F8c
Sham coil 1 Hz, 90%
RMT
600 pulses, 10 sessions Improved speech on the CCAT, object
and action naming accuracy and
reaction time at the end of the 2-week
rTMS protocol, lasting at least
3 months beyond the last session for
the CCAT score
II
Wang et al. (2014a) 43 patients at
16 months post-
stroke on
average (real:
29; sham: 14)
Right
IFG
(BA45),
F8c
Sham coil 1 Hz, 90%
RMT
1200 pulses, 10 sessions (with
concomitant (n = 15) or
subsequent (n = 14) naming
task, plus 60-minute speech
training twice a week)
Improved speech on the CCAT, object
and action naming accuracy at the
end of the 2-week rTMS protocol, only
in case of concomitant naming
training, with benefit lasting at least
3 months beyond the last session
II
Yoon et al. (2015) 20 patients at
5.2–6.8 months
post-stroke on
average (real:
10; sham: 10)
Right
IFG
(BA45),
F8c
No
stimulation
1 Hz, 90%
RMT
1200 pulses, 20 sessions
(followed by 45-minute
speech and language therapy)
Improved repetition and naming
scores of the WAB at the end of the 4-
week rTMS protocol
III
Hu et al. (2018) 20 patients at
6.8–7.5 months
post-stroke on
average (real:
10; sham: 10)
F4, F8c Tilted coil 1 Hz, 80%
RMT
600 pulses, 10 sessions Improved aphasia quotients,
spontaneous speech and auditory
comprehension scores of the WAB at
the end of the 2-week rTMS protocol,
lasting at least 2 months beyond the
last session
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Real rTMS was found to improve basic linguistic skills and func-
tional communication, measured on the Aachen Aphasia Test
(AAT) and the Amsterdam-Nijmegen Everyday Language Test
(ANELT), one day after the treatment peiod. Therefore, the conclu-
sion for this clinical context remains the same, with no recommen-
dation for the use of LF-rTMS of the right IFG in patients with non-
selected type of aphasia at a postacute post-stroke stage.
However, since 2014, more consistent studes assessing a single
type of aphasia in larger samples of patients at the chronic stage of
stroke have been published. Most of these studies assessed the
value of LF-rTMS for the rehabilitation of nonfluent aphasia, in
which the Broca’s area is usually damaged by middle cerebral
artery infarction (Table 7). Broca’s area consists of the pars opercu-
laris and pars triangularis of the IFG of the dominant (left) hemi-
sphere, corresponding to Brodmann areas (BAs) 44 and 45. In
most studies, post-stroke aphasia was intended to be treated by
LF-rTMS specifically applied to the right BA 45 region, i.e. the con-
tralesional homologue of Broca’s area, using image-guided naviga-
tion. As it was the case in the studies published before 2014 and
also for motor stroke, the rationale for these studies was to
down-regulate an increased cortical activity in the contralesional
hemisphere, thus reducing the interhemispheric inhibition onto
the lesioned cortical regions which was supposed to interfere with
successful language recovery.
Yoon et al. (2015) used combination of LF-rTMS of the right IFG
with speech and language therapy in 10 patients with nonfluent
aphasia at the beginning of the chronic post-stroke phase and com-
pared them with similar group of 10 patients receiving speech and
language therapy only. This combined therapy improved repetition
and naming performance on the Western Aphasia Battery (WAB,
Korean version) at the end of a 4-week protocol in contrast to
the control group where no significant improvement was seen.
Hu et al. (2018) further showed that a 10-day protocol of LF-
rTMS delivered at 1 Hz over the right homologous of Broca’s area
(defined by F4 site of the 10–20 EEG system) was able to improve
some variables of the WAB (Chinese version) in 10 patients with
nonfluent aphasia at the beginning of the chronic post-strokephase. At the end of rTMS protocol, spontaneous speech, auditory
comprehension, and aphasia quotients were improved after LF-
rTMS, but not HF-rTMS delivered over the same contralesional tar-
get. This beneficial effect lasted for at least 2 months.
One research group assessed the value of LF-rTMS of the right
IFG in patients with nonfluent aphasia at a more chronic stage. In
a first study (Tsai et al., 2014), 31 stroke patients (22 patients in
the sham group) underwent 10 sessions of real LF-rTMS applied
at 1 Hz over the contralesional pars triangularis (right IFG, BA
45). They improved on the Concise Chinese Aphasia Test (CCAT)
score, object and action naming accuracy and reaction time after
real stimulation, with benefit persisting at 3 months following
intervention, at least for the CCAT score. A lower RMT was a predic-
tor of a favorable outcome. The same research group applied LF-
rTMS of the right BA 45 during or immediately before a naming
training session for 10 daily sessions in 29 stroke patients with
nonfluent aphasia (14 patients in the sham group) (Wang et al.,
2014a). Patients improved on the CCAT and object and action nam-
ing accuracy only when LF-rTMS and speech therapy were con-
comitantly performed, with benefit persisting at 3 months
following intervention.
From all these results, including a duet of Class II studies from
one research group (Tsai et al., 2014; Wang et al., 2014a), and
two Class III studies from two other independent groups (Yoon
et al., 2015; Hu et al., 2018), a level B of evidence (probable effi-
cacy) can now be proposed for LF-rTMS of the right IFG in patients
with nonfluent aphasia at a chronic post-stroke stage, especially if
combined with speech and language therapy.
In our previous work (Lefaucheur et al., 2014), due to the pau-
city of data (few studies published were all Class IV), no recom-
mendation could be made regarding the use of excitability-
increasing protocols (HF rTMS or iTBS) involving a cortical target
located in the ipsilesional hemisphere to promote recovery of
patients with nonfluent aphasia. The situation remains the same
following the review of the studies published between 2014 and
2018.
A few additional sham-controlled studies deserve to be cited.
Firstly, Khedr et al. (2014) applied a dual-hemisphere rTMS proto-
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at the postacute stage (5 weeks post-stroke on average). Each
patient received 1000 rTMS pulses delivered at 1 Hz and 110% of
RMT over the unaffected IFG (right BAs 44 and 45) and 1000 pulses
delivered at 20 Hz and 80% of RMT over the affected Broca’s area
(left BAs 44 and 45) for 10 consecutive days followed by speech
and language training. A significantly greater improvement in the
Hemispheric Stroke Scale (HSS) and the Stroke Aphasic Depression
Questionnaire-Hospital Version (SADQ-H) was observed after real
rTMS compared with sham rTMS, which remained significant
2 months after the last session.
Similarly, Vuksanovic´ et al. (2015) reported the improvement of
several language functions in a right-handed patient with chronic
poststroke nonfluent aphasia following the application of 15 daily
sessions of bilateral TBS of the IFG, combining cTBS on the right
and iTBS on the left hemisphere, followed by 45 minutes of speech
and language therapy. Although scarce, these results suggest poten-
tial for use of dual-hemisphere protocols in aphasia treatment.
Regarding fluent aphasia, the target is conceivably located in
the superior temporal gyrus (STG) (Hamilton et al., 2010). In our
previous work, only one Class IV study reporting the effects of LF
rTMS applied to the homologue of Wernicke’s area in the right
hemisphere in patients with fluent aphasia was found, and conse-
quently no recommendation could be made for this type of apha-
sia. The situation remains the same following the review of the
studies published between 2014 and 2018.
Finally, one study did not address aphasia, but dysarthria (Kwon
et al., 2015). Contralesional LF-rTMS was delivered at 1 Hz (1500
pulses/session, 5 days/week for 2 weeks) over the orbicularis oris
motor hot spot on the non-affected side in a series of 20 stroke
patients (10 real, 10 sham) at the postacute stage (26.5 days
post-stroke on average). All rTMS sessions were combined with
speech therapy for 30 minutes. Dysarthria significantly improved
at the end of the rTMS protocol, better after real than sham stimu-
lation in various aspects.
4.9. Neglect
A PubMed search (keywords: (rTMS OR theta burst stimulation)
AND neglect) identified 32 papers, including only 3 original sham-
controlled studies with at least 10 patients receiving real stimula-
tion for several daily sessions.
Hemispatial neglect preferentially occurs on the left side fol-
lowing stroke in the territory of the right middle cerebral artery,
most often related to a lesion of the right posterior parietal cortex
(PPC) or the posterior part of the STG. The description of spatial
attention deficits following left-hemispheric stroke are scarce
(Timpert et al., 2015). The PPC includes the superior parietal lobule
(BA 7, above the intraparietal sulcus), corresponding to the P3-P4
sites of the EEG 10–20 System (Homan et al., 1987) and the inferior
parietal lobule (below the intraparietal sulcus), with two parts
named anteriorly the supramarginal gyrus (BA 40, corresponding
to the CP3-CP4 sites of the EEG 10–10 System) and posteriorly
the angular gyrus (BA 39, corresponding to the P5-P6 sites).
Most rTMS studies assessed excitability-decreasing paradigms
(LF-rTMS or cTBS) applied to the contralesional left PPC following
a right-hemispheric stroke. From 2014, only one study assessed
the effects of LF-rTMS delivered at 1 Hz over the contralesional left
PPC (P5 site), 5 days/week for two weeks, in patients with left hem-
ineglect in the postacute stage (about 40 days post-stroke on aver-
age) (Yang et al., 2017). Three experimental groups were
considered: real LF-rTMS alone (19 patients) or combined with
sensory cueing intervention (i.e., a device placed on the left wrist,
which emitted vibration every 5 minutes for 3 hours/day to remind
the patient to focus on the neglected side) (18 patients) and con-
ventional rehabilitation program alone (19 patients). The combina-tion of LF-rTMS with sensory cueing was better than either rTMS or
conventional rehabilitation alone in producing a stronger and long-
lasting improvement in unilateral neglect, measured on the Beha-
vioural Inattention Test (BIT).
Conversely, in a sham-controlled study, Cha and Kim (2016)
applied LF-rTMS to the right lesioned PPC (P4 site, 1 Hz), five
days/week for 4 weeks, in 30 patients (15 real, 15 sham) with
hemispatial neglect in the late post-acute phase (4 months post-
stroke on average). Improvement on Line Bisection test (LBT), Albert
test, Box-and-Block test (BBT), and grip strength was significantly
greater in the real than the sham rTMS group in this Class II study.
Before 2014, only one sham-controlled study (Kim et al., 2013)
compared the respective effects of real LF-rTMS of the contrale-
sional left PPC (P3 site, 1 Hz, 9 patients), sham LF-rTMS (tilted coil,
9 patients), and HF-rTMS of the ipsilesional right PPC (P4 site,
10 Hz, 9 patients). Sessions were performed five days/week for
2 weeks in patients with visuospatial neglect in the early post-
acute phase (15 days post-stroke on average). This study showed
a better improvement of neglect (measured on LBT) in the ipsile-
sional (right hemisphere) HF-rTMS group than in the contrale-
sional (left hemisphere) LF-rTMS and sham groups.
No recommendation can be proposed regarding the use of con-
ventional LF- or HF-rTMS over parietal regions in the treatment of
visuospatial neglect, because of methodological differences in the
two sham-controlled studies: LF-rTMS applied to the contrale-
sional (Kim et al., 2013) or ipsilesional (Cha and Kim, 2016) hemi-
sphere, or ipsilesional HF-rTMS (Kim et al., 2013).
Other studies assessed the value of cTBS delivered to the con-
tralesional left PPC. This was the case of one sham-controlled study
based on sessions repeated for several days and published before
2014 (Koch et al., 2012). In this Class II study, 20 patients in the
postacute stage of stroke (24–102 days post-stroke) were equally
randomized to receive a real or sham cTBS protocol (10 patients
in each group) delivered 5 days/week for 2 weeks over the left
PPC (P3 site). This study showed that cTBS but not sham stimula-
tion decreased the severity of spatial neglect as assessed by the
BIT, with after-effects lasting at least for two weeks after
treatment.
A more recent study of Class III (Fu et al., 2015) also assessed
the efficacy of cTBS for improving visuospatial neglect (Table 8).
The same cTBS protocol was similar to that used as in Koch et al.
(2012), i.e. 2 trains separated by 15 minutes and consisting of 3-
pulse bursts delivered at 30 Hz (not 50 Hz) and repeated at 5 Hz
for 40 s at 80% of RMT (not AMT). Patients with right hemisphere
stroke and visuospatial neglect at the post-acute stage (17–
114 days post-stroke) underwent real or sham cTBS sessions (10
patients in each group) over the PPC (P5 site) of the unaffected left
hemisphere, combined with conventional rehabilitation therapy
for 2 weeks and were followed up for 4 weeks. The scores for
two paper–pencil tests for visuospatial neglect (star cancellation
and line bisection tests) significantly improved after real stimula-
tion (but not after sham stimulation) by 21–37% at the end of 2-
week rTMS therapy and by 36–47% after 4-week follow-up.
A third research group also reported significant improvement of
neglect after cTBS of the left PPC (P3 site) (Nyffeler et al., 2009,
2019; Cazzoli et al., 2012), but they used a large circular coil (Mag-
Pro MC-125, 114 mm outer diameter) and a slightly different cTBS
protocol, consisting of 4 cTBS trains per session (two cTBS trains
separated by an interval of 15 minutes with the third and the
fourth trains delivered 60 and 75 min after the first one, respec-
tively). In a first study (Nyffeler et al., 2009), they showed that
the beneficial effect of a single session of 4 cTBS trains lasting for
more than 24 h in 11 patients with left-sided visuospatial neglect
at the postacute or chronic stage. Then they assessed the effect
of 8 trains of cTBS delivered over 2 consecutive days in 16 patients
with left-sided visuospatial neglect at the postacute stage (mean
Table 8
rTMS (cTBS) studies in hemispatial neglect (target: left posterior parietal cortex).
Articles Number of
patients
Target,
coil
type
Control
condition
Stimulation
frequency and
intensity
Number of
pulses/
session and
number of
sessions
Significant clinical effects of real versus sham
condition
Class
of
the
study
Fu et al. (2015) 20 (17–
114 days after
stroke) (real:
10, control:
10)
P5, F8c Tilted coil cTBS (3-pulse bursts
delivered at 30 Hz and
repeated at 5 Hz for
40 s), 80% RMT
4 cTBS trains
(15-min
interval), 14
sessions
Improvement in tests for visuospatial neglect
(star cancellation and line bisection tests) by
21–37% at the end of 2-week rTMS therapy and
by 36–47% after 4-week follow-up
III
Nyffeler et al. (2019) 30 (12–
1080 days
after stroke)
(real: 20,
control: 10)
P3, Cc Sham F8c cTBS (3-pulse bursts
delivered at 30 Hz and
repeated at 6 Hz for
44 s) 100% RMT
4 cTBS trains
(15 to 45-min
interval), 2 or
4 sessions
Improvement in the impact of neglect-related
deficits on the activities of daily life and in
various tests for visuospatial neglect up to
3 months after either 2 or 4 cTBS sessions
II
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controlled crossover study (Cazzoli et al., 2012): cTBS, but not
sham stimulation, significantly improved neglect (detection of
left-sided visual targets, paper-pencil assessment, and impact on
activities of daily living), with benefit lasting for at least 3 weeks.
Finally, in a third study of Class II (Nyffeler et al., 2019), they
showed that either 8 or 16 trains of cTBS delivered over 2 or 4 con-
secutive days reduced the impact of spatial neglect-related deficits
on the activities of daily life and improved several neuropsycholog-
ical neglect tests up to 3 months, in a series of 20 patients with left-
sided visuospatial neglect at the postacute stage (mean 22.9–
26.8 days post-stroke), compared to 10 patients stimulated for
only 2 days with a sham coil, which was a figure-of-8 coil (MagPro
MC-B70, 97 mm outer diameter). Moreover, cTBS significantly
improved global functioning after stroke and overall no significant
difference was observed according to the number of cTBS sessions
(either 2 or 4). Further analyses showed that the variability in the
response to cTBS was determined by the integrity of interhemi-
spheric connections within the corpus callosum (parieto-parietal
connections). In cTBS responders, in whom neglect and global
functioning were significantly improved, the corpus callosum
was intact, whereas this was not the case in cTBS non-responders.
Thus, three independent research groups have reported benefi-
cial results of the application of cTBS to the contralesional left PPC
in the treatment of visuospatial hemineglect in the post-acute
phase of stroke, but given various methodological differences (P3
or P5 site of stimulation, 30 Hz- or 50 Hz-cTBS trains, 2 or 4 trains
per session, and especially the use of a figure-of-8 or a circular
coil), the recommendation remains at Level C (‘‘possible efficacy”)
from these three Class II/III studies.
5. Multiple sclerosis
A PubMed search (keywords: (rTMS OR theta burst stimulation)
ANDmultiple sclerosis) identified 23 papers in the 2014–2018 per-Table 9
iTBS of M1 in multiple sclerosis.
Articles Number of
patients
Target, coil
type
Control
condition
Stimulation
frequency and
intensity
Azin et al. (2016) 36 RR patients
(real: 19;
sham: 17)
Left or right
(?) hand M1,
F8c
Tilted coil iTBS, 80% AMT
Korzhova et al.
(2019)
22 SP patients
(real: 12;
sham: 10)
Bilateral (?)
leg M1, F8c
Coil away
from the
head
iTBS, 80% MSOiod, but only 2 original sham-controlled studies of Class II with at
least 10 patients receiving real stimulation for several daily ses-
sions (Table 9).
The first study (Azin et al., 2016) assessed the effect of iTBS
delivered over the hand representation of the left M1 in a series
of 36 patients with remitting-relapsing multiple sclerosis (RR-
MS) (19 real, 17 sham). At the end of iTBS therapy consisting of
10 daily sessions performed over two weeks, there was an
improvement of manual dexterity only in the real iTBS group, as
revealed by a reduction in the time required to complete the
nine-hole peg test (9HPT) and an increased performance in the
Box-and-Block test (BBT) when compared to the sham group.
The second study (Korzhova et al., 2019) assessed the effect of
iTBS, but also HF-rTMS (20 Hz) delivered over the leg representa-
tion of both right and left M1 in 34 paraparetic patients with sec-
ondary progressive MS (SP-MS). The primary outcome was the
degree of lower limb spasticity measured on the Modified Ash-
worth Scale (mAS) and the Subjective Evaluating Spasticity Scale
(SESS). Following 10 daily sessions performed over two weeks,
spasticity was reduced up to 12 weeks after stimulation in patients
who received a real stimulation, especially iTBS. Conversely, reduc-
tion in pain and fatigue was found in the HF-rTMS group.
One additional sham-controlled study (of Class III) was pub-
lished on the application of iTBS of M1 to treat lower limb spastic-
ity in MS patients (Boutière et al., 2017). However, this study
included less than 10 patients in the real stimulation group and
therefore did not appear in Table 9. Boutière et al. (2017) assessed
the effect of real or sham iTBS targeted to the leg M1 area of one
hemisphere using image-guided neuronavigation in 17 patients
(9 real, 8 sham) with MS of RR or SP type (4 and 13 patients,
respectively). The iTBS protocol was performed during the first
13 working days of a 5-week rehabilitation program. At the end
of stimulation period, lower limb spasticity (measured on a VAS)
improved greater after real than sham iTBS at the end of the rTMS
therapy, with no differential lasting effects two weeks between theNumber of pulses/
session and number
of sessions
Significant clinical effects of real versus
sham condition
Class of
the
study
600 pulses (?), 10
sessions
Improved manual dexterity (9HPT and
BBT) at the end of the 2-week rTMS
protocol
II
1200 pulses, 10
sessions
Improved spasticity (mAS, SESS) at the
end of the 2-week rTMS protocol, lasting
at least 12 weeks beyond the last session
for the SESS score
II
J.-P. Lefaucheur et al. / Clinical Neurophysiology 131 (2020) 474–528 493two conditions. The beneficial effect on spasticity was associated
with a change in interhemispheric functional connectivity between
both motor cortices in resting-state fMRI.
Before 2014, two sham-controlled randomized studies with
parallel-arm design also assessed the effect of iTBS on lower limb
spasticity in MS patients (Mori et al., 2010, 2011). In the first study,
Mori et al. (2010) showed that iTBS applied 5 days a week for
2 weeks significantly improved spasticity assessed on the H/M
amplitude ratio and the mAS in the real iTBS group (10 patients),
but not in the sham group (10 patients), with benefit lasting for
one or two weeks beyond the last iTBS session. In the second study
(Mori et al., 2011), a significant improvement of spasticity assessed
on the mAS was also found after 10 sessions of real iTBS performed
alone (10 patients) or immediately prior to 2 hours of exercise
training (10 patients) over 2 weeks. No significant change occurred
in a control group of 10 patients who received sham stimulation. In
these two studies, issued from the same research group, iTBS was
targeted to only one hemisphere, as in Boutière et al. (2017), on the
leg representation of M1 contralateral to the most affected limb,
since spasticity predominated in one lower limb. In addition, only
patients with RR-MS type were enrolled. These were two major
differences with the study reported by Korzhova et al. (2019).
However, we may also consider a similar pathogenesis of spasticity
in all these studies, whether the involvement was predominantly
unilateral in RR-MS patients or bilateral in SP-MS patients with a
more advanced disease. Therefore, according to the beneficial
results reported in Class II studies issued from two independent
groups (Mori et al., 2010, 2011; Korzhova et al., 2019), not to men-
tion a positive Class III study of a third group (Boutière et al., 2017),
a Level B of evidence (probable efficacy) is reached for the use of
iTBS targeted to the leg motor cortex to treat lower limb spasticity
in patients with MS. Conversely, no recommendation can be made
for iTBS targeted to the hand motor cortex to improve manual
dexterity.
Finally, one study (Gaede et al., 2017) assessed the efficacy of a
non-focal HF-rTMS of the left prefrontal cortex (PFC) using an H6-
coil (1800 pulses/session delivered at 18 Hz and 120% of RMT) in
19 MS patients (9 real, 10 sham), while a third group of 9 MS
patients received a non-focal bihemispheric HF-rTMS over M1
regions using an H10-coil (800 pulses/session delivered at 5 Hz
and 90% of RMT). In this study, all patients had fatigue related to
RR-type of MS, except two patients with SP-MS. The stimulation
protocol consisted of 18 consecutive rTMS sessions over 6 weeks,
followed by a 6-week follow-up. A significant reduction in fatigue,
measured on the Fatigue Severity Scale (FSS), was observed only
after M1 stimulation at the end of the stimulation protocol, up to
the end of follow-up. Of course no recommendation can be made
concerning the use of an H-coil in MS, on the basis of this single
study.6. Epilepsy
A PubMed search (keywords: (rTMS OR theta burst stimulation)
AND epilepsy) identified 47 papers, but no original sham-
controlled studies with at least 10 patients receiving real
stimulation.
From 2014 to date, only one sham-controlled rTMS trial (Class
III) has been published in the domain of epilepsy (Seynaeve
et al., 2016). In this single-center, crossover study, 7 patients with
focal neocortical drug-resistant epilepsy received 3 treatments
consisting of 10 sessions of navigated rTMS delivered at 0.5 Hz
and 90% of RMT over the cortical focus (1500 pulses/session) by
means of a figure-of-8 coil, a round coil, or a sham coil. The primary
endpoint was the mean daily number of seizures, which did not
differ at baseline among the conditions. After LF-rTMS therapy,no difference in mean seizure rate was detected in any of the three
coil conditions compared to baseline or between any of these con-
ditions. In one patient, after an initial reduction of seizure fre-
quency, a rebound was even observed up to 20 weeks after the
end of the study. Thus, this ‘‘negative” study did not confirm pos-
itive meta-analytical findings of rTMS in epilepsy treatment (Hsu
et al., 2011). However, differences in the paradigm of rTMS inter-
ventions, the type and clinical profile of the epilepsy, or the num-
ber of antiepileptic drugs taken by each patient (e.g., up to 5 in
Seynaeve et al., 2016) are confounding factors to be taken into
account. Hence, the level of recommendation C for LF-rTMS in epi-
lepsy did not change. Finally, the acute administration of rTMS
trains to treat status epilepticus was not considered in the present
review because all published studies are case reports, including
less than 10 patients (Zeiler et al., 2015).7. Disorders of consciousness
A PubMed search (keywords: (rTMS OR theta burst stimulation)
AND disorders of consciousness OR minimally conscious state OR
unresponsive wakefulness syndrome OR vegetative state) identi-
fied 19 papers, but only one original sham-controlled studies with
at least 10 patients receiving real stimulation for several daily ses-
sions (Cincotta et al., 2015).
From 2014 to date, several Class III studies assessed the clinical
efficacy of rTMS in patients with disorder of consciousness (DOC),
including minimally conscious state (MCS) and unresponsive
wakefulness syndrome (UWS), which was previously called ‘‘vege-
tative state”. They used different approaches and targets; mostly
the left M1 (Cincotta et al., 2015; He et al., 2018; Liu et al., 2018)
and the left or right DLPFC (Naro et al., 2015; Xia et al., 2017a, b).
In a randomized, crossover, sham-controlled study of 11
chronic UWS patients (9 post-anoxic and 2 post-traumatic),
Cincotta et al. (2015) applied rTMS at 20 Hz and 90% of RMT to
the left M1 for 5 consecutive days. The stimulation pattern was
unusual, consisting of 100 blocks of 30-sec (5 trains of 1 sec with
5-sec intertrain), for a total of 1000 pulses/day. Compared to base-
line, no improvement was observed on either the JFK Coma Recov-
ery Scale-Revised (CRS-R) or the Clinical Global Impression of
Improvement (CGI-I) scale at the end of treatment, real or sham,
as well as one week or one month later. No further significant
changes were seen on EEG activity.
In two other comparable studies (He et al., 2018; Liu et al.,
2018), HF-rTMS of left M1 neither produced significant clinical
improvement in patients with DOC at overall group level, but indi-
vidual patients may have benefited from the procedure. In a sham-
controlled, crossover study of 6 patients with MCS or UWS, He
et al. (2018) showed that a 5-day protocol of 20 Hz rTMS delivered
over the left M1 produced a behavioral and neurophysiological
improvement in only one patient after the real rTMS stimulation,
measured on the CRS-R and EEG reactivity, respectively. The bene-
fit was still present one week after the last rTMS session. In another
sham-controlled, crossover study of 7 patients with MCS or UWS,
Liu et al. (2018) showed that the same 5-day protocol of 20 Hz
rTMS delivered over the left M1 also improved only one patient
clinically (on the CRS-R score) after the real rTMS stimulation.
The clinical benefit in consciousness was associated with an
enhanced functional connectivity in a frontotemporoparietal
network.
The other assessed target was the DLPFC. In a pilot study, Naro
et al. (2015) found that a single session of 10 Hz rTMS (10 trains of
10 sec with 60-sec intertrain, for a total of 1000 pulses) delivered
over the right DLPFC (F4 site) did not produce any significant clin-
ical change (measured on the CRS-R score) at group level. However,
this session may have improved conscious motor behavior in 3/10
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enhanced cortical excitability (measured by single- and paired-
pulse TMS methods) and a partially restored pattern of cortico-
cortical interactions (assessed by dual-coil TMS).
Another research group assessed the value of HF-rTMS, but
delivered over the left DLPFC in studies with an open-label design
(Xia et al., 2017a, b). In a series of 16 patients (5 MCS and 11 UWS)
who underwent 20 consecutive days of stimulation, the impact of
the treatment was clinically significant at group level on the CRS-R
score measured 10 days after the last rTMS session compared to
baseline (Xia et al., 2017a). The clinical benefit was significant from
the half of the course of the stimulation protocol in the 5 MCS
patients who all improved (although remaining in MCS condition),
but not in the UWS patients, of whom only 4 benefited from the
procedure, three of them switching to a MCS condition. On a
CGI-I scale rated by the caregivers, 10 patients improved (mini-
mally to considerably), 6 patients remained stable, and none wors-
ened (Xia et al., 2017a). In a satellite work, the same authors
provided some EEG correlates of the effect of HF-rTMS of the left
DLPFC in patients with DOC, i.e. an EEG signal power reduced in
the low-frequency bands and increased in the high-frequency
bands (Xia et al., 2017b).
Finally, one study was published in which an iTBS protocol (600
pulses/session delivered at 80% of AMT) was delivered over the left
DLPFC for 5 consecutive days in a series of 8 patients with MCS or
UWS (Wu et al., 2018). At the end of the 5-day iTBS protocol, the
CRS-R scores increased in all 4 patients with MCS and in 3 out of
4 patients with UWS, with a level of consciousness rising to emer-
gence and MCS, respectively. The clinical benefit was only at the
limit of statistical significance one week after the last rTMS session.
On EEG assessment, rTMS was found to increase power in the alpha
band, especially in a frontoparietal network. However, this study
was not sham-controlled.
In conclusion, although a clinical benefit on the level of con-
sciousness has been reported after HF-rTMS of the left M1 in some
individuals or after HF-rTMS or iTBS of the left DLPFC at group level
(but in open-label studies), all published series are characterized
by a too small sample size to propose any level of evidence or to
make any recommendation for the use of rTMS in patients with
chronic DOC. Therefore, the therapeutic efficacy of non-invasive
brain stimulation procedures remains matter of debate in this clin-
ical condition and in any case, future studies could benefit from
various neurophysiological techniques, such as evoked potentials,
event related potentials, or TMS-EEG co-registration to objectively
evaluate the impact of the intervention (Ragazzoni et al., 2017;
André-Obadia et al., 2018b).8. Mild cognitive impairment and Alzheimer’s disease
A PubMed search (keywords: (rTMS OR theta burst stimulation)
AND mild cognitive impairment OR Alzheimer’s disease) identified
86 papers, including 6 original sham-controlled studies with at
least 10 patients receiving real stimulation for several daily ses-
sions in the context of mild cognitive impairment (MCI)
(Drumond Marra et al., 2015) or Alzheimer’s disease (AD)
(Rutherford et al., 2015; Wu et al., 2015; Lee et al., 2016; Zhao
et al., 2017; Koch et al., 2018).8.1. HF-rTMS of the left DLPFC
In sham-controlled study of Class II including 34 patients with
MCI diagnosed for at least one year, Drumond Marra et al. (2015)
applied 10 Hz rTMS at 110% of RMT over the left DLPFC defined
as located 5 cm anterior to the hand motor hot spot. It is worth
mentioning that this distance is known to be too short to correctlydefine the anatomical location of the DLPFC (Herwig et al., 2001;
Fitzgerald et al., 2009b; Ahdab et al., 2010). The rTMS protocol con-
sisted in 10 sessions over two weeks with 2000 pulses/session,
underwent by 15 patients in real condition and 19 patients in sham
condition. No adjunctive cognitive rehab was carried out during
the trial. The primary objective was the improvement of everyday
and episodic memory, assessed by the Rivermead Behavioural
Memory Test (RBMT). At the end of the rTMS protocol, up to one
month after the last session, the RBMT score improved (i.e.,
increased) in the real stimulation group more than in the sham
group, while secondary variables, such as logical, auditory-verbal,
and working memory functions, cognitive functions, assessed by
the Mini-Mental State Examination (MMSE), executive functions,
assessed by the Trail Making Test (TMT), or verbal fluency did
not change after real rTMS.
A second sham-controlled study of Class III with a crossover
design (Padala et al., 2018) included only 8 MCI patients who
received 10 Hz-rTMS at 120% of RMT over the left DLPFC defined
as located 5.5 cm anterior to the hand motor hot spot (10 sessions
over two weeks with 3000 pulses/session). The primary objective
was the improvement of apathy, assessed on the Apathy Evalua-
tion Scale-Clinician version (AES-C). At the end of the rTMS proto-
col, the AES-C score improved (i.e., decreased) in the real
stimulation group more than in the sham group and the difference
was considered clinically meaningful. In addition, several changes
in secondary variables also favored the real rTMS condition, with a
benefit observed on cognitive and executive functions, assessed on
the MMSE and TMT, respectively.
These results remain insufficient to propose any statement
regarding a given level of evidence for HF-rTMS of the left DLPFC
in patients with MCI. A similar protocol was also proposed in
patients with AD.
In a sham-controlled study of Class II, Wu et al. (2015) applied
20 Hz-rTMS at 80% of RMT over the left DLFPC (probably defined
according to the 5 cm-rule) for a total of 20 sessions (5 sessions/
week for 4 consecutive weeks) in 52 patients with AD (26 real,
26 sham). The rTMS protocol (real or sham) was performed con-
comitantly with the administration of low doses of risperidone,
an atypical antipsychotic. The primary objective was the improve-
ment of behavior, assessed on the Behavioral Pathology in Alzhei-
mer’s Disease Rating Scale (BEHAVE-AD). At the end of the rTMS
protocol, the BEHAVE-AD score improved (i.e., decreased) in the
real stimulation group more than in the sham group, especially
on 5 subscale scores, i.e., activity disturbances, diurnal rhythm dis-
turbances, aggressiveness, affective disturbances, and anxiety or
fear. In terms of clinically meaningful individual responses (at least
30% reduction of the BEHAVE-AD score), the real rTMS condition
provided 73% of responders (19/26 patients), whereas the sham
rTMS provided 42% of responders (11/26 patients). Cognitive func-
tions, assessed on the Alzheimer’s Disease Assessment Scale-
Cognitive Subscale (ADAS-Cog), also improved with a significant
decrease of the ADAS-Cog total score after real rTMS.
In a sham-controlled study of Class III with a crossover design
(Rutherford et al., 2015), 10 patients with AD received 20 Hz-
rTMS at 90–100% of RMT over both the right and left DLPFC defined
by using measurements from anatomical landmarks (DaSilva et al.,
2011). The protocol consisted of 13 sessions over four weeks with
2000 pulses to each of the right and left hemispheres/session. The
primary objective was the improvement of cognitive functions,
assessed by the Montreal Cognitive Assessment (MoCA) and the
ADAS-Cog. No significant difference between the real and sham
conditions was observed on these scales at the end of the 4-week
rTMS protocol, but the MoCA score improved (i.e., increased) dur-
ing the rTMS protocol at weeks 2–3, only in the real stimulation
condition. Clinical benefit was prolonged by 2 additional weeks
of treatment, however performed using an open-label design, and
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result is in line with previous studies showing prodromal alter-
ation of cortical excitability early in the course of the disease
(Nardone et al., 2013, 2014). In this regard, the degree of grey mat-
ter atrophy in AD-related brain regions may contribute to variabil-
ity of rTMS-induced cognitive after-effects, at least if delivered to
the superior temporal gyrus (STG) (Anderkova et al., 2015). There-
fore, future studies should focus particularly on early stage of AD,
which can be better identified using a combination of various
biomarkers (McKhann et al., 2011).
As for patients with MCI, the results reported with HF-rTMS of
the left DLPFC remains insufficient to make any recommendation
regarding a therapeutic application of such a procedure for
patients with AD. Finally, regarding types of dementia other than
AD, only preliminary data can be mentioned, i.e. two reports of
the beneficial effects on cognitive performance or linguistic skills
of bilateral DLPFC HF-rTMS using a figure-of-8 coil in an open-
label study of 7 patients with frontotemporal dementia and 2
patients with primary progressive aphasia (Antczak et al., 2018)
or using a H-coil in one patient with primary progressive aphasia
(Trebbastoni et al., 2013).
8.2. HF-rTMS of the precuneus
A more recent study (Koch et al., 2018) assessed the value of an
rTMS protocol aimed at stimulating the precuneus, i.e. the medial
aspect of the superior parietal lobule, involved in episodic memory,
visuospatial processing, and various aspects of consciousness,
probably through its engagement in large-scale neural networks,
such as the default mode network (DMN) and its strong connection
with hippocampus. In healthy subjects, a single session of iTBS of
the left superior parietal lobule can significantly increase resting-
state connectivity in the dorsal attention network and lead to pos-
itive cognitive after-effects (Anderkova et al., 2018), while 5 ses-
sions of HF-rTMS targeting another DMN node (the left inferior
parietal lobule) can significantly improve a memory association
task (Wang et al., 2014c).
In the above mentioned sham-controlled study of Class II with a
crossover design (Koch et al., 2018), 14 patients at an early stage of
AD received 20 Hz-rTMS at 100% of RMT over the left precuneus
region defined by image-guided navigation (10 sessions over two
weeks with 1600 pulses/session). The primary objective was the
improvement of cogntive functions, assessed by the Alzheimer Dis-
ease Cooperative Study Preclinical Alzheimer Cognitive Composite
(ADCS-PACC) test battery. At the end of the 2-week rTMS protocol,
a selective improvement in episodic memory but not in other cog-
nitive domains was found in the real condition, as compared to
sham stimulation. A modification of functional connections
between the precuneus and medial frontal areas within the
DMN, as well as an enhancement of beta-rhythm activity in the
precuneus, were revealed by a combined TMS-EEG approach. This
original targeting strategy, based on the known alteration of func-
tional connectivity within the DMN and other cognitive networks
at very early stages of AD (Palmqvist et al., 2017) remains to be fur-
ther studied by other research groups.
8.3. Multisite HF-rTMS
In the domain of AD, which includes multiple aspects of cogni-
tive dysfunction and problems with memory, language, tem-
porospatial orientation, motivation, self-care, or behavior,
multisite rTMS strategies may theoretically provide more benefits
than single-site rTMS strategies. Conversely, one study showed
that a simple 5 Hz-rTMS protocol targeting only the left DLPFC
could produce similar clinical improvement in AD patients com-
pared to a multisite rTMS protocol stimulating six cortical regionsof interest (Alcalá-Lozano et al., 2018). In this study, 19 AD patients
were randomized to receive one of these protocols (10 patients for
single-site rTMS of the left DLPFC vs. 9 patients for multisite rTMS)
over 3 weeks. The clinical improvement (measured on the ADAS-
Cog and MMSE scores) was similar in both groups and maintained
at least for 4 weeks after the intervention. These authors explained
their result by the large-scale structural and functional connectiv-
ity of the left DLFPC with a variety of brain structures potentially
involved in the pathophysiological progression of AD (Alcalá-
Lozano and Garza-Villarreal, 2018).
However, the multisite rTMS procedure performed by Alcalá-
Lozano et al. (2018) did not use neuronavigation targeting and
was not combined with cognitive training. Indeed, multisite rTMS
protocols gain in evidence in the treatment of AD, especially when
combined navigated rTMS with cognitive training. A specific
approach, usually called rTMS-COG therapy, consists in delivering
rTMS trains over different cortical targets for priming cognitive
training tasks during a sequential program of treatment. This type
of therapeutic protocol has been formalized and structured in the
NeuroAD System (Bentwich et al., 2011).
In a sham-controlled study of Class II (Lee et al., 2016), 26
patients with probable AD (18 real, 8 sham) received 5 sessions
of rTMS-COG therapy per week for 6 consecutive weeks. Each ses-
sion consisted of a combination of active cognitive training and
rTMS delivered over three different cortical regions targeted using
an image-guided navigation system. Thus, on alternate days, either
Broca’s area, Wernicke’s area, and the right DLPFC (days 1, 3, and 5)
or the left DLPFC and both parietal somatosensory association cor-
tices (PSAC) (days 2 and 4) are stimulated during the daily session.
For each stimulated cortical target, the protocol consisted of a ser-
ies of 20 trains of 10 Hz-rTMS of 2 seconds (20 pulses/train deliv-
ered at 90–110% of RMT with a figure-of-8 coil under
neuronavigation) followed by 40 seconds of specific cognitive tasks
performed between each 2-sec train of 10 Hz-rTMS. The patients
performed cognitive tasks displayed on a touch screen in front of
them, with a level of difficulty adjusted to their cognitive perfor-
mance assessed in the preceding sessions. The cognitive tasks dif-
fered according to the stimulated cortical region, including syntax
and grammar tasks for Broca’s area, comprehension of lexical
meaning and categorization tasks for Wernicke’s area, naming of
actions and objects, word recall and spatial memory tasks for both
DLPFC areas, and spatial attention tasks for shapes and letters for
both PSAC areas. Thus, for each cortical target, the protocol
resulted in 400 rTMS pulses priming cognitive training for about
15 min and since each session included 3 targets, the whole session
lasted less than one hour with a total of 1200 rTMS pulses deliv-
ered per day over the brain. In the study of Lee et al. (2016), no
time  group interaction emerged at the end of the 6-week treat-
ment and after 6-week follow-up regarding the ADAS-Cog score
(primary endpoint), but the patients who received real rTMS
improved significantly more than those who were in the sham
group in the domains of memory and language, especially patients
with mild AD. The improvement (decrease) in the ADAS-Cog score
provided by real rTMS-COG therapy in patients with mild AD
(5.5) was twice as much as usually observed with cholinesterase
inhibitors in comparable AD patients over 6 months (2.7).
Before 2014, another sham-controlled study, but including less
than 10 patients in the real rTMS group (Class III), had been pub-
lished using the same procedure (Rabey et al., 2013). In this study,
15 AD patients were randomized to receive real (7 patients) or
sham (8 patients) rTMS-COG therapy. The improvement (decrease)
in the ADAS-Cog score was significantly better in the real condition
group (3.8) than in the sham group (0.5) at the end of the 6-
week protocol. A maintenance treatment was performed with 2
sessions of one hour per week for 3 months. At the end of
follow-up (4.5 months after treatment initiation), the clinical ben-
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condition group (3.5) than in the sham group (+0.4). The Clinical
Global Impression of Change (CGIC) was in favor of a mild
improvement in the real condition group (3.6 on the 7-point Likert
scale) and mild worsening in the sham group (4.3).
Still using the same approach, several open-label studies have
been published (Class IV). For example, the same researchers as
for the aforementioned sham-controlled study published their
experience in 30 patients with mild-to-moderate AD (Rabey and
Dobronevsky, 2016). At the end of the 6-week treatment, patients
improved regarding both ADAS-Cog (2.4) and MMSE (+1.7)
scores. In 5 patients who were reevaluated at 10 months from
treatment initiation and in whom the ADAS-Cog score was
returned to baseline, a second rTMS-Cog protocol treatment
allowed the same benefit to be obtained as after the first treatment
(2.4).
Another group reported the results obtained by performing real
rTMS-COG therapy for 5 consecutive weeks in 10 patients with AD
(Nguyen et al., 2017). In addition to the combination of rTMS and
cognitive training above described, a short series of 5 trains of 20
pulses at 10 Hz (100 pulses/session) was delivered everyday over
the left or right DLPFC combined with a ‘‘word recall’’ training,
for promoting episodic memory recovery (Rossi et al., 2001). The
primary endpoint of the study was improvement of the ADAS-
Cog score, which was reached at the end of intervention (2.9),
but not at 6-month follow-up, with the exception of 5 ‘‘best
responders” in whom the clinical benefit was maintained (ADAS-
Cog score: 2.5 compared to baseline). Then, the 5 ‘‘poor respon-
ders” of this study received two additional weeks of rTMS-COG
therapy between 6 and 12 months after the initial treatment and
these additional sessions clearly reduced the progression slope of
cognitive decline in these patients (Nguyen et al., 2018). Apathy
and dependence scores, as secondary endpoints, also improved
after rTMS-COG therapy in this work. Conversely, no adverse
events occurred, including no seizure, while these patients are
known to have a low epileptogenic threshold.
Zhao et al. (2017) also applied multisite rTMS therapy com-
bined with cognitive tasks for 6 weeks (1 session/day and 5 days/
week for total of 30 sessions) in 30 patients diagnosed with mild
or moderate AD (17 real, 13 sham). However, the protocol was
frankly different from that of the NeuroAD System with a lot of
ambiguous statements. The authors report a series of 20 trains of
20 Hz-rTMS of 10 seconds (200 pulses/train delivered at unknown
intensity with unknown coil type) followed by only 20–40 seconds
of specific cognitive tasks performed between rTMS trains, while
intertrain interval was reported to last only 20 seconds. In this arti-
cle, the cognitive tasks are not described and more importantly, the
stimulated areas are reported to include only four parietal and
temporal regions, defined as P3/P4 and T5/T6 according to the
10–20 EEG System, while the authors considered ‘‘three brain
areas” to be targeted and stimulated separately in each session.
No significant time  group interaction was observed in the whole
series of patients at the end of the 6-week treatment and at 6-week
follow-up for any of the neuropsychological tests performed in this
study. However, in the 20 patients with mild AD, defined by a
MMSE score  21, clinical improvement was significantly better
at 6-week follow-up in the real condition group (12 patients) than
in the sham group (8 patients), regarding ADAS-Cog (6.4), MMSE
(+4.1), MoCA, and World Health Organization University of
California-Los Angeles Auditory Verbal Learning Test (WHO-UCLA
AVLT) scores.
In conclusion, taking into account at least one Class II and one
Class III study, a Level C of Evidence is reached to consider that
multisite rTMS-COG is possibly effective to improve apathy, cogni-
tive function, memory, and language in AD patients, especially at a
mild/early stage of the disease. Clinical use of this type of treat-ment requires additional observational studies to confirm that
the long-term effect of multisite rTMS-COG may actually exceed
that of rTMS over a given region of interest. In addition, various
imaging and/or neurophysiological techniques should be
employed to provide an objective readout and improve our under-
standing of the neural basis of the effects induced by multisite
rTMS (Sale et al., 2015; Bergmann et al., 2016).9. Tinnitus
A PubMed search (keywords: (rTMS OR theta burst stimulation)
AND tinnitus) identified 59 papers, including 11 original sham-
controlled studies with at least 10 patients receiving real stimula-
tion for several daily sessions (Langguth et al., 2014; Yilmaz et al.,
2014; Bilici et al., 2015; Folmer et al., 2015; Schecklmann et al.,
2016; Wang et al. 2016b; Cacace et al., 2017; James et al. 2017;
Landgrebe et al., 2017a; Sahlsten et al., 2017; Formánek et al.,
2018).9.1. LF-rTMS of the auditory cortex
The usual rTMS procedure to treat chronic tinnitus is to apply
LF-rTMS over the auditory temporal cortex of the left hemisphere
or contralateral to the most affected ear (Table 10). The rationale
of this approach is to reduce a possible hyperactivity of the audi-
tory cortex. Indeed, in one sham-controlled crossover study
(Cacace et al., 2017), 25 patients with chronic tinnitus received 5
daily sessions of real and sham 1 Hz-rTMS (separated by a wash-
out period of 2–5 weeks) delivered on the left temporal lobe (half-
way between T3 and T5 site of the 10–20 EEG System). The clinical
efficacy of real LF-rTMS on tinnitus loudness (measured psychoa-
coustically) and self-perceived changes in the Tinnitus Handicap
Questionnaire (THQ) (including the Social-Emotional-Behavioral
subscale), was highly correlated with a down-regulation of excita-
tory glutamate contents in the stimulated area (left auditory cor-
tex), assessed by single voxel proton magnetic resonance
spectroscopy (1H-MRS).
Two large randomized sham-controlled studies (Folmer et al.,
2015; Landgrebe et al., 2017a) investigated the effects of 10 days
of 1 Hz-rTMS delivered over the left temporal lobe, with the
figure-of-8 coil centered on a point located 1.5 cm posterior to
the midline of the T3-C3 line, as initially described by Langguth
et al. (2006). One of these studies was positive (Folmer et al.,
2015), but only half of the patients were stimulated on the above
described left hemisphere target, whereas the other half were
stimulated on the homologous temporal target of the right hemi-
sphere. In this study, 64 patients were equally randomized in the
real and sham stimulation groups to receive 2,000 pulses per ses-
sion on 10 consecutive workdays. Results were analyzed according
to the percentage of responders on the Tinnitus Functional Index
(TFI) at the end of the treatment, which was higher in the real stim-
ulation group (56%) than in the sham group (22%). In contrast, no
significant difference between real and sham rTMS was found in
the study of Landgrebe et al. (2017a), including 146 patients with
chronic tinnitus, all stimulated over the left auditory cortex. In this
study, no significant difference in the change in the sum score of
the Tinnitus Questionnaire compared to baseline was found
between a group of 71 patients who received the real treatment
and 75 patients who were treated by sham stimulation.
As discussed in the literature (Folmer, 2017; Landgrebe et al.,
2017b), potential explanations for this discrepancy may be related
to differences in: (i) patients’ sample characteristics (e.g., regarding
age, disease duration, or hearing loss level); (ii) laterality of the
stimulation side (left hemisphere only in Landgrebe et al. (2017a)
vs. either right or left temporal cortex in Folmer et al. (2015));
Table 10
LF-rTMS of the auditory cortex in chronic tinnitus.
Articles Number of patients Target, coil type Control condition Stimulation
frequency
and
intensity
Number of
pulses/
session and
number of
sessions
Significant clinical effects of real versus sham
condition
Class
of
the
study
Langguth et al. (2014) 139 (real: 95; sham:
44)
Post-T3-C3-line target (real, n = 48) or
navigated target on the region of the most
increased PET activation within the left
auditory cortex (real, n = 47 or sham,
n = 44), F8c
Sham coil 1 Hz, 110%
RMT
2000 pulses,
10 sessions
No significant reduction of average TQ score between real
and sham treatment, but more responders on the TQ
score after targeting the post-T3-C3 site only (real: 38%,
sham: 13%) at the end of 2-week rTMS protocol
I
Yilmaz et al. (2014) 60 (real: 30; sham:
30)
Target not specified, F8c Sham not specified 1 Hz,
intensity not
specified
1800 pulses,
10 sessions
Significant reduction in THI score and tinnitus loudness
one month after real rTMS
III
Bilici et al. (2015) 60 (real rTMS alone/
+paroxetine: 15/15;
paroxetine alone: 15;
sham rTMS alone:
15)
Left TPC, Cc Sham coil 1 Hz, 110%
RMT
900 pulses,
10 sessions
Improvement of the THI score 2 weeks to 6 months after
the end of the 2-week rTMS protocol alone, and only at 6
moths in case of paroxetine intake. No effect on the TSI
score, except if combined with paroxetine
III
Folmer et al. (2015) 64 (real: 32;
sham:32)
Post-T3-C3-line target, F8c Sham coil 1 Hz, 110%
RMT
2000 pulses,
10 sessions
More responders on the TFI score at the end of 2-week
rTMS protocol (real: 56%, sham: 22%) and significant
reduction of average TFI score after real (vs. sham) rTMS
at 1 and 2 weeks and especially 26 weeks after rTMS
intervention
I
Wang et al. (2016b) 24 (real: 14; sham:
10)
Halfway between T5 and C3, F8c Coil away from the
head
1 Hz, 110%
RMT
1000 pulses,
10 sessions
More responders in terms of reduction in tinnitus
annoyance (assessed on a VAS) and loudness (evidenced
by gaps in noise detection) at the end of 2-week rTMS
protocol (with positive correlation between these score
reductions)
III
Cacace et al. (2017) 25 (crossover) Halfway between T3 and T5, F8c Sham coil 1 Hz 110%
RMT
1200 pulses,
5 sessions
Reduction in tinnitus loudness level and THQ score at the
end of 1-week rTMS protocol
III
James et al. (2017) 12 (crossover) Navigation-defined STG opposite to
tinnitus side if unilateral or left STG if
bilateral, F8c
Realistic sham coil
procedure
1 Hz 110%
RMT
1800 pulses,
4 sessions
Improved tinnitus awareness, annoyance and loudness at
the end of 1-week rTMS protocol
III
Landgrebe et al. (2017a) 146 (real: 71; control
75)
Post-T3-C3-line target, F8c Tilted coil 1 Hz 110%
RMT
2000 pulses,
10 sessions
No significant difference between real and sham
treatment (TQ sum score, quality of life)
I
Sahlsten et al. (2017) 39 (real: 19; control
20)
Navigation-defined left STG, targeted
roughly according to the tonotopic
presentation of tinnitus pitch, F8c
Coil away from the
head (a 15-cm
plastic block being
attached under the
coil)
1 Hz, 100%
RMT
4000 pulses,
10 sessions
No significant difference between real and sham
treatment (Tinnitus intensity, annoyance, distress and
THI scores). Trend towards more responders (real: 42–
37%, sham: 15–10%) at 1 to 3 months after rTMS
intervention
II
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tions, such as in pain domain (André-Obadia et al., 2008;
Lefaucheur et al., 2010)); (iv) magnetic stimulator type (efficiency
and direction of the current induced in the cortex differ according
to manufacturers (Kammer et al., 2001; Thielscher and Kammer,
2004)); (v) outcome measures (TQ sum score in Landgrebe et al.
(2017a) vs. percentage of responders on TFI in Folmer et al. (2015)).
A large open-label study with 289 participants aimed at identi-
fying the clinical predictors of LF-rTMS delivered over the left tem-
poroparietal cortex (TPC) (10 sessions over 2 weeks, 1000 pulses/
session) for chronic tinnitus treatment (Wang et al., 2016a). Signif-
icant tinnitus suppression (reduced loudness on VAS score) corre-
lated with normal hearing level, absence of sleep disturbance, and
shorter tinnitus duration (less than one year). Another open-label
study even assessed the effects of rTMS in a series of 34 patients
with sudden hearing loss and acute tinnitus (Zhang and Ma,
2015). The protocol consisted of 20 sessions of 1 Hz-rTMS deliv-
ered over 4 weeks (1200 pulses/session) to the temporoparietal
junction (TPJ) ipsilateral to the symptomatic ear. Both hearing
function and tinnitus perception improved after rTMS, as com-
pared to patients who did not receive rTMS treatment. In this
study, rTMS was performed in addition to standard corticosteroid
and hyperbaric oxygen therapy. One further sham-controlled trial
with limited specifications of methods showed reductions in Tinni-
tus Handicap Inventory (THI), tinnitus loudness and tinnitus sub-
jective scores for the real stimulation condition (30 patients) but
not the sham group (30 patients) (Yilmaz et al., 2014).
Two studies aimed at determining the most efficacious stimula-
tion protocol using LF-rTMS over the left auditory cortex. First, Lo
et al. (2014) compared the effect of 5 sessions based on 1000 vs.
2000 pulses/session in 28 tinnitus patients equally randomized.
They did not find any difference related to the number of pulses/
session in the reduction of tinnitus assessed on the Tinnitus Hand-
icap Inventory (THI) rating scale, up to 4 weeks after the interven-
tion. Second, Lehner et al. (2015) addressed the issue of
maintenance therapy in an open-label study of 55 patients who
underwent 2 rTMS protocols over 10 days separated by several
months. The more patients worsened between both treatment
courses, the more they improved after the second treatment, sug-
gesting that the repeated application of rTMS protocols may be
useful in the therapeutic management of patients with tinnitus,
regardless of the response to the first treatment course. Long-
term efficacy was also assessed in one open-label study of a small
sample of 8 patients (Labar et al., 2016). The rTMS protocol con-
sisted of weekly perfomed 1 Hz-rTMS sessions applied to the TPJ
over 5 weeks and then monthly sessions for the next five months.
Significant tinnitus reduction was observed in 4 of 8 patients at
week 5, but only in 1 patient at the end of follow-up (7 months).
One important issue is to determine the optimal target location
for enhancing the efficacy of LF-rTMS of the auditory cortex. One
research group compared the effects of 1 Hz-rTMS (600 pulses
per daily session for 5–10 days) delivered over the TPC, either con-
tralaterally or ipsilaterally to the symptomatic ear, in 40 patients
(Kim et al., 2014b) and 61 patients (Kim et al., 2014c), respectively,
with unilateral tinnitusà. These authors found a similar benefit in
the THI and VAS scores for tinnitus loudness, awareness, and
annoyance for the two approaches both immediately after treat-
ment (Kim et al., 2014b) and at follow-up visits one and six months
later (Kim et al., 2014c). Thus, the laterality of LF-rTMS application
could be not a decisive factor in relieving tinnitus, as also sug-
gested by the results reported in the study of Folmer et al. (2015).
Another point is to precisely define the target location within
the auditory cortex. One randomized study (Noh et al., 2017b)
showed that tinnitus was similarly improved by 1 Hz-rTMS deliv-
ered over the left auditory cortex when anatomically targeted with
an image-guided navigation system or defined as posterior to theT3-C3 line, i.e. based on the 10–20 EEG System, according to
Langguth et al. (2006). Another randomized study came up with
the same conclusion that navigated rTMS was not superior over
non-navigated rTMS (Sahlsten et al., 2019). In this latter study,
chronic tinnitus improved significantly in both rTMS groups, and
treatment response was even better in the non-navigated group
regarding tinnitus intensity reduction.
The same research group attempted to optimize rTMS targeting,
based on the known tonotopy of the auditory cortex in the superior
temporal gyrus (STG), where higher frequencies are represented
posteriorly and lower frequencies anteriorly (Sahlsten et al.,
2015, 2017). Using an MRI-guided neuronavigation system that
visualizes electric field (in V/m) induced by TMS pulses into the
brain, these authors determined the location of rTMS target within
the left STG roughly according to the tonotopic representation of
tinnitus pitch in each individual patient. After an open-label pilot
study based on 13 patients with very severe tinnitus symptoms
(Sahlsten et al., 2015), a series of 39 tinnitus patients was investi-
gated in a sham-controlled study based on 10 daily rTMS sessions
over 2 weeks with a 6-month follow-up (Sahlsten et al., 2017). The
session protocol was extraordinarily long, consisting of 4000
pulses delivered at 1 Hz over 1 hour. This latter study revealed sig-
nificant beneficial effects of rTMS on the THI and VAS scores for
tinnitus intensity, distress, and annoyance but no differences
between real and sham stimulation groups beyond one month
after stimulation period, possibly due to a large placebo effect
and wide inter-individual variability.
In contrast, a large, non-focal stimulation was applied in one
sham-controlled study for 10 days using a circular coil to deliver
rTMS at 1 Hz or 10 Hzover the left temporal lobe, possibly com-
bined with paroxetine (Bilici et al., 2015). This study showed an
improvement on the THI score at 1- and 6-month follow-up after
both real 1Hz- and 10Hz-rTMS, but not after the sham procedure.
The Tinnitus Severity Index (TSI) score also frankly improved at
6-month follow-up after HF-rTMS, but not after LF-rTMS.
Finally, one sham-controlled study (Wang et al., 2015) com-
pared the respective efficacy of neuronavigation-guided LF-rTMS
protocols delivered over the left TPC and a region defined by
high-density EEG source analysis (10 sessions over 2 weeks, 1000
pulses/session). This study enrolled 21 patients with tonal tinnitus
and no hearing loss (7 patients in each experimental group: real
rTMS of the left TPC or EEG-defined target, or sham rTMS). Signif-
icant reduction of tinnitus severity and loudness (measured on the
THI and a VAS) was observed at the end of the 2-week rTMS proto-
col, but significantly more marked in the group of patients stimu-
lated over the target defined by EEG source analysis. This target
site was mostly located in the right orbitofrontal cortex (BA 11).
Another study further showed that the grey matter volume mea-
sured in the orbitofrontal cortex at baseline correlated with clinical
improvement observed after LF-rTMS delivered for 10 days over
the left temporal cortex in a series of 77 tinnitus patients (Lehner
et al., 2014). It was also found that a single session of LF-rTMS over
the left temporal cortex (posterior to T3-C3 line, according to
Langguth et al. (2006)) was able to modulate resting-state EEG
oscillatory activity in frontal cortical regions, increasing the high-
to-low frequency power ratio (Schecklmann et al., 2015). The same
group, in a large series of 116 patients with chronic tinnitus,
showed that the improvement of tinnitus (assessed on the TQ
score) induced by a 10-day protocol of LF-rTMS applied to the left
auditory cortex was associated with a significant reduction in
short-interval intra-cortical inhibition (SICI), reflecting a modula-
tion of GABAergic transmission in the left motor frontal area
(Schecklmann et al., 2014b). Thus, LF-rTMS delivered to the audi-
tory cortex is surely able to modulate a large-scale brain network.
Two studies assessed methodological variants of the inhibitory
stimulation of the left auditory cortex. First, Thabit et al. (2015)
J.-P. Lefaucheur et al. / Clinical Neurophysiology 131 (2020) 474–528 499studied combination of LF-rTMS of the left TPC and a ‘‘peripheral”
stimulation, consisting of direct cochlear low-level laser therapy
(LLLT) associated with laser acupuncture applied to the affected
ear(s) in a 10-day protocol. These authors showed in a series of
30 patients with chronic tinnitus that only this combination of
treatment, but not LF-rTMS or LLLT applied alone, was able to
reduce tinnitus severity, assessed on THI and a VAS, up to 4 weeks
after the end of the treatment.
Second, in a sham-controlled trial, Schecklmann et al. (2016)
assessed the value of a cTBS protocol delivered over the left audi-
tory cortex. These authors did not find superior effects of 10 ses-
sions of real cTBS versus sham stimulation in a series of 23
patients (12 real, 11 sham), despite significant changes in sound-
evoked brain oxygenation at the site of stimulation measured by
near-infrared spectroscopy (NIRS) (Schecklmann et al., 2014a).
Finally, one sham-controlled crossover study aimed at identify-
ing neuronal markers as predictors for treatment outcome of rTMS
(4 daily sessions over one week, 1800 pulses/session) delivered to
the STG in 12 patients with tinnitus (James et al., 2017). In this
study, real rTMS was delivered at 1 Hz or 10 Hz over the hemi-
sphere opposite to tinnitus or the left hemisphere in case of sym-
metrical bilateral tinnitus. The greatest clinical effect of rTMS
was observed on tinnitus awareness (-16% compared to baseline,
assessed on a VAS) after both 1 Hz- and 10 Hz-rTMS, while tinnitus
annoyance and loudness were more slightly reduced (-7/11%, also
assessed on a VAS), but only significantly after 1 Hz-rTMS. In addi-
tion, patients underwent fMRI while performing an attentional
conflict task, the Multi-Source Interference Task (MSIT), before
and after rTMS treatment. A greater recruitment of bilateral pre-
frontal and parietal regions by MSIT at baseline corresponded with
poorer treatment response, while activity changes in the left DLPFC
explained the greatest reduction in tinnitus awareness following
1 Hz stimulation. Thus, a predominant effect of LF-rTMS of STG
on tinnitus awareness may relate to change in attentional process-
ing due to the connections between the STG and regions of the pre-
frontal cortex that mediate attention. This study paved the way for
considering the left DLPFC as a potential rTMS target to treat
tinnitus.
9.2. HF-rTMS of the left DLPFC
The therapeutic value of HF-rTMS of the left DLPFC as a single-
site protocol in chronic tinnitus was not supported by one recent
study. Noh et al. (2017a) compared HF-rTMS of the left DLPFC per-
formed alone vs. combined with LF-rTMS delivered to the left audi-
tory cortex in a protocol consisting of 3000 pulses delivered per
session for 4 days in both conditions. The improvement in THI
score was significant for the combined procedure but not for HF-
rTMS of the left DLPFC performed alone. However, this study
enrolled only 8 and 9 patients in each condition and was not
sham-controlled.
The combination of HF-rTMS of the left DLPFC and LF-rTMS of
the left auditory cortex was also investigated by several studies
before 2014 in the treatment of chronic tinnitus (Kleinjung et al.,
2008; Kreuzer et al., 2011; Lehner et al., 2013; Park et al.,
2013b). In a series of 32 patients, Kleinjung et al. (2008) first
showed that a 10-day protocol of LF-rTMS of the left TPC (1000
pulses/session at 1 Hz and 110% of RMT) preceded by HF-rTMS of
the left DLPFC (1000 pulses/session at 20 Hz and 110% of RMT)
could produce the same reduction of tinnitus severity (assessed
on TQ score) as LF-rTMS of the left TPC performed alone (2000
pulses/session at 1 Hz and 110% of RMT), but with a significantly
more prolonged effect at 3-month follow-up. A similar result was
obtained in a series of 56 patients, replacing 20 Hz-rTMS of the left
DLPFC by 1 Hz-rTMS of the right DLPFC (Kreuzer et al., 2011). Actu-
ally, an open-label study of 7 patients with chronic tinnitus (DeRidder et al., 2013) previously reported that a 10-day protocol of
LF-rTMS delivered at 1 Hz over the right DFLPC could significantly
reduce tinnitus loudness (assessed on a VAS).
In another series of 45 patients, the same research group
replaced LF-rTMS of the left TPC by LF-rTMS of both the right
and left TPC (Lehner et al., 2013). Such a triple-site rTMS protocol
produced similar improvement as single-site LF-rTMS of the left
temporal cortex, but, again, with more prolonged significance
(clinical benefit being still present at 3-month follow-up only in
the multisite group). This study was replicated by the same
research group in 49 patients (Lehner et al., 2016). The conclusion
was that ‘‘no significant superiority of the multisite protocol was
observed”, but no firm conclusion could be drawn since these stud-
ies were not sham-controlled
Only two studies assessed multisite rTMS strategy in tinnitus,
including a sham group and more than 10 patients in the real stim-
ulation group (Langguth et al., 2014; Formánek et al., 2018)
(Table 11).
First, Langguth et al. (2014) showed that a 10-day rTMS proto-
col combining 20 Hz-rTMS over the left DLPFC, followed by 1 Hz-
rTMS over the left auditory cortex was able to reduce tinnitus
severity (assessed on TQ score) in a group of 46 patients receiving
the real stimulation. Overall, the average reduction of the TQ score
was not superior in this group than in the groups of patients trea-
ted by real or sham LF-rTMS delivered to the left auditory cortex
alone. However, the real rTMS protocols provided a higher percent-
age of individual responders compared to the sham condition.
In a second sham-controlled study, the combined HF-rTMS/LF-
rTMS protocol was not found to provide any clinical benefit
(Formánek et al., 2018). In this series of 32 patients with chronic
tinnitus (20 real, 12 sham), the left DLFPC was stimulated at
25 Hz combined with 1 Hz-rTMS of the auditory cortex of both
hemispheres for 5 consecutive days. No significant effect of rTMS
was found at 1- or 6-month follow-up on the Tinnitus Reaction
Questionnaire (TRQ) or THQ scores, as well as on the Beck Depres-
sion Inventory (BDI). Only a statistical but clinically irrelevant
effect on the THI score was observed. This study questioned the
value of multisite rTMS protocols in tinnitus, but this protocol
may have been less effective because of both auditory cortices
were stimulated. Indeed, two previous studies showed no signifi-
cant treatment effect of real versus sham rTMS following bilateral
temporal cortex stimulation (Plewnia et al., 2012; Hoekstra et al.,
2013).
The other studies compared two real stimulation protocols,
without sham condition. Following a first pilot study (Park et al.,
2013b), Park et al. (2015) compared two protocols combining LF-
rTMS of the left auditory cortex and HF-rTMS of the left DLPFC with
2000 pulses/session for 3 days vs. 3000 pulses/session for 4 days.
Only the latter protocol provided significant tinnitus relief assessed
on THI and VAS scores. However, this study only enrolled 6 and 8
patients in each condition.
Kreuzer et al. (2015a) compared the combination of 10 Hz-rTMS
of the left DLPFC followed by 1 Hz-rTMS of the left TPJ to another
multisite protocol, combining mediofrontal HF-rTMS over the
anterior cingulate cortex (ACC) using a double-cone coil followed
by LF-rTMS of the left TPJ with a figure-of-8 coil. In both protocols,
2000 pulses were delivered to each target per session. In this study
conducted in 40 patients with chronic tinnitus, responder rates
(assessed on the TQ score) did not differ between both groups.
The combination of rTMS with relaxation techniques was inves-
tigated in one pilot study (Kreuzer et al., 2016). Compared to his-
torical control groups having received the same rTMS protocol
(active control) and sham treatment (placebo) without relaxation
techniques, the 38 patients who listened to relaxation audios dur-
ing stimulation (10 sessions of rTMS applied to the left DLPFC and
TPC targets) tended to have a better outcome (reduction in TQ
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relaxation and tinnitus improvement
Since chronic tinnitus is often accompanied by comorbid mus-
cular tension, Vielsmeier et al. (2018) studied the value of adding
a repetitive peripheral magnetic stimulation (rPMS) of the neck
and back muscles before and after rTMS sessions combining HF-
rTMS of the left DLPFC followed by LF-rTMS of the left TPC. In a ser-
ies of 41 patients treated by 10 sessions of such a protocol, no
improvement was found in either tinnitus severity (measured on
the TQ score) or neck pain.
Taken together there has been a substantial amount of new data
on different aspects of rTMS application for the treatment of tinni-
tus in the 2014–2018 period. However, these results still do not
allow firm conclusions about the efficacy of rTMS in this clinical
condition. Comprehensive analyses of the literature up to 2014
(Soleimani et al., 2016) and since 2014 (Londero et al., 2018)
showed a medium-to-large effect size in favor of rTMS therapy,
but with a high variability of study design and inter-individual out-
comes. However, a definitive conclusion about the efficacy of rTMS
for the treatment of tinnitus is still not possible. Some of the avail-
able clinical studies are positive, others are negative. Even the
available Class I studies based on large samples revealed contradic-
tory results. Folmer et al. (2015, 2017) found a superiority of real
versus sham rTMS, whereas Landgrebe et al. (2017a,b) could not
detect a significant difference between real and sham rTMS. Thus,
systematic meta-analyses are needed for drawing a clearer picture
of the effectiveness of rTMS in chronic tinnitus.
To date, there is no robust evidence to prefer a dual- or triple-
site rTMS procedure (LF-rTMS over the auditoy cortex of one or
both hemispheres combned with HF-rTMS of the left DLPFC) rather
than a single-site LF-rTMS procedure over the auditory cortex of
the left hemisphere or contralateral to the most affected ear.
Therefore the general recommendation remains of Level C (‘‘possi-
ble effect of repeated sessions of LF-rTMS of the TPC (on the left
hemisphere or contralateral to the affected ear) in tinnitus”). Many
questions remain concerning the use of this technique in everyday
practice, such as what could be the optimal treatment target(s) and
protocol and what could be the role of individual susceptibility to
auditory cortex stimulation in influencing outcome or side effects,
e.g., related to genetic factors (BDNF genotype, Yang et al., 2016) or
the presence of hyperacusis or hearing loss (Lefaucheur et al.,
2012b; Tringali et al., 2013).
Therefore, one of the most promising approaches could be to
perform a stimulation protocol tailored to the individual patient.
A recent pilot study explored this concept (Kreuzer et al., 2017),
by delivering rTMS at various frequencies over the left and right
DLPFC or TPC targets in a single test session to select the type of
protocol subsequently applied for several days. Among 25 tested
patients, immediate effect on tinnitus perception was detected in
12 patients who received 9 further treatment sessions with a com-
bined rTMS protocol over the most effective DLPFC and TPC targets
found in the test sessions. In the remaining 13 patients, a standard
combined protocol (20 Hz-rTMS over left DLPFC followed by 1 Hz-
rTMS over the left TPC) was performed. The responders of the test
sessions who received the individualized protocol had a higher
benefit than the patients receiving the standard protocol. This
result provides a basis for a ‘‘tailored” application of rTMS in tinni-
tus, since usual ‘‘standardized” rTMS protocols have shown signif-
icant but only moderate efficacy with high interindividual
variability in treatment response.10. Depression
Available therapeutic strategies for depression include medica-
tion optimization (by combining antidepressants, add-on therapy
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(with lithium, thyroid hormone, and atypical antipsychotics), elec-
troconvulsive therapy (ECT), and rTMS. It is estimated that treat-
ment resistance occurs in 50% of depressed patients who are
receiving proper antidepressant medication and over 10% of these
patients remain resistant to various psychopharmacological inter-
ventions (Fagiolini and Kupfer, 2003). In addition, the risk of
relapse (up to 85% of the cases) or chronicization (about 20% of
the cases) must also be considered (Ferrari et al., 2013). However,
when to apply rTMS in this context and the place of rTMS in the
antidepressant treatment algorithm has not been clearly defined
yet. Clinical practice shows that rTMS may have a higher chance
of success when it is administered in the year of onset of an ongo-
ing depressive episode, to patients below the age of 65 years, and
in cases known to have a limited level of resistance to treatment
(one or two failed pharmacological trials, with or without addi-
tional psychotherapy) (George and Post, 2011). These criteria
should be considered as merely indicative as most of rTMS
research in the domain of depression has been conducted in
MDD patients with some form of treatment resistance. On the
other hand, in geriatric samples, beneficial effects of rTMS have
been reported on mood (Dardenne et al., 2018), but not on execu-
tive functions (Ilieva et al., 2018).
10.1. General results
A PubMed search (keywords: (rTMS OR theta burst stimulation)
AND depression) identified 526 papers, including 11 original
sham-controlled studies with at least 10 patients receiving real
stimulation for several daily sessions. These 11 studies examined
the efficacy of HF-rTMS of the left DLPFC (n = 3), LF-rTMS to the
right DLPFC (n = 1), or bihemispheric rTMS over both DLPFC
(n = 1), compared right and left DLPFC stimulation (n = 1), or eval-
uated new settings (deep rTMS, TBS, or accelerated rTMS protocol)
(n = 5)
In the past decades, two different approaches for the treatment
of MDD episodes with rTMS emerged: either HF-rTMS of the left
DLPFC (aimed at correcting an alleged hypoactivity) or LF-rTMS
of the right DLPFC (aimed at reducing an alleged hyperactivity)
(De Raedt et al., 2015).
HF-rTMS of the left DLPFC received a recommendation corre-
sponding to a Level A of evidence in our previous guidelines
(Lefaucheur et al., 2014). This was also in accordance with the U.
S. Food and Drug Administration (FDA) approval, first issued in
December 16, 2008 following the report of beneficial results by
two large multicenter studies: 301 and 199 patients enrolled in
O’Reardon et al. (2007) and George et al. (2010), respectively. In
the 2014–2018 period, 4 additional studies were retained for fur-
ther analysis, one of Class I (Blumberger et al., 2016), one of Class
II (Theleritis et al., 2017) and two of Class III (Kang et al., 2016; Li
et al., 2016a) (Table 12).
The Class I study (Blumberger et al., 2016) failed to show a sig-
nificantly differential effect between real and sham HF-rTMS pro-
tocols unilaterally delivered to the left DLPFC in terms of
remitter or responder rate measured on the 17-item HDRS
(HDRS-17) (remission defined as HDRS-17 score  7, response
defined as HDRS-17 score reduction > 50%). Conversely, all the
other recent sham-controlled studies (Kang et al., 2016; Li et al.,
2016a; Theleritis et al., 2017) reported beneficial results of the real
stimulation compared to sham control. One of these studies
(Theleritis et al., 2017) showed the additional effect of performing
rTMS sessions twice a day rather than once a day. The remaining
two studies revealed some functional brain changes produced by
rTMS or associated with the outcome using fMRI, PET, or EEG
assessments (Kang et al., 2016; Li et al., 2016a). Consequently,
the Level A of evidence of definite efficacy did not change concern-
502 J.-P. Lefaucheur et al. / Clinical Neurophysiology 131 (2020) 474–528ing HF-rTMS applied to the left DLPFC. A recent meta-analysis also
concluded to a significant antidepressant effect of HF-rTMS of the
left DLPFC (Brunoni et al., 2017).
In our previous work, a Level B of evidence (probable efficacy) of
LF-rTMS of the right DLPFC was proposed (Lefaucheur et al., 2014),
since most studies showed a beneficial antidepressant effect of this
procedure compared to placebo, but with lower statistical power
than for HF-rTMS of the left DLPFC (Level A). Although the tolera-
bility of LF-rTMS appears better than HF-rTMS, unfortunately, no
new sham-controlled studies examined the effects of LF-rTMS
applied to the right DLPFC in large MDD samples in the 2014–
2018 period. So at this point we can only keep a Level B of evidence
for this procedure.
Of note, the published rTMS studies often showed a large vari-
ability in the number of sessions proposed (10–30) and the number
of stimuli per session (120–3000), and these variables are usually
lower when applying LF-rTMS of the right DLPFC as compared to
HF-rTMS of the left DLPFC. One recent meta-analysis (Teng et al.,
2017) showed that increasing the number of sessions and the total
number of pulses per session (with an optimal value of 1200–1500
pulses/session) was associated with an increased antidepressant
efficacy of HF-rTMS of the left DLPFC. A few studies compared
the both types of stimulation (LF-rTMS on the right vs. HF-rTMS
on the left) and rather showed a similar antidepressant efficacy,
even when rTMS was used in augmentation or as an add-on treat-
ment to antidepressants in pharmacological refractory MDD (Eche
et al., 2012; Dell’Osso et al., 2015). One meta-analysis specifically
addressed this question and concluded that HF and LF-rTMS had
a comparable antidepressant efficacy (Chen et al., 2013). However,
other authors pointed out that HF-rTMS might have a greater
potential ability to accelerate and improve the clinical response
to antidepressants than LF-rTMS, whereas LF-rTMS might have a
better tolerability profile than HF-rTMS (Berlim et al., 2013b).
Therefore, considering the few studies that have directly compared
the efficacy and safety profiles of the two techniques, we prefer to
propose only a Level C of evidence to conclude that there is possi-
bly no difference between HF-rTMS of the left DLPFC and LF-rTMS
of the right-DLPFC in their therapeutic use for patients with
depression.
In our previous analysis of the literature (Lefaucheur et al.,
2014), we found that bilateral rTMS of the DLPFC (LF on the right
hemisphere and HF on the left one) was compared to unilateral
HF-rTMS of the left DLPFC in 7 studies, with only one study show-
ing a superior efficacy of bilateral rTMS and even two studies
reporting a lower efficacy of bilateral rTMS. The efficacy of bilateral
rTMS was also compared to a sham condition in 7 studies, with a
significantly better efficacy of the real stimulation condition
observed in only 3 studies. Therefore, no recommendation was
made regarding bilateral rTMS of the DLPFC in depression because
of highly contradictory results. In the 2014–2018 period, the effi-
cacy provided by the combination of LF-rTMS of the right DLPFC
and HF-rTMS of the left DLPFC during the same sessions in the
same patients was assessed in 12 studies (2 Class I studies, 6 Class
II studies and 4 Class III studies). These studies did not report any
superior efficacy of bilateral stimulation, as compared to unilateral
stimulation, except one Class I study (Blumberger et al., 2016). In
this study, only bilateral rTMS (600 pulses at 1 Hz on the right
DLPFC followed by 1500 pulses at 10 Hz on the left DLPFC), but
not unilateral HF-rTMS of the left DLPFC (2100 pulses at 10 Hz),
produced significantly greater antidepressant effects compared to
sham procedure in terms of remission or response (measured on
the HDRS-17 score). Therefore, we propose to make a recommen-
dation in favor of a probable antidepressant efficacy (Level B of evi-
dence) of bilateral rTMS protocols over the DLPFC (LF on the right
side and HF on the left) in patients with MDD with possibly no dif-
ferential antidepressant efficacy between bilateral rTMS versusunilateral right LF-rTMS or left HF-rTMS delivered to the DLPFC
(Level C of evidence).
Another issue is the relationship between rTMS efficacy and
antidepressant pharmacotherapy. In fact, there are two different
questions: (i) is there a difference between rTMS and antidepres-
sants in terms of therapeutic efficacy?; (ii) is there an augmenting
effect of rTMS when introduced in patients already under stable
antidepressant medication or an additive or potentiating effect of
rTMS when introduced concomitantly with antidepressant medi-
cation (‘‘add-on therapy”)?
Since 2014, regarding comparisons between antidepressant
effects of rTMS and medication, one large multicenter Class I study
of 170 depressed patients (Brunelin et al., 2014) showed that LF-
rTMS of the right DLPFC was as effective as venlafaxine adminis-
tered alone or the combination of both treatments. This study
was in favor of the absence of differential efficacy of rTMS per-
formed alone vs. combined with antidepressants, as was one previ-
ous study of Class I (Herwig et al., 2007) and 2 of Class III (Garcia-
Toro et al., 2001; Bretlau et al., 2008), whereas 2 studies of class II
were in favor of a superiority of an ‘‘add-on” effect of the combined
procedure (Rossini et al., 2005b; Rumi et al., 2005). More recently,
one retrospective Class III study of 32 patients (Verma et al., 2018)
showed that HF rTMS of the left DLPFC was an effective add-on
treatment strategy in patients with treatment-resistant depres-
sion. Regarding the augmenting effect of rTMS, another Class III
study (Dell’Osso et al., 2015) showed that either HF-rTMS of the
left DLPFC or LF-rTMS of the right DLPFC had comparable rate of
efficacy in the treatment of acute unipolar and bipolar MDD epi-
sodes in a series of 29 patients with poor drug response or treat-
ment resistance. Therefore, we modify our recommendations to
state that there is possibly no differential antidepressant efficacy
between rTMS therapy performed alone vs. combined with antide-
pressants (Level C), although one older meta-analysis concluded to
the superiority of combining rTMS and antidepressant medication
(Berlim et al., 2013a).
In the 2014–2018 period, no study further compared the effi-
cacy of rTMS vs. ECT. In this domain, as stated in our previous work
(Lefaucheur et al., 2014), the main issue is the lack of sham-
controlled studies. Several meta-analyses suggested that rTMS
has a lower efficacy compared to ECT (Slotema et al., 2010;
Berlim et al., 2013b, Ren et al., 2014), especially in depression with
psychotic features (Grunhaus et al., 2003). However, one meta-
analysis (Chen et al., 2017) suggested that even if ECT was more
efficacious, it was less tolerated and bilateral rTMS had the most
favorable balance between efficacy and acceptability. On the other
hand, the absence of significant differences between ECT and rTMS
in some studies may be explained by statistical bias due a small
sample size. Regarding bipolar depression, only two studies of
Class III with heterogeneous outcomes (Fitzgerald et al., 2016;
Hu et al., 2016) were reported in the 2014–2018 period. Although
the published data appear to be generally insufficient to draw
definitive conclusions, rTMS seems to be ineffective in cases of
MDDwith psychotic features, a condition which is, on the contrary,
a major clinical indication of ECT. Finally, there is currently no evi-
dence to suggest that rTMS is associated with an increased risk of
hypomanic switch.
One last issue is the DLPFC targeting method used in rTMS stud-
ies to treat depression. To date, most of the rTMS studies, including
those that resulted in the FDA clearance for rTMS therapy of
medication-resistant MDD and those on which our Level A recom-
mendation was based, were performed with a ‘‘standard proce-
dure” of targeting, defining the DLPFC as located 5 cm anterior to
the hand motor hotspot (‘‘5cm-rule”) (Pascual-Leone and Hallett,
1994; Pascual-Leone et al., 1996). However, several studies using
image-guided navigation systems demonstrated that such a proce-
dure was anatomically incorrect, the DLPFC being more anterior in
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Bradfield et al., 2012; Wall et al., 2016). On average, the DLPFC was
found to be located about 7 cm in front of the motor hotspot on
scalp measurement (Ahdab et al., 2010). In addition, the DLPFC tar-
get showed a significantly greater interindividual variability in
terms of anatomical location with the ‘‘standard procedure” com-
pared to neuronavigated methods which integrate individual
imaging data (Peleman et al., 2010; Rusjan et al., 2010). This could
be due to the proper anatomical variability of hand motor hotspot
location, which is also large (Ahdab et al., 2016). Thus, on an
anatomical point-of-view, the most accurate method for targeting
the DLPFC should be to use individual MRI data and a neuronaviga-
tion system, as suggest by several neuroimaging studies (Fox et al.
2012; Luber et al., 2017; Dubin et al., 2017). Various neuronavi-
gated algorithms were furthermore proposed to define the DLPFC
target at the junction between BA 9 and BA 46 (Mylius et al.,
2013) or within BA 46 (Pommier et al., 2017).
However, a navigation system is costly and not available for all
rTMS practitioners. Therefore, a non-navigated targeting alterna-
tive to the 5 cm-rule was suggested as being probably more
anatomically accurate. This procedure locates the left/right DLPFC
at the F4/F3 sites of the 10–20 EEG System. A simple and dedicated
method (the ‘‘Beam F3” algorithm) to estimate the scalp location of
the F3 site from only three measurements over the skull was then
proposed by Will Beam and Jeff Borckardt (Beam et al., 2009) who
also developed a free web interface calculator based on their
method (http://clinicalresearcher.org/F3/calculate.php). The acccu-
racy of this method of left DLPFC targeting was confirmed by a
comparative study with a neuronavigated approach based on indi-
vidual MRI data (Mir-Moghtadaei et al., 2015), even if the ‘‘Beam
F3” target appears to be more anterior than the real F3 site of the
10–20 EEG System (Nikolin et al., 2019). In fact, navigated studies
showed that the DLPFC representation could be slightly more lat-
eral than the F3 or ‘‘Beam F3” site (Wall et al., 2016), corresponding
rather to the F5 site of the 10–10 EEG System (Rusjan et al., 2010).
Finally, taken into account the functional relationship between the
DLPFC and the autonomic nervous system, another DLPFC target
location (FC3/FC4) was recently proposed, based on the site of
stimulation where short trains of 10 Hz-rTMS produced the largest
heart rate deceleration (Iseger et al., 2017).
Actually, definite evidence of a clinical impact of the DLPFC tar-
geting method is still lacking. One study showed that using the
‘‘standard procedure” (5 cm-rule), rTMS produced a better antide-
pressant response when the provided target was more anterior andTable 13
Deep HF-rTMS of the left DLPFC in major depressive disorder.
Articles Number of
patients
Target,
coil
type
Control
condition
Stimulation
frequency
and
intensity
Number of
session an
of sessions
Levkovitz
et al.
(2015)
181 (real: 89,
sham: 92), without
bipolar MDD
Left
DLPFC,
H1-coil
Sham coil 18 Hz, 120%
RMT
1980 pulse
sessions (a
additional
maintenan
Tavares
et al.
(2017)
43 (real: 20, sham:
23), with drug-
resistant bipolar
MDD
Left
DLPFC,
H1-coil
Sham coil 18 Hz, 120%
RMT
1980 pulse
sessions
Kaster
et al.
(2018)
52 (real: 25, sham:
27), without
bipolar MDD
Left
DLPFC,
H1-coil
Sham coil 18 Hz, 120%
RMT
6012 pulse
sessionslateral, predicting better efficacy for targeting over F3 or even
superior for targeting at the junction between BA 9 and BA 46
(Herbsman et al., 2009). Fitzgerald et al. (2009a) compared the
effect of HF-rTMS of the DLPFC targeted with the 5 cm-rule (27
patients) vs. at the junction between BA 9 and BA 46 using neuron-
avigation (24 patients). A significanty better antidepressant out-
come was observed in case of neuronavigated approach vs. the
‘‘standard procedure”. Thus, the use of a more anatomically accu-
rate method of DLPFC targeting appears to enhance the response
to rTMS treatment in depression, but this remains to be replicated
and confirmed in large clinical trials. Although the 5 cm-rule has
the best evidence to support its use and is simpler compared to
the other targeting methods, the ‘‘Beam F300 and MRI-guided navi-
gated procedures may be preferred to reduce interindividual vari-
ability of target anatomical location and possibly enhance the
efficacy of antidepressant rTMS therapy.
10.2. Novel rTMS protocols to treat depression: Deep HF-rTMS over the
left DLPFC
Left HF-rTMS and right LF-rTMS delivered to the DLPFC are
effective in the treatment of MDD, but the effect size remains quite
low (Brunoni et al., 2017), yielding between 30 and 50% of respon-
ders, with remission rates even lower. This led to the development
of novel forms of rTMS therapy in MDD.
First, we have to mention the use of deep HF-rTMS delivered
with the H1-coil to stimulate larger prefrontal cortical regions
(Table 13). In several studies, the H1-coil, placed 6 cm anterior to
the motor hotspot, was intended to stimulate lateral prefrontal
regions bilaterally, but more intensely the left DLPFC, according
to electric field models (Parazzini et al., 2017). Following several
pilot studies, Levkovitz et al. (2015) reported a multicenter
sham-controlled study of Class I initially including 212 patients
(101 real, 111 sham) who received such type of deep HF-rTMS pro-
tocol (sessions of 1980 pulses delivered at 18 Hz and 120% of RMT,
daily for 4 weeks (20 sessions) and then biweekly for 12 weeks).
From the 212 enrolled patients, 181 completed the primary end-
point assessment (89 real, 92 sham). In this per-protocol analysis
sample, a significant reduction of depression scores after real vs.
sham treatment (6.4 vs. 3.3, respectively, on the 21-item HDRS
score) at the end of the 5-weeks protocol was observed. Improve-
ment was also significant between real and sham stimulation con-
ditions in terms of response rate (38.4 vs. 21.4%, respectively,
defined as HDRS-21 score reduction  50%) and remission ratepulses/
d number
Significant clinical effects of real versus sham
condition
Class
of the
study
s, 20
nd 24
sessions for
ce)
Reduction of depression score (HDRS-21: real: 6.4,
sham: 3.3) and higher rates of remission (HDRS-21
score < 10: real: 32.6%, sham: 14.6%) and response
(HDRS-21 score reduction  50%: real: 38.4%, sham:
21.4%) at the end of 5-week rTMS protocol, with benefit
maintained after 12-week maintenance therapy
I
s, 20 Reduction of depression score (HDRS-17: real: 12.3,
sham: 7.1) and a trend towards higher rate of response
(HDRS-17 score reduction  50%: real: 54.6%, sham:
26.1%) but not of remission (HDRS-17 score  7: real:
31.8%, sham: 17.4%) and at the end of 4-week rTMS
protocol, but not at 4-week follow-up
II
s, 20 No reduction of depression score (HDRS-24), but higher
rate of remission (HDRS-24 score  10: real: 40.0%,
sham: 14.8%) and response (HDRS-24 score
reduction > 50%: real: 44.0%, sham: 18.5%) at the end of
4-week rTMS protocol
I
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the significant benefit of real deep HF-rTMS of the left DLPFC
remained stable during the 12-week maintenance phase. Based
on these results, the FDA approved the deep rTMS device for the
treatment of MDD episodes in patients who have failed to respond
to antidepressant medications as substantially equivalent to super-
ficial rTMS systems (January 7, 2013).
A second sham-controlled Class I study (Kaster et al., 2018)
assessed the effect of deep HF-rTMS of the left DLPFC in MDD
patients, but of older age (between 60 and 85 years vs. less than
68 years in Levkovitz et al. (2015)). In this study, 52 old MDD
patients received real (n = 25) or sham (n = 27) deep HF-rTMS
using a H1-coil (20 sessions of 6012 pulses (vs. 1980 in Levkovitz
et al. (2015)) delivered at 18 Hz and 120% of RMT). The rate of
responders (defined as HDRS-24 score reduction > 50%) was higher
after real vs. sham deep HF-rTMS (44.0% vs. 18.5%, respectively),
although the averaged value of HDRS-24 score reduction was not
different between both groups. The remission rate was also signif-
icantly higher after real vs. sham deep HF-rTMS (40.0% vs. 14.8%,
respectively, defined as a score  10 on the 24-item HDRS with a
reduction  60% from baseline).
From these two Class I studies, we propose to retain a Level A of
evidence (definite efficacy) for deep HF-rTMS of the left DLPFC in
MDD patients, even in the elderly.
A third sham-controlled study (Tavares et al., 2017) assessed
the effect of deep HF-rTMS of the left DLPFC in depression, but in
a series of 50 patients who had bipolar depression (43 completed
the study: 20 real, 23 sham). The parameters of stimulation were
the same as in the study of Levkovitz et al. (2015), but the clinical
profile of the patients was substantially different. Tavares et al.
(2017) found showed a significant reduction of depression score
after real vs. sham treatment (12.3 vs. 7.1, respectively, on
HDRS-17 score) at the end of the 4-week protocol, but not at 4-
week follow-up. There was a trend towards a greater response rate
between real and sham stimulation conditions (54.6 vs. 26.1%,
respectively, defined as HDRS-17 score reduction 50%), but no
significant difference in terms of remission rate (31.8 vs. 17.4%,
respectively, defined as HDRS-17  7). No treatment-emergent
mania switch occurred. This study remains to be replicated before
providing any recommendation on the efficacy of deep HF-rTMS of
the left DLPFC in bipolar disorder.
Larger and deeper stimulation than that provided by usual
figure-of-8 coils can be produced by coils other than H-coil, such
as the double-cone coil. This type of coil was used to bilaterally tar-
get the dorsomedial prefrontal cortex (dmPFC) or the dorsal ante-
rior cingulate cortex (dACC) in several rTMS studies for various
indications, including tinnitus or craving, for example (Kreuzer
et al., 2019). In the context of depression, beyond various open-
label studies (e.g., Bakker et al., 2014; Downar et al., 2014;
Salomons et al., 2014), only one sham-controlled study was
reported using this procedure (Kreuzer et al., 2015b). In this Class
II study, 40 depressed patients were randomly allocated to receive
15 sessions of conventional 10 Hz-rTMS delivered to the left DLPFC
using a figure-of-8 coil (15 patients), 10 Hz-rTMS delivered to the
dACC using a double-cone coil (13 patients), or sham rTMS (12
patients). The deep HF-rTMS of the dACC produced significantly
greater reduction of depression score (assessed on the HDRS-21)
than other conditions at the end of the 3-week treatment, but
not lasting at follow-up assessments.
10.3. Novel rTMS protocols to treat depression: iTBS over the left
DLPFC or cTBS over the right DLPFC
The TBS protocols offer the potential advantage of producing
similar (if not larger) effects on cortical excitability and plasticitythan conventional HF/LF-rTMS protocols, but for frankly shorter
session duration (e.g., 3 minutes for an iTBS protocol vs. more than
20 minutes for a standard rTMS session). Huang et al. (2005) pro-
posed two different TBS protocols, which consisted of 50 Hz triplet
bursts repeated at 5 Hz (600 pulses delivered at 80% of AMT), as an
uninterrupted train for 40 seconds (cTBS) or according to 2-
second-on/8-second-off cycle (iTBS): the first protocol was thought
to reduce cortical excitability and the second one to increase it. In
the context of depression therapy, several studies aimed at replac-
ing LF-rTMS by cTBS delivered to the right DLPFC or HF-rTMS by
iTBS delivered to the left DLPFC (Chung et al., 2015) (Table 14).
In 2010, two case series revealed the potential value of TBS in
the treatment of depression (Chistyakov et al., 2010; Holzer and
Padberg, 2010). Holzer and Padberg (2010) showed that 5 of 7
patients who received a 3-week course of two 600-pulse iTBS
sequences delivered per day over the left DLPFC met the criteria
of antidepressant response (reduction of the HDRS score  50%).
Conversely, Chistyakov et al. (2010) found only 2 responders (with
the same definition) in a series of 7 patients treated by a similar
iTBS protocol for 10 consecutive working days. In this study, 3 of
6 patients (50%) responded to a cTBS protocol delivered to the right
DLPFC with the same number of pulses per day (1200 stimuli) for
10 days. An even better response rate (71%) was observed in a ser-
ies of 14 additional patients who received a cTBS sequence of 1800
stimuli twice daily for 10 days.
However, this prominent antidepressant action of right-sided
cTBS was not confirmed by subsequent sham-controlled studies,
including a study by the same group that initially reported benefi-
cial results of this procedure (Chistyakov et al., 2015). In this latter
study, 29 MDD patients received either real or sham cTBS to the
right DLPFC (real 15, sham 14) for 10 consecutive working days.
After the 10th session, all patients received real cTBS for additional
10 treatments. Overall, no significant difference in the degree of
clinical improvement (assessed on HDRS-21 score) was found
between real and sham cTBS groups.
In three studies, another research group assessed the respective
efficacy of cTBS of the right DLPFC, iTBS of the left DLPFC, and the
combination of both protocols, compared to a sham TBS procedure
(Li et al., 2014a, 2018; Cheng et al., 2016). These studies included a
series of 60 patients with treatment-resistant MDD episodes (15
patients in each group). After 2 weeks of treatment, depression
improved in all groups, but a significantly better antidepressant
response was found after real left-sided iTBS and bilateral TBS pro-
tocols compared to the sham procedure (Li et al., 2014a). In con-
trast, the antidepressant effect of right-sided cTBS was similar to
sham. Refractoriness to drug treatment was a negative predictive
factor for TBS protocol efficacy. In a subsequent analysis, Cheng
et al. (2016) showed that only responders to left-sided iTBS proto-
col improved executive functions assessed by the Wisconsin Card
Sorting Test (WCST). Finally, the same authors found that iTBS
decreased brain metabolism in the ACC and dmPFC, whereas cTBS
increased it (Li et al., 2018).
Overall, with two negative studies of Classes II-III (Li et al.,
2014a; Chistyakov et al., 2015), cTBS protocol delivered unilater-
ally to the right DLFPC appears to be possibly ineffective to produce
antidepressant effects (Level C).
Conversely, right-sided cTBS combined with left-sided iTBS was
found to produce better antidepressant responses than the sham
procedure by Li et al. (2014a) and Plewnia et al. (2014). In this lat-
ter study, 32 MDD patients received a sequential TBS protocol
combining cTBS of the right DLPFC and iTBS of the left DLPFC or
bilateral sham TBS for 6 weeks (30 sessions) in addition to ongoing
medication and psychotherapy. Primary outcome measure was the
proportion of treatment response defined as depression score
reduction  50% compared to baseline. As assessed on the
Table 14
cTBS/iTBS of the right/left DLPFC in major depressive disorder.
Articles Number of
patients
Target, coil type Control
condition
Stimulation
frequency and
intensity
Number of pulses/
session and number
of sessions
Significant clinical effects of real versus
sham condition
Class
of
the
study
Li et al.
(2014)
60 (real: 15
x3, sham: 15),
with unipolar
MDD
Left/right DLPFC
defined as
navigated BA9/
BA46, F8c
Titled coil Left-sided iTBS,
right-sided cTBS,
combination of
both, 80% RMT
1800 pulses on each
site, 10 sessions
Reduction of depression score (HDRS-17:
bilateral TBS: 52.5%, left iTBS: 42.3%, sham:
17.4%) and higher rates of response (HDRS-
17 score reduction  50%: bilateral TBS: 66.7%,
left iTBS: 40.0%, sham: 13.3%) at the end of the
2-week rTMS protocol
II
Plewnia
et al.
(2014)
32 (real: 16,
sham: 16),
with unipolar
MDD
Left/right DLPFC
defined as F3/F4
sites, F8c
Tilted coil Left-sided iTBS
+ right-sided
cTBS, 80% RMT
600 pulses on each
site, 30 sessions
Higher rate of response (MADRS score
reduction  50%: real: 56%, sham: 25%) and a
trend towards higher rate of remission
(MADRS/BDI score  7/8: real: 44/38%, sham:
19/6%)
II
Chistyakov
et al.
(2015)
29 (real: 15,
sham: 14),
with unipolar
or bipolar
MDD
Right DLPFC
defined as 5 cm
anterior to hand
motor hotspot, F8c
Sham coil cTBS, 100% AMT 3600 pulses, 10
sessions (followed by
10 additional real
stimulation sessions)
No significant difference in depression score
reduction (HDRS-21) between real and sham
stimulation groups
III
Prasser
et al.
(2015)
56 (real: 39,
sham: 17),
with unipolar
or bipolar
MDD
Left/right DLPFC
defined as 6 cm
anterior to hand
motor hotspot, F8c
Sham coil Left-sided iTBS
+ right-sided
cTBS, 80% RMT
1200 pulses on each
site, 15 sessions
No significant difference in depression score
reduction (HDRS-21) between real and sham
stimulation groups, but a trend towards higher
responder rate at the end of the follow-up
period
III
Duprat
et al.
(2016)
47 (crossover),
with unipolar
MDD
Left DLPFC defined
as navigated BA9/
BA46, F8c
Sham coil iTBS, 110% RMT 1620 pulses, 20
sessions (in 4 days: 5
sessions/day)
No significant difference in depression score
reduction (HDRS-17) between real and sham
stimulation groups
II
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number of responders were found after real vs. sham bilateral pre-
frontal stimulation.
Another sham-controlled study also assessed bilateral TBS com-
pared to bilateral conventional LF-/HF-rTMS protocol (Prasser
et al., 2015). In this study, 56 patients received 15 daily sessions
of bilateral TBS (cTBS of the right DLPFC + iTBS of the left DLPFC),
bilateral rTMS (1 Hz-rTMS of the right DLPFC + 10 Hz-rTMS of the
left DLPFC), or sham TBS. There was no significant effect in the pri-
mary outcome measure (change of the HDRS-21 score). However,
there was a trend towards an increased responder rate at the end
of the follow-up period for both real TBS and rTMS treatments as
compared to sham, and this tendency was most pronounced for
the TBS group.
Overall, compared to sham condition, beneficial antidepressant
effects were observed after the combination of cTBS of the right
DLFPC and iTBS of the left DLPFC in two Class II studies (Li et al.,
2014a; Plewnia et al., 2014), with a trend towards higher respon-
der rate in a third study of Class III (Prasser et al., 2015). Thus,
according to a recent meta-analysis of Berlim et al. (2017), a Level
B of evidence (probable antidepressant efficacy) could be proposed
for a sequential bilateral left-sided iTBS + right-sided cTBS protocol
applied to the DLPFC in the context of patients with unipolar MDD.
In contrast to the original protocol by Huang et al. (2015), uni-
lateral iTBS over the left DLPFC has often been applied with pro-
longed or intensified protocols (i.e. 1200–1800 pulses/day for
10 days, instead of 600 pulses/day, at an intensity of stimulation
up to 120% of RMT, instead of 80% of AMT). Moreover, few studies
compared unilateral iTBS to sham treatment (Li et al., 2014a, 2018;
Cheng et al., 2016). Other researchers investigated the antidepres-
sant efficacy of iTBS versus 10 Hz-rTMS of the left DLPFC, first in a
large, naturalistic, retrospective series of 185 patients (87 versus
98 patients) (Bakker et al., 2015) and then in a controlled study
but without comparison with a sham procedure (Blumberger
et al., 2018). This latter study showed the efficacy of an iTBS proto-
col delivered over the left DLPFC (targeted using a neuronavigation
system) for 5 weekdays during 4 weeks in a large series of 193
patients with drug resistant MDD episodes. The trial had a non-inferiority design and the iTBS protocol was compared to a stan-
dard HF-rTMS protocol delivered over the same left DLPFC target
(192 patients), without a control group receiving sham stimula-
tion. At the end of the 4-week treatment, the reduction in depres-
sion score (10 on average on the HDRS-17 score) was similar in
both groups, including similar safety and tolerability profiles. Since
August 14, 2018, following the report of this study, several compa-
nies have received FDA clearance to include iTBS of the left DLPFC
as a therapeutic option in adult patients with MDD episode who
have failed to receive satisfactory improvement from prior antide-
pressant medication in the current episode. In addition, the
response to either iTBS or 10 Hz-rTMS of the left DLPFC could be
predicted by similar baseline clinical characteristics (Kaster et al.,
2019) or functional and effective connectivity in fronto-insular
and salience networks (Iwabuchi et al., 2019).
However, it is difficult to estimate the value of iTBS delivered
unilaterally to the left DLPFC in depressed patients at its current
state. On one hand, the large and convincing non-inferiority study
of Blumberger et al. (2018) showed no difference between left-
sided prefrontal iTBS and HF-rTMS in depression, while HF-rTMS
of the left DLPFC has established efficacy (Level A in this review).
On the other hand, iTBS protocols considerably varied across previ-
ous studies, only one group showed the antidepressant benefit of
left-sided iTBS in sham-controlled trials, and replication studies
are missing. Thus, the evidence for iTBS is still insufficient to make
a recommendation according to the methodology of our study.
Therefore, sham-controlled studies assessing the antidepressant
effect of iTBS delivered unilaterally to the left DLPFC are awaited,
although it is difficult to conceive of such a study from a regulatory
and ethical point of view, given the non-inferiority finding pub-
lished by Blumberger et al. (2018).
Finally, another approach using iTBS of the left DLPFC was
developed by one group, based on an accelerated protocol consist-
ing of 20 sessions (1620 pulses per session) delivered in 4 days
(Desmyter et al., 2016; Duprat et al., 2016, 2018). This procedure
is significantly different from the conventional procedure (one iTBS
session per day for 5 weekdays during 2–4 weeks) and will there-
fore be discussed in the next chapter.
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To intensify the antidepressant response and to reduce the
number of stimulation days, it has been proposed that increasing
the number of rTMS sessions performed per day (more than one
daily session) could be more effective (Brunoni et al., 2017;
Baeken, 2018; Rachid, 2019; Sonmez et al., 2019). These protocols
were referred as ‘‘accelerated rTMS protocols”, after the first open-
label report made by Holtzheimer et al. (2010) of a protocol con-
sisting of 15 rTMS sessions administered over 2 days in 14
depressed patients. This accelerated procedure performed over a
very limited number of days should not be confused with some
studies based on twice-daily rTMS sessions applied for at least
two weeks (Loo et al., 2007; McGirr et al., 2015; Desbeaumes
Jodoin et al., 2018), closer to conventional once-daily rTMS
treatments.
Accelerated rTMS protocols seem to be safe and well-tolerated
in depressed patients (Hadley et al., 2011; Baeken et al., 2017),
even in the elderly (Dardenne et al., 2018). The main objective of
accelerated rTMS protocols is to reduce the burden for the patients
and the operators of repeated sessions over several weeks.
However, only a few sham-controlled studies based on acceler-
ated rTMS protocols for the treatment of depression were pub-
lished to date, most studies in this domain having an open label.
Before 2014, Baeken et al. (2013) reported a crossover sham-
controlled study of 20 MDD patients who received 20 sessions of
20 Hz-rTMS of the left DLPFC spread over 4 days (5 sessions/day).
No significant difference in the reduction of HDRS scores was found
between real and sham stimulation conditions, but all responders
(HDRS score reduction > 50%) were found in the real stimulation
condition. In satellite studies, the same research group showed
that a higher metabolic activity in the subgenual ACC (sgACC)
and a stronger negative functional connectivity with the left supe-
rior medial prefrontal cortex at baseline could predict the response
to the accelerated HF-rTMS protocol (Baeken et al., 2014, 2015).
George et al. (2014) reported a randomized, sham-controlled
study assessing the safety and efficacy of a protocol consisting of
9 sessions of 10 Hz-rTMS of the left DLPFC (6000 pulses per ses-
sion) performed over 3 days (3 sessions per day) in a series of 41
suicidal inpatients. The Suicidal Ideation score decreased in both
real and sham groups, but with a trend for more rapid decline fol-
lowing real rTMS.
One recent study compared the efficacy of an accelerated HF-
rTMS (3 sessions per day over 1 to 3 days for 3 weeks) to a standard
protocol based on a single daily session (over 5 days per week for
4 weeks) (Fitzgerald et al., 2018). In this study of 115 MDD patients
(58 accelerated, 57 standard), no significant difference was found
betwen the two treatment groups in terms of remission or
response rates or reduction in depression scores. However, this
study did not include a sham group.
Finally, one sham-controlled study was published, based on an
accelerated iTBS protocol delivered to the left DLPFC (Duprat et al.,
2016). In this crossover study, 47 patients received 20 sessions of
either real or sham rTMS in 4 days (5 sessions per day). A similar
reduction of depression score (measured on the HDRS-17) was
observed in both treatment groups, but response and remission
rates appeared to primarily increase with some delay (2 weeks)
following real stimulation. The same group published several satel-
lite studies based on the same series, showing in particular no dif-
ferential overall change in the suicidal risk or reward
responsiveness following either real or sham accelerated iTBS
(Desmyter et al., 2016; Duprat et al., 2018).
In conclusion, although evidence supports a similar efficacy of
accelerated rTMS protocols and classical rTMS protocols with only
once-daily stimulation session, it is premature to provide any rec-ommendation for the use of accelerated rTMS protocols in the
treatment of depression.10.5. Novel rTMS protocols to treat depression: Miscellaneous
Other efforts to increase antidepressant response rates using
innovative rTMS protocols are currently under investigation. First,
we have to mention a protocol in which a 15-minute train of LF-
rTMS delivered at 1 Hz over the right DLPFC was ‘‘primed” by 20
short bursts of 6 Hz-rTMS delivered at low-intensity (Fitzgerald
et al., 2008, 2013). In a Class I study performed in 60 MDD patients
(30 real, 30 sham), Fitzgerald et al. (2008) showed a significantly
greater reduction of depression scores on the Montgomery-
Asberg Depression Rating Scale (MADRS) in the real-priming vs.
sham-priming group. In a second study, the same research group
compared this primed LF-rTMS protocol to a sequential bilateral
rTMS protocol (LF-rTMS of the right DLPFC followed by HF-TMS
of the left DLPFC) in a large series of 179 patients (Fitzgerald
et al., 2013). There was a significant average reduction > 50% of
the HDRS-17 score (with a response rate of 56% and a remission
rate of 40%) in both treatment groups but no difference between
groups at the end of the 4-week protocol.
Another innovative protocol was reported in a sham-controlled
study published by Leuchter et al. (2015). The protocol was based
on low-field TMS synchronized to individual EEG activity recorded
prior to the first rTMS session. In a large series of 120 MDD patients
who completed the study, a greater reduction of depression score
was found after real low-field TMS synchronized to individual
alpha-frequency vs. sham stimulation (9.0 vs. 6.6, respectively,
on the HDRS-17 score). This new modality of stimulation remains
to be investigated by other research groups for the treatment of
depression.10.6. Summary
Although rTMS therapy is applied worldwide in depressed
patients, there is still a large heterogeneity in the published data
concerning the populations included and the stimulation settings.
A recent network meta-analysis showed a higher response to real
vs. sham stimulation condition for bilateral prefrontal rTMS or
iTBS, LF-rTMS of the right DLPFC, and HF-rTMS of the left DLPFC
(Mutz et al., 2019). The present recommendations are in favor of
a definite antidepressant efficacy of HF-rTMS of the left DLPFC
(using either a focal figure-of-8 coil or a deep H1-coil) and a prob-
able antidepressant efficacy of LF-rTMS of the right DLPFC. They
mostly apply to patients in an acute phase of a drug resistant
MDD episode in the context of unipolar depression. Efficacy does
not seem to differ significantly whether patients are concomitantly
treated by antidepressant medication. Unfortunately, there are still
no robust data or consensus regarding the way of treating depres-
sion by rTMS beyond the acute phase with maintenance sessions
(Rachid, 2018a; Senova et al., 2019). The issue of how to manage
the maintenance phase for the long-term safety and efficacy of
rTMS treatment of depression should be a major focus in this field
of research for the years to come. Also, additional studies are
needed to investigate the efficacy of rTMS in bipolar depression.
Our recommendations on the use of rTMS in the treatment of mood
disorders are consistent with those of CANMAT (Canadian Network
for Mood and Anxiety Treatments) (Milev et al., 2016) that con-
cluded to an evidence level 1 for HF- and LF-rTMS in the treatment
of depression. No firm recommendations can be provided yet about
new rTMS protocols, such as those based on TBS or accelerated
protocols.
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A PubMed search (keywords: (rTMS OR theta burst stimulation)
AND (schizophrenia OR hallucinations OR negative symptoms))
identified 147 papers, including 23 original sham-controlled stud-
ies with at least 10 patients receiving real stimulation for several
daily sessions.11.1. Auditory-verbal hallucinations
In the treatment of auditory-verbal hallucinations (AVH), most
original sham-controlled rTMS studies concerned LF-rTMS or some
cTBS protocols applied to the left TPC (including STG and TPJ tar-
gets). As emphasized in our previous work (Lefaucheur et al.,
2014), highly controversial results were reported concerning the
effect of LF-rTMS applied to the left STG/TPJ on auditory hallucina-
tions, with as many ‘‘positive” studies showing rTMS efficacy as
many ‘‘negative” studies showing rTMS inefficacy. However, con-
sidering effect size calculated in various meta-analyses, literature
data appeared to be in favor of a possible efficacy of LF rTMS of
the left TPC on auditory hallucinations (Level C). Since 2014, the
results of only a few additional sham-controlled studies have been
published in this setting (Table 15), which were not able to change
our previous recommendations. This statement is consistent with
two recent meta-analyses investigating the efficacy of 1 Hz-rTMS
of the left TPC for the treatment of AVH (Slotema et al., 2014; He
et al., 2017), which remained slightly positive, despite a decreasing
effect size and an increasing placebo effect concerning studies pub-
lished over time (Vercammen et al., 2009; Slotema et al., 2011,
2012; Dollfus et al., 2016). With regard to moderating variables,
there is evidence to suggest that the treatment is more effective
in young patients and in females (Koops et al., 2018). In addition,
it has been suggested that a smaller scalp-to-cortex distance (as
measured with an MRI-scan) at the stimulation site is associated
with better response (Nathou et al., 2015).
For other protocols of stimulation, data are too scarce to give
clinical recommendations. Some studies applied LF-rTMS sequen-
tially over temporal regions of both hemispheres. For example, in
Hoffman et al. (2013), patients received 1 Hz-rTMS for 16 minutes
over the left STG (Wernicke’s area) or the right homologous region
for 5 sessions and then the site of stimulation was switched to the
opposite hemisphere for 5 additional sessions. A third block of 5
stimulation sessions was delivered to the site associated with the
greatest improvement from the two previous periods. This protocol
produced a significant improvement measured on the Hallucina-
tion Change Score after real stimulation vs. sham condition. Bais
et al. (2014) compared the efficacy of 1 Hz-rTMS of the TPJ (defined
according to the T3P3 method of targeting) delivered for six con-
secutive days twice daily to both hemispheres (15 patients), to
only the left hemisphere (16 patients), or with a sham procedure
(16 patients). No differences were observed between groups onTable 15
LF-rTMS of the left TPC in auditory hallucinations (schizophrenia).
Articles Number of
patients
Target, coil type Control
condition
Stimulation
frequency and
intensity
Bais et al.
(2014)
32 (real: 16, sham:
16)
Left TPC (halfway
between T3 and
P3), F8c
Sham coil 1 Hz, 90% RMT
Paillère-
Martinot
et al.
(2017)
27 (real: 15;
sham: 12)
Left superior or
middle temporal
gyrus (fMRI–based
navigation), F8c
Sham coil 1 Hz, 100%
RMTthe Positive and Negative Syndrome Scale (PANSS) and Auditory
Hallucination Rating Subscale (AHRS) scores, except for a small
decrease of hallucination severity on the P3 item of the PANSS in
the left treatment group. In Kim et al. (2014d), 22 patients were
randomized to one of four conditions: 1 Hz-rTMS of both TPJ tar-
gets (defined as halfway between T3/T4 and P3/P4), 20 Hz-rTMS
of both TPJ targets, 20 Hz-rTMS of both Broca’s areas (defined as
the crossing point between T3/T4-Fz and F7/F8-Cz), or sham proce-
dure, with rTMS sessions performed twice daily for 3–5 days. No
superior effect of the real stimulation protocols over the sham con-
dition was found on AVH severity and frequency.
One study assessed the efficacy of priming a 20-minute train of
LF-rTMS of the left TPC by 20 bursts of 6 Hz-TMS of 5-second dura-
tion delivered at the same site (Ray et al., 2015). Priming LF-rTMS
did not result in significantly greater improvement, except for
reducing the loudness of AVH.
Other research groups assessed the value of HF-rTMS (rather
than LF-rTMS) applied to the left TPC. In three studies (de Weijer
et al., 2014; Kimura et al., 2016; Dollfus et al., 2018), 20 Hz-rTMS
was applied to the left temporal lobe and the effect on the severity
of AVH was assessed on the AHRS. Two of these studies were
sham-controlled (Kimura et al., 2016; Dollfus et al., 2018)
(Table 16) and used the same cortical target, which was precisely
defined under MRI-guided neuronavigation at the crossing
between the projection of the ascending branch of the left lateral
sulcus and the superior temporal sulcus (Montagne-Larmurier
et al., 2009). The identification of this target location resulted from
an fMRI study based on a language task and was found to have less
interindividual anatomical variability than the classical location of
T3P3 based on the 10–20 EEG System (Montagne-Larmurier et al.,
2009). No significant change in the AHRS score was observed after
4 sessions (in 2 days) of either real or sham HF-rTMS in the first
study (Kimura et al., 2016). Exactly the same rTMS protocol was
performed in the second study (Dollfus et al., 2018), in which the
primary outcome was negative (no significant reduction of the per-
centage of patients showing a decrease of more than 30% in the
AHRS frequency item at 2 successive ratings between the real
and sham stimulation groups). The rTMS-induced change in AHRS
total score also did no differ between both groups. However, as
secondary outcome, this study showed that the percentage of
responders on the AHRS total score (reduction > 30%) at day 14
after treatment initiation was greater after real (34.6%) than sham
(9.1%) stimulation. The third study was not sham-controlled (de
Weijer et al., 2014) and based on small groups of 10 patients
who received 1 Hz-rTMS and 8 patients who received 20 Hz-
rTMS for 5 days, followed by a maintenance treatment of one ses-
sion per week for 3 weeks. Both groups improved (on AHRS score)
at the end of the first week of stimulation, but without lasting
effects at 4-week follow-up. It is impossible to draw any conclu-
sion from this study, since target location was based on AVH-
related activation identified on individual fMRI, which resulted in
highly variable stimulation sites, scattered on both right and leftNumber of pulses/
session and number
of sessions
Significant clinical effects of real versus
sham condition
Class
of the
study
1200 pulses, 12
sessions (2/day)
Trend towards reduction of hallucination
(item P3 of the PANSS)
II
1000 pulses, 10
sessions
No significant difference in hallucination
reduction (on SAPS) between real and
sham stimulation groups
II
Table 16
HF-rTMS of the left TPJ in auditory hallucinations (schizophrenia).
Articles Number
of
patients
Target, coil type Control
condition
Stimulation
frequency
and
intensity
Number of
pulses/session
and number of
sessions
Significant clinical effects of real versus sham
condition
Class
of
the
study
Kimura et al.
(2016)
30 (real:
16,
sham:
14)
Navigated left TPJ
according to
Montagne-Larmurier
et al. (2009), F8c
Sham coil 20 Hz, 80%
RMT
2600 pulses, 4
sessions (2/day)
No significant effect on AHRS II
Dollfus et al.
(2018)
59 (real:
26;
sham:
33)
Navigated left TPJ
according to
Montagne-Larmurier
et al. (2009), F8c
Sham coil 20 Hz, 80%
RMT
2600 pulses, 4
sessions (2/day)
No significant reduction of AHRS total score
between real and sham treatment, but more
responders (AHRS decrease > 30%) in the real
stimulation group (real: 34.6%, sham: 9.1%) at
2 weeks after rTMS protocol
II
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making recommendation for HF-rTMS delivered over a navigated
TPJ target defined as the intersection between the ascending
branch of the left lateral sulcus and the superior temporal sulcus.
Finally, some studies assessed the value of using cTBS rather
than classical LF/HF-rTMS protocols. First, Plewnia et al. (2014)
delivered cTBS over the both TPC for 15 sessions in a small series
of 16 patients (8 real, 8 sham) and found a beneficial effect of real
vs. sham cTBS protocol. A Class II study (Koops et al., 2016), based
on a larger sample size (71 patients: 37 real, 34 sham), showed that
even unilateral application of a real cTBS protocol over the left TPC
for 10 sessions (2/day) was able to significantly reduce AVH
(assessed on the Psychotic Symptom Rating Scales (PSYRATS)).
Another study did not find any difference in the value of 1 Hz-
rTMS and cTBS delivered to the left TPC to improve patients with
AVH on the same PSYRATS score (Kindler et al., 2013).
11.2. Negative symptoms
In this clinical application, the therapeutic rTMS protocol usu-
ally consists of HF-rTMS of the left DLPFC, as for major depression.
Since 2014, most sham-controlled studies showed beneficial
results of the procedure, excluding the largest and only multicenter
trial (Wobrock et al., 2015), in which the patients who received
either real (n = 76) or sham (n = 81) rTMS improved similarly on
the PANSS negative subscale, and also regarding symptoms ofTable 17
HF-rTMS studies of the left DLPFC in negative symptoms of schizophrenia.
Articles Number
of
patients
Target, coil type Control
condition
Stimulation
frequency and
intensity
Wölwer et al.
(2014)
32 (real
18, sham:
14)
Left DLPFC (5 cm
anterior to motor
hotspot), F8c
Sham coil 10 Hz, 110%
RMT
Zhao et al. (2014) 69 (real
47, sham:
22)
Left DLPFC (site
not defined), F8c
Titled coil 10 Hz or 20 Hz,
80–110% RMT
Wobrock et al.
(2015)
157 (real:
76; sham:
81)
Left DLPFC (F3
site), F8c
Tilted coil 10 Hz, 110%
RMT
Li et al. (2016c) 47 (real:
25; sham:
22)
Left DLPFC (site
not defined), F8c
(?)
Sham coil
(?)
10 Hz, 110%
RMTdepression and cognitive function. Subsequent re-analyses of this
study further showed unspecific improvements in the real stimula-
tion group (Hasan et al., 2016; Hansbauer et al., 2018; Wagner
et al., 2019), except for the reduction of antipsychotic-induced
parkinsonian symptoms (Kamp et al., 2019). In addition, some
structural changes in various brain regions quantified on MRI
examination before or after the rTMS procedure were associated
with negative symptom improvement in the real stimulation group
and the baseline MRI pattern was predictive for real treatment
response (Hasan et al., 2017; Koutsouleris et al., 2018).
Overall, details on the recent sham-controlled studies based on
a HF-rTMS protocol delivered over the left DLPFC to treat negative
symptoms of schizophrenia are presented in Table 17. Our previ-
ous work retained 10 original sham-controlled studies with at least
10 patients who received real HF-rTMS of the DLPFC to treat neg-
ative symptoms of schizophrenia (Lefaucheur et al., 2014). Among
these studies, there were 3 ’positive’ Class II studies, 4 ’positive’
Class III studies, and 3 ’negative’ Class III studies, leading to a Level
B of evidence for the probable efficacy of HF-rTMS of the left
DLPFC. In the 2014–2018 period, two additional ’positive’ Class
II/III studies were published, whereas one Class I and one Class III
studies were ’negative’ (Table 17). Overall, the final balance to date
consists of one ’negative’ multicenter Class I study based on a large
sample versus four ’positive’ smaller Class II studies. Therefore, it
seems reasonable to reduce the level of evidence from B to C, in
favor of a possible efficacy of HF-rTMS of the left DLPFC on the neg-Number of pulses/
session and number
of sessions
Significant clinical effects of real versus
sham condition
Class of
the
study
1000 pulses, 10
sessions
Similar improvement on the PANSS
negative subscale and total scores in the
real and sham stimulation groups at the
end of the 2-week rTMS protocol.
However, facial affect recognition
improved significantly more after real
rTMS
III
1500 pulses, 20
sessions
Decreased PANSS negative subscale and
SANS scores at the end of the 4-week real
(but not sham) rTMS protocol
II
1000 pulses, 15
sessions
Similar improvement on the PANSS
negative subscale and total scores in the
real and sham stimulation groups at the
end of the 3-week rTMS protocol and up
to 12 weeks later
I
1500 pulses, 20
sessions
Decreased SANS total score after real but
not sham stimulation, with between-
group difference not at the end of the 4-
week rTMS protocol but 4 weeks later. No
difference on PANSS total score between
real and sham treatments.
III
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the profile of the patients enrolled in these studies and the place of
rTMS therapy is not definite regarding its clinical meaningfulness
and deserves further investigation. Actually, meta-analyses found
a moderate effect size (Dlabac-de Lange et al., 2010; Slotema
et al., 2010; Shi et al., 2014; He et al., 2017; Aleman et al., 2018;
Osoegawa et al., 2018), but the total number of studies and
patients on which this is based remains relatively limited: 827
patients distributed over 22 studies, in the largest meta-analysis
to date (Aleman et al., 2018). Moreover, the control of depressive
symptoms was not addressed in most studies, although depressive
symptoms may overlap with negative symptoms of schizophrenia.
Therefore, in this context, rTMS efficacy may also relate to an
antidepressant effect of the rTMS protocol, although this is not nec-
essarily the case (Dlabac-de Lange et al., 2015a). Next, the use of
the PANSS scale to evaluate negative symptoms is critically
debated (Garcia-Portilla et al., 2015) and future studies must use
standardized definitions of a predominant negative syndrome.
Finally, the long-term effects of rTMS or the value of a maintenance
therapy was not studied yet in this application.
In several studies of patients with negative symptoms of
schizophrenia, the HF-rTMS protocol differed from focal stimula-
tion of the left DLPFC using a figure-of-8 coil. In one Class I/II study
performed on a large sample size (Quan et al., 2015), the left DLPC
(defined according to the 5 cm-rule) was stimulated using a large
circular coil. A series of 117 patients (real 78, sham 39) received
2 courses of 10 daily sessions (800 pulses/session) over two weeks,
separated by a 2-week interval. The clinical benefit on the total and
negative subscale scores of the PANSS was significantly superior in
the real than the sham stimulation group.
A circular coil was also used in another Class II/III study per-
formed on a large sample size (Zhao et al., 2014), but to deliver
an iTBS protocol over the left DLPFC (site not defined) in a group
of 24 patients. This protocol was found to be even more efficacious
than classical HF-rTMS protocols applied at 10 Hz or 20 Hz over the
same target with a focal figure-of-8 coil to reduce negative symp-
toms of schizophrenia, assessed on the negative subscale of the
PANSS and the Scale for Assessment of Negative Symptoms (SANS).
In this study, the sham procedure (10 Hz-rTMS performed with a
tilted coil at 180) did not produce any significant clinical effect.
In a third Class III study (Rabany et al., 2014), the stimulated
area was even larger, using a H-coil (H1 type) over both DLPFC
regions (defined as 5.5 cm anterior to the motor hotspot), although
the stimulation was rather lateralized to the left hemisphere. A ser-
ies of 30 patients (20 real, 10 sham) received 20 daily sessions of
20 Hz-rTMS over 4 weeks (1680 pulses/session) that produced a
significant reduction of negative symptoms (assessed on the SANS)
at the end of the real (7.7) but not the sham (1.9) stimulation.
However, the difference between real and sham stimulation
groups was not significant regarding both the average reduction
of SANS total score and the rate of responders (defined as SANS
score reduction > 20%). Furthermore, no significant change was
observed on other clinical scales (such as the PANSS negative sub-
scale or total scores).
A bihemispheric stimulation was also performed over the
DLPFC regions (defined as F3/F4 EEG sites) by Dlabac-de Lange
et al. (2015a), but using a figure-of-8 coil. In this Class II study,
32 patients were equally randomized to receive 30 daily sessions
of 10 Hz-rTMS over 3 weeks (2000 pulses per hemisphere and
per session, two sessions per day, only working days). Depression
was controlled, but the comparison between the real and sham
stimulation groups provided ambiguous results. Indeed, a signifi-
cant efficacy of the real procedure to improve negative symptoms
was found when measured on the SANS but not on the PANSS. In a
satellite fMRI study (Dlabac-de Lange et al., 2015b), the same
authors found that, compared to the sham procedure, the realbihemispheric stimulation of the DLPFC resulted in an increased
activation in right (pre)frontal regions when a cognitive task aimed
at assessing planning function was performed. In a second satellite
study (Dlabac-de Lange et al., 2017), these authors reported that
the clinical benefit of real bihemispheric DLPFC stimulation was
associated with an increase in the concentration of glutamine (pre-
cursor of glutamate) in the left DLPFC of the treated patients, as
measured with 1H-Magnetic Resonance Spectroscopy (1H-MRS).
All these studies based on non-focal or bihemispheric stimula-
tion of DLPFC areas are too heterogeneous to make any recommen-
dations concerning the use of such protocols to treat negative
symptoms of schizophrenia.
Finally, in a sham-controlled study (Garg et al., 2016), a totally
different rTMS protocol was proposed, since the vermal part of the
cerebellum was stimulated at 5–7 Hz using a double-cone coil. In
this study, 40 patients were equally randomized to receive real
or sham stimulation for 10 daily sessions (600 pulses/session).
The negative syndrome subscore of the PANSS significantly
improved in the real compared to sham stimulation group. This
type of cerebellar stimulation protocol was not replicated to date
in this clinical context.12. Substance abuse, addiction and craving
A PubMed search (keywords: (rTMS OR theta burst stimulation)
AND (substance abuse OR addiction OR craving)) identified 135
papers, including only 8 original sham-controlled studies with at
least 10 patients receiving real stimulation for several daily
sessions.
12.1. Alcohol craving
In the 2014–2018 period, only one sham-controlled study of
Class III (with at least 10 patients receiving real stimulation) con-
cerned alcohol craving (Del Felice et al., 2016): no effect of 4 ses-
sions of 100 pulses of HF-rTMS delivered over the left DLPFC was
observed in both real and sham stimulation groups (10 patients
each). In contrast, in patients with alcohol dependence, Jansen
et al. (2015) suggested a beneficial effect of LF-rTMS of the right
DLPFC on cognitive control for maintaining abstinence by showing
rTMS-induced increased fronto-parietal connectivity on fMRI
investigation.
Among other studies, one could also mention that of Mishra
et al. (2015), showing a reduction in craving scores in patients with
alcohol dependence receiving 10 sessions of 10 Hz-rTMS delivered
to the right or left DLPFC, without significant difference between
both groups. In a sham-controlled study but with small sample size
(9 patients in both real and sham stimulation groups) (Ceccanti
et al., 2015), 20 Hz-rTMS was delivered to the dmPFC using a H1-
coil. Ten sessions of real deep HF-rTMS was able to reduce craving
and maximum alcohol intake compared to sham stimulation. In an
even smaller study (5 and 6 patients in real and sham stimulation
groups, respectively) (Addolorato et al., 2017), four weeks of deep
10 Hz-rTMS over bilateral DLPFC region reduced alcohol intake in
correlation with a reduction in striatal dopamine transporter avail-
ability only in patients of the real stimulation group.
However, there is still insufficient data for making any recom-
mendation regarding LF- or HF-rTMS application to the left and/
or right DLPFC in alcohol craving.
12.2. Nicotine craving
Until 2014, two studies (of Class II/III) reported beneficial
effects of HF rTMS (10–20 Hz) of the left DLPFC on cigarette craving
and especially on cigarette consumption and nicotine dependence
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From these results, a level C of evidence (possible effect) was pro-
posed for HF-rTMS of the left DLPFC in the treatment of nicotine
craving and consumption. However, these sham-controlled studies
were rather heterogeneous regarding various methodological
issues, one of these studies being performed in patients with
schizophrenia (Prikryl et al., 2014), for example.
Since 2014, a few additional studies have been published. One
sham-controlled study was based on a protocol of focal HF-rTMS,
but delivered to the right DLPFC and not the left DLPFC (Sheffer
et al., 2018). In this study including 29 patients (16 real, 13 sham),
HF-rTMS of the right DLPFC (8 sessions with 900 pulses/session
over 2 weeks) was combined to the use of a standardized manual
for smoking cessation and resulted in an increased abstinence rate
in the real vs. sham stimulation group.
Another sham-controlled study was in favor of the efficacy of
HF-rTMS of prefrontal regions (Dinur-Klein et al., 2014), but in this
study a large H4-coil was used in place of a focal figure-of-8 coil. A
lateral prefrontal region was stimulated simultaneously on both
hemispheres for 13 daily sessions over 3 weeks (600–990 pulses/
session). Compared to two groups of patients who received real
1 Hz-rTMS (n = 14) or sham rTMS (n = 31), the group of patients
who received 10 Hz-rTMS (n = 32) showed a significantly benefi-
cial effect on nicotine consumption.
Conversely, Trojak et al. (2015) applied LF-rTMS to the right
DLPFC for 10 sessions over 2 weeks (360 pulses/session) in a series
of 37 smokers (real 18, sham 19) and they found reduced craving
and more abstinent patients in the real vs. sham stimulation group.
Finally, Dieler et al. (2014) delivered iTBS over the right DLPFC
for 4 sessions over 2 weeks (600 pulses/session) in a series of 74
smokers (real 38, sham 36). In this study, rTMS was combined with
a cognitive behavioural therapy (CBT) consisting of a smoking ces-
sation program and resulted in a higher abstinence rate in the real
iTBS group, but with no change in craving.
In summary, all these recent data showed heterogenous proto-
cols and resulting data, not replicated to date. Therefore, no new
recommendation other than that previously proposed for a possi-
ble efficacy of HF-rTMS of the left DLPFC (Lefaucheur et al., 2014)
can be made for all these alternative rTMS procedures in cigarette
craving and consumption.
12.3. Methamphetamine or drug craving
In a study by Su et al. (2017), 30 methamphetamine-addicted
patients were equally randomized to receive 5 sessions of real or
sham 10 Hz-rTMS of the left DLPFC. Real rTMS reduced craving sig-
nificantly compared to sham and also improved learning and
memory capacities. In a more recent open-label study (Liu et al.,
2019), 20 sessions of 10 Hz-rTMS of the left DLPFC over 4 weeks
was performed in a group of 52 methamphetamine users and
showed an add-on effect to routine addiction rehabilitation pro-
gram, lasting for at least 30 days after the last rTMS session.
On the other hand, beneficial results on methamphetamine
craving were reported using 1 Hz-rTMS (and not HF-rTMS) of the
left DLPFC (Li et al., 2013). Liu et al. (2017) conducted a study in
50metamphetamine users assigned to 1 Hz-rTMS of the left or right
DLPFC (100% RMT, 600 pulses, 5 days), 10 Hz-rTMS of the left or
right DLPFC (100% RMT, 2000 pulses, 5 days) or 10 Hz-rTMS of the
left PPC (P3 site, 100% RMT, 2000 pulses, 5 days) as a control condi-
tion, but no sham. All DLPFC interventions reduced craving, but did
not differ between each other. Thus, there is still no robust evidence
to make any recommendation concerning the use of any specific
rTMS protocol in the context of methamphetamine addiction.
In the context of cocaine addiction, one study showed beneficial
effects of focal navigated HF-rTMS of the left DLPFC (using a figure-
of-8 coil and a navigation system) vs. standard psychopharmaco-logical treatment in 32 cocaine-addicted patients (Terraneo et al.,
2016). In another study (Bolloni et al., 2016), a H1-coil was used
to stimulate the dmPFC bilaterally at 10 Hz. At the end of a protocol
of 12 daily sessions of such large and deep rTMS performed over
4 weeks no difference between real and sham stimulation condi-
tions regarding cocaine intake was observed. However, at 3 months
after rTMS intervention, the amount of cocaine intake was found to
be reduced in the real vs. sham stimulation group, suggesting ben-
eficial effects of this procedure in the long term. Rapinesi et al.
(2016) also used a H1-coil, but centred more laterally over the left
DLPFC. In this small open-label study of 7 patients with cocaine use
disorder, 3 weekly sessions of 15 Hz-rTMS over 3 weeks resulted in
lasting beneficial effect on craving lasting for several weeks. Finally,
in a pilot study of 18 patients with moderate to severe cocaine use
disorder, Martinez et al. (2018) used a H7-coil (rather than a H1-
coil) to stimulate bilaterally the mPFC-ACC area. The patients were
equally randomized to receive 10 Hz-rTMS, 1 Hz-rTMS, or sham
rTMS (6 patients in each group) for 15 sessions over 3 weeks. A
reduced choice for cocaine intake was observed over the course of
HF-rTMS protocol, but not in the other conditions. However, these
heterogeneous results did not allow any recommendation to be
made for the indication of a specific protocol of HF-rTMS delivered
over prefrontal regions in the context of cocaine use disorders, as
for any other type of drug addiction.
12.4. Eating disorders
Before 2014, one sham-controlled study showed that 10 Hz-
rTMS over the left DLPFC was ineffective to relieve bulimia nervosa
(Walpoth et al., 2008): 14 bulimic women were first submitted to
one week of sham stimulation, then followed by 3 weeks of real or
sham stimulation after excluding placebo responders. The average
number of binges per day declined significantly at the end of the 3-
week rTMS protocol in both groups with no significant difference
between sham and real stimulation. This result was confirmed by
Gay et al. (2016) who showed no significant improvement in
bingeing and purging symptoms in the 15 days following 10 ses-
sions of 10 Hz-rTMS over the left DLPFC in a series of 42 patients
with bulimia nervosa.
Finally, Dunlop et al. (2015) showed that 10 Hz-rTMS delivered
over the dmPFC using a double-cone coil rTMS was able to reduce
weekly binge/purge frequency by more than 50% in 16 of 28
patients (57%) who received 20–30 daily sessions. Clinical response
was associated an enhanced frontostriatal connectivity at resting-
state fMRI investigation. However, this study was not sham-
controlled.
Regarding anorexia nervosa, only one sham-controlled study
with repeated sessions performed in a sample size larger than 10
patients has been published to date (Dalton et al., 2018). In this
study, 32 patients with anorexia nervosa lasting for at least 3 years
were equally randomized to receive 20 sessions of either real or
sham HF-rTMS of the left DLPFC. The real stimulation was superior
to the sham one especially for mood measures, rather than for eat-
ing disorder symptoms or weight gain. Thus, it is still premature to
consider rTMS therapy for eating disorders in clinical practice
(Rachid, 2018b).
12.5. Gambling disorders
Since 2014, only two sham-controlled crossover studies have
been published in this domain, but based on the effect of single
sessions. Focal HF-rTMS was assessed, applied to the left DLPFC
in 22 patients (Gay et al., 2017) or to the right DLPFC in 30 patients
(Sauvaget et al., 2018). In a third study (Zack et al., 2016), two pro-
tocols were found to reduce gambling reinforcement in 9 patients
with pathological gambling, either a 10 Hz-rTMS protocol using a
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figure-of-8 coil targeting the right DLPFC. From these sparse and
heterogenous data, no conclusion can be drawn.13. Miscellaneous psychiatric conditions
13.1. Anxiety disorders
A PubMed search (keywords: (rTMS OR theta burst stimulation)
AND (anxiety OR panic OR phobia)) identified 120 papers, includ-
ing only 5 original sham-controlled studies with at least 10
patients receiving real stimulation for several daily sessions.13.1.1. Generalized anxiety disorder
Since 2014, three sham-controlled studies have evaluated the
therapeutic efficacy of rTMS in generalized anxiety disorder (GAD).
In one Class III study, 1 Hz-rTMS was applied using a neuronav-
igation system to the right DLPFC (defined by its stereotactic coor-
dinates) in 25 patients with GAD but only 19 completed the study
(9 real, 10 sham) (Diefenbach et al., 2016b). After 30 daily sessions
(5 days/week for 6 weeks with 900 pulses/session at 90% of RMT),
compared to the sham group, the real stimulation group showed
significantly more responders and remitters, defined as a reduction
of the Hamilton Anxiety Rating Scale (HARS) score  50% and a
post-rTMS HARS score < 8, respectively. This difference was found
at the end of the rTMS protocol and maintained at the 3-month
follow-up. In satellite studies, the same authors showed that real
LF-rTMS of the right DLPFC also significantly improved self-
reported emotion regulation (Diefenbach et al., 2016a) and sleep
quality (Diefenbach et al., 2019), in correlation with functional
connectivity changes in the default mode network. Finally, a ‘‘nor-
malization” of functional connectivity between dorsal and subgen-
ual ACC regions was found after real, but not sham rTMS, related to
the improvement in worry symptoms (Assaf et al., 2018).
In another study (Dilkov et al., 2017), 20 Hz-rTMS was applied
at 110% of RMT to the right DLPFC (defined according to 5 cm-
rule) in 40 patients with GAD, randomized to receive either real
(n = 15) or sham (n = 25) stimulation. After 25 rTMS sessions (over
6 weeks with 360 pulses/session), the real stimulation group
showed a significant reduction in anxiety (HARS score) compared
to sham group, maintained and even slightly improved up to
one-month follow-up.
In a third study (Huang et al., 2018a), the right PPC (P4 EEG
electrode site) rather than the DLPFC was the target. A protocol
of 1 Hz-rTMS was applied to this target for 10 days (1500 pulses/
session at 90% of RMT) in 36 patients with comorbid GAD and
insomnia equally randomized to a real or a sham procedure. A sig-
nificant improvement of anxiety (assessed on HARS score) was
only observed in the real stimulation group, positively correlated
with the improvement in the Pittsburgh Sleep Quality Index (PSQI)
score. The rate of responders and remitters, defined on HARS scores
as in Diefenbach et al. (2016b), was also significantly higher after
real than sham stimulation.
Overall, these three studies did not allow any recommendation
to be made for the use of rTMS protocols to treat GAD, given the
heterogeneity in targets and stimulation frequencies.13.1.2. Other anxiety disorders
Since 2014, two randomized sham-controlled trials reported
therapeutic efficacy of rTMS for other anxiety disorders, namely
panic disorder and a specific phobia (acrophobia, or the fear of
heights). Regarding the latter, the single available study
(Herrmann et al., 2017) tested only two sessions of 10 Hz-rTMS
of the mPFC, and thus was not considered.For the study on panic disorder, results were reported in two
papers (Deppermann et al., 2014, 2017). This double-blind trial
was performed in 44 patients, with or without agoraphobia,
equally randomized to real or sham iTBS delivered to the left DLPFC
for 15 daily sessions in the first third of a 9-week course of Cogni-
tive Behavioral Therapy (CBT). While symptom improvement was
reported overall, no differences were found between the two
groups (real vs. sham). Previously, two RCTs had described the
effects of 1 Hz-rTMS delivered at 110% RMT to the right DLPFC
for either 10 (Prasko et al., 2007) or 20 days (Mantovani et al.,
2013). The first study was based on a smaller sample (15 patients)
and did not result in significant differences between real vs. sham
stimulation groups (Prasko et al., 2007). Conversely, in Mantovani
et al. (2013) a significantly greater improvement was observed in
the 12 patients who received real stimulation than in the sham
group (13 patients). Nevertheless, heterogeneity between these
studies does not allow for a recommendation regarding rTMS to
treat panic disorder.
13.2. Post-traumatic stress disorder
In post-traumatic stress disorder (PTSD), the main cortical tar-
get that was evaluated was the right DLPFC, stimulated at low or
high frequency. Regarding studies published prior to 2014, benefi-
cial effects on the core symptoms of PTSDwere found in three Class
III sham-controlled studies, including at least 10 patients in the
real stimulation group. Two studies showed beneficial effects of
HF-rTMS delivered to the right DLPFC in small series of 16 patients
(10 real, 6 sham) (Cohen et al., 2004) and 20 patients (10 real, 10
sham) (Boggio et al., 2010). One study showed beneficial effects
of LF-rTMS delivered to the right DLPFC in 20 patients (10 real,
10 sham) (Watts et al., 2012). In the study of Cohen et al. (2004),
8 additional patients received real 1 Hz-rTMS over the right DLPFC
(10 daily sessions with 100 pulses per session), but the protocol
was less beneficial than HF-rTMS. Finally, Boggio et al. (2010) also
showed a significant decrease in PTSD symptoms after HF-rTMS
applied to the left DLPFC, but to a lesser extent than after right-
sided stimulation. In this study, mood improved after left-sided
HF-rTMS, while anxiety was reduced after right-sided HF-rTMS.
The reduction of anxiety following HF-rTMS of the right DLPFC
was also found by Cohen et al. (2004). Thus, 10 daily sessions of
HF-rTMS of the right DLPFC was found to provide the greatest ther-
apeutic impact in patients with PTSD, with a Level C of Evidence
(Lefaucheur et al., 2014). This procedure was able to provide
long-lasting improvement in PTSD symptoms, still significant
3 months after the last session (Boggio et al., 2010), while in case
of LF-rTMS, therapeutic efficacy was already decreasing at 2-
month follow-up (Watts et al., 2012).
Since 2014, only one additional sham-controlled study based on
HF-rTMS of the right DLPFC was reported (Ahmadizadeh and
Rezaei, 2018). In this study, 58 patients with PTSD were random-
ized to receive real 20 Hz-rTMS over the right DLPFC only
(n = 19) or the both right and left DLPFC (n = 19) or a sham proce-
dure with a sham coil (n = 20). The parameters of stimulation con-
sisted of 10 sessions over 4 weeks (3 sessions/week for the first
two weeks and 2 sessions/week for the last two weeks) with
2400 pulses/session (all over the right DLPFC, or 1200 pulses over
the right DLPFC followed by 1200 pulses over the left DLPFC), per-
formed at 100% of RMT, with the DLPFC target defined according to
the 5 cm-rule. The proportion of responders (defined as PTSD
checklist military version (PCL-M) total score improvement  2
standard deviations) was significantly higher after real unilateral
or bilateral rTMS compared to sham rTMS (41.2%, 62.5%, and 0%
of responders, respectively). At the end of the 4-week protocol, a
greater reduction in the PCL-M total score was found in the real
stimulation groups (without significant difference between unilat-
512 J.-P. Lefaucheur et al. / Clinical Neurophysiology 131 (2020) 474–528eral and bilateral stimulation) compared to the sham group. The
’positive’ results of this Class II study, in addition to those of the
two Class III studies previously reported (Cohen et al., 2004;
Boggio et al., 2010), allow a Level B of Evidence (probable efficacy)
to be reached concerning the application of HF-rTMS to the right
DLPFC in the treatment of PTSD.
Regarding LF-rTMS of the right DLPFC, the study of Watts et al.
(2012) showed advantage of real stimulation relative to sham on
20 patients (10 real, 10 sham), and that of Cohen et al. (2004)
showed no real benefit of the procedure in 14 patients (8 real, 6
sham). Since then, additional sham-controlled studies assessed this
procedure only in small samples (less than 10 patients receiving
real LF-rTMS protocol). For example, in a series of 16 patients (7
real, 9 sham), Nam et al. (2013) showed a greater improvement
over time (up to 5-week follow-up) in the Clinician-Administered
PTSD Scale (CAPS) total score and the reexperiencing subscore after
real versus sham stimulation. The rTMS protocol consisted of 15
daily sessions (over 3 weeks) of 1 Hz-rTMS (1200 pulses per ses-
sion) delivered at 100% of RMT over the right DLFPC (defined with
the 5 cm-rule).
Other studies combined LF-rTMS of the right DLFPC and cogni-
tive therapy. First, in a sham-controlled crossover study of 9
patients with PTSD, Osuch et al. (2009) found a moderate improve-
ment in hyperarousal subscore of the CAPS after such a combined
protocol. Kozel et al. (2018) applied 1 Hz-rTMS to the right DLPFC
(defined with the Beam-F4 method) just prior to Cognitive Process-
ing Therapy (CPT) for 12–15 daily sessions (1800 pulses/session at
110% of RMT) in a large series of 62 military veterans (32 real, 30
sham). A 6-month follow-up was completed by 59 patients. The
real rTMS + CPT group showed greater improvement (assessed on
CAPS and PCL-M) compared to the sham rTMS + CPT group at the
end of the rTMS protocol with sustained benefit up to 6 months
post-treatment.
Thus, LF-rTMS of the right DLPFC could be an alternative to HF-
rTMS of the right DLPFC in patients with PTSD. These two protocols
were compared in a recent study (Kozel et al., 2019), including 27
patients (14 patients treated by 1 Hz-rTMS and 13 by 10 Hz-rTMS
for 5 sessions/week during 6 weeks). Both groups significantly
improved on various PTSD and depression scores without any
advantage for either LF- or HF-rTMS, except the Inventory of Psy-
chosocial Functioning (IPF) score, in which there was significant
advantage for 10 Hz-rTMS. In conclusion, regarding LF-rTMS of
the right DLPFC, one Class III study was positive (Watts et al.,
2012), two studies did not meet the requirement of 10 patients
receiving real rTMS and showed conflicting results (Cohen et al.,
2004; Nam et al., 2013), while two other positive studies assessed
the effects of combined cognitive therapy and rTMS (Osuch et al.,
2009; Kozel et al., 2018). Thus, and even though one study (Kozel
et al., 2019) did not find substantial differences of efficacy for LF-
rTMS compared to HF-rTMS of the right DLPFC (which has Level
B of Evidence, see above), further work is still required before mak-Table 18
LF-rTMS of the DLPFC in obsessive compulsive disorder.
Articles Number
of
patients
Target,
coil type
Control
condition
Stimulation
frequency
and
intensity
Numbe
pulses
and nu
session
Elbeh et al. (2016) 30 (real:
15,
sham:
15)
Right
DLPFC
(5 cm-
rule), F8c
Tilted coil 1 Hz, 100%
RMT
2000 p
session
Seo et al. (2016) 27 (real
14, sham
13)
Right
DLPFC
(5 cm-
rule), F8c
Sham coil 1 Hz, 100%
RMT
1200 p
sessioning a relevant recommendation on the use of LF-rTMS of the right
DLPFC in the treatment of PTSD.
Finally, one research group applied a protocol of 20 Hz-rTMS in
patients with PTSD after a brief exposure to a script of the trau-
matic event within the same session, for 12 sessions over 4 weeks
(Isserles et al., 2013). In this study, a bihemispheric mPFC area
(rather than the right DLPFC) was stimulated using a H1-coil. The
real stimulation, performed in 9 patients, reduced the Clinician-
Administered PTSD Scale (CAPS) total score and various CAPS sub-
scores, while no change was observed in cases of sham stimulation
(9 patients) or previous exposure to a non-traumatic script (8
patients). Such larger and more medial HF-rTMS application over
prefrontal regions was not replicated to date.13.3. Obsessive compulsive disorder
A PubMed search (keywords: (rTMS OR theta burst stimulation)
AND obsessive compulsive disorder) identified 51 papers, includ-
ing 9 original sham-controlled studies with at least 10 patients
receiving real stimulation for several daily sessions.
To treat obsessive compulsive disorder (OCD), either LF- or HF-
rTMS was applied, using either a focal or a non-focal coil, over var-
ious cortical targets, such as the DLPFC (of the right or both right
and left hemispheres), the right orbitofrontal cortex (OFC), or more
medial regions, including the mPFC-ACC and the (pre-)SMA
(Lusicic et al., 2018).13.3.1. LF-rTMS of orbitofrontal/prefrontal regions
Regarding focal stimulation (using a figure-of-8 coil) delivered
at 1 Hz over the right DLPFC, two independent sham-controlled
studies were published since 2014 (Table 18). One study (Elbeh
et al., 2016) showed the superiority of 1 Hz-rTMS of the right
DLPFC as compared with 10 Hz-rTMS or sham rTMS delivered to
same target, to improve OCD symptoms, assessed on the Yale-
Brown-Obsessive-Compulsive Scale (YBOCS), as well as anxiety,
assessed on HARS. In this study, 45 patients were equally random-
ized to receive 10 session of real LF-rTMS, real HF-rTMS, or a sham
procedure. The second study (Seo et al., 2016) also reported the
efficacy of 1 Hz-rTMS of the right DLPFC, compared to a sham con-
dition, in a series of 27 patients with OCD of at least moderate
severity and no comorbid psychiatric disorders other than depres-
sion. In contrast, one sham-controlled study performed before
2014 (Alonso et al., 2001) had reported ’negative’ results with no
significant change in YBOCS score after real LF-rTMS of the right
DLPFC. However, this older study was based on a very small sample
(10 patients in the real stimulation group and 8 patients in the
sham group) and a non-focal stimulation using a circular coil. Focal
1 Hz-rTMS of the left DLPFC also did not show any effect on OCD
symptoms in an earlier study (Prasko et al., 2006). However, from
the two recent sham-controlled Class II/III studies providing ’posi-r of
/session
mber of
s
Significant clinical effects of real versus sham condition Class
of the
study
ulses, 10
s
Significant reduction of YBOCS and HARS scores at the end
of the 2-week protocol (YBOCS: real: 45%, sham: 6%;
HARS: real: 41%, sham: 6%) and 3 months after YBOCS:
real: 41%, sham: 8%; HARS: real: 40%, sham: 11%)
II
ulses, 15
s
Significant reduction of YBOCS score at the end of the 3-
week protocol (real: –32%, sham: 12%).
III
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posed for focal LF-rTMS of the right DLPFC in OCD.
Two studies also performed 1 Hz-rTMS, but using a large, non-
focal coil. Firstly, in a crossover study of 19 patients with OCD,
Nauczyciel et al. (2014) delivered 1 Hz-rTMS over the right OFC
using a large double-cone coil for 10 daily sessions (1200 pulses/
session). Only a trend towards a better improvement was observed
after real vs. sham stimulation (19% vs. 6% reduction on YBOCS
score, respectively). More beneficial results had been previously
published by Ruffini et al. (2009) using 1 Hz-rTMS applied to the
left OFC using a focal figure-of-8 coil.
Secondly, Carmi et al. (2018) used an H7 coil, designed to stim-
ulate a bihemispheric mPFC area including the ACC. A daily rTMS
session was performed for five weeks at 1 Hz, but also at 20 Hz,
or according to a sham procedure. Clinical improvement, measured
on the YBOCS, was observed following HF-, but not LF-rTMS, com-
pared to sham. From these results, no conclusion can be drawn for
the use of non-focal LF-rTMS of orbitofrontal/prefrontal regions in
OCD.
13.3.2. HF-rTMS of prefrontal regions
Other research groups assessed the efficacy of HF-rTMS (rather
than LF-rTMS) delivered with either a focal or a non-focal coil over
prefrontal regions to improve OCD symptoms.
Before 2014, two sham-controlled studies assessed the value of
focal HF-rTMS delivered to the right DLPFC, both showing no sig-
nificant difference between the real and sham procedures
(Sarkhel et al., 2010; Mansur et al., 2011). These results are consis-
tent with those reported by Elbeh et al. (2016) showing the
absence of superiority of 10 Hz-rTMS of the right DLPFC compared
to a sham procedure. Similarly, focal HF-rTMS of the left DLPFC was
proved to be ineffective for improving treatment-resistant OCD
(Sachdev et al., 2007).
Focal, but bilateral HF-rTMS of DLPFC regions was performed in
3 studies published by the same group of authors (Haghighi et al.,
2015; Jahangard et al., 2016; Shayganfard et al., 2016). They deliv-
ered bihemispheric 20 Hz-rTMS using a figure-of-8 coil over the
left then the right DLPFC (targeted according to the 5 cm-rule)
within the same session (750 pulses per hemisphere and per ses-
sion at 100% of RMT) for 10 sessions. These 3 crossover studies,
including 10–21 patients, reported the superiority of real HF-
rTMS as compared with the sham procedure (tilted coil) to
improve OCD symptoms (30–35% reduction of YBOCS score on
average in the real stimulation condition compared to less than
5% reduction in the sham condition). Cognitive, but not executive
functions also improved.
In one study (Ma et al., 2014), a circular coil was used to stim-
ulate a more medial region, centered halfway between the right
and left DLPFC (defined accoding to F4-P4 and F3-P3 sites, respec-
tively). In this sham-controlled study of 46 patients (25 real, 21
sham), rTMS pulse frequency was synchronized to the alpha fre-
quency (8–12 Hz) of EEG activity previously recorded in each indi-
vidual. Beneficial effects of 10 sessions of HF-rTMS (648–872
pulses/session delivered at 80% of RMT) were reported at the end
of 2-week treatment and 1-week follow-up in the real vs. sham
stimulation group, both on YBOCS score (32–34% vs. 15–18%
reduction, respectively) and HARS score (34–36% vs. 14–22%
reduction, respectively).
As aforementioned, Carmi et al. (2018) used an H7 coil to stim-
ulate a large and deep bihemispheric mPFC-ACC region, with indi-
vidualized symptom provocation preceding rTMS sessions. Clinical
improvement was observed after 20 Hz-rTMS (n = 7), but not LF-
rTMS (n = 8), compared to sham (n = 8), with a significantly higher
percentage of responders (defined as YBOCS reduction > 30%) for at
least one month following the last rTMS session. Due to this
interim analysis, recruitment for the LF group was interrupted,and results from a larger multicenter trial comparing HF-rTMS to
sham, coordinated by the same group, were recently published
(Carmi et al., 2019). A significant difference in reduction of YBOCS
scores was found among patients that completed the trial when
comparing HF-rTMS (n = 42, 45.2% responders) to sham (n = 45,
17.8% responders), which has allowed for FDA clearance of non-
focal HF-rTMS for bilateral stimulation of mPFC-ACC regions, com-
bined with individualized symptom provocation, in OCD.
A large and deep HF-rTMS protocol was also assessed in OCD
patients using a double-cone coil to stimulate the dmPFC-ACC con-
nectivity, as performed by the same research group in depression
(Bakker et al., 2014; Downar et al., 2014; Salomons et al., 2014).
In a Class IV study with an open-label design (Dunlop et al.,
2016), 20 patients with treatment-resistant OCD received 20 daily
sessions (over 4 weeks) of 10 Hz-rTMS delivered on the left then
the right dmPFC within the same session (3000 pulses per hemi-
sphere and per session) using with a double-cone coil and a navi-
gation system. Target location corresponded to 25% of the total
distance from nasion to inion, slightly anterior to the location of
pre-SMA target. Ten patients (50%) were responders to the rTMS
procedure (improvement  50% on YBOCS score). The clinical
response correlated to the reduction of a higher dmPFC-ventral
striatal connectivity at baseline, assessed on resting-state fMRI.
While there were several positive Class II and III studies for pre-
frontal HF-rTMS in OCD, the methods used are too heterogenous to
make any recommendation on the use of rTMS, delivered focally
over the right and/or left DLPFC, or less focally over prefrontal
regions using a circular, H7, or double-cone coil. However, as men-
tioned above, the FDA recently approved the use of deep rTMS as
an adjunct for the treatment of adult patients suffering from OCD
(on August 16, 2018), according to the protocol described in the
study of Carmi et al. (2018) and the subsequent findings reported
in a multicenter randomized trial of approximately 100 OCD
patients (Carmi et al., 2019). This protocol consists in using an
H7 coil to stimulate a bihemispheric mPFC-ACC region at 20 Hz.
13.3.3. LF-rTMS of pre-SMA
Before 2014, two sham-controlled studies reported results of
1 Hz-rTMS delivered bilaterally to the pre-supplementary motor
area (pre-SMA) for 4 weeks in 18 patients (9 real, 9 sham)
(Mantovani et al., 2010) or 2 weeks in 22 patients (12 real, 10
sham) (Gomes et al., 2012). Both studies assessed the average
reduction of YBOCS score and the rate of responders after real stim-
ulation compared to a sham procedure. Beneficial results were
reported, but they were significant compared to sham control only
in the study of Gomes et al. (2012).
Since 2014, 3 additional sham-controlled studies investigated
the efficacy of LF-rTMS similarly targeted to the pre-SMA
(Table 19). When compared to a sham condition, real stimulation
was found to be more efficacious to improve OCD symptoms in
one study (Hawken et al., 2016). In contrast, bilateral pre-SMA
stimulation was found to be ineffective in the other two studies
(Pelissolo et al., 2016; Arumugham et al., 2018). In one of these
studies (Pelissolo et al., 2016), the pre-SMA target location was
defined on individual MRI using a navigation system and all
patients had severe, drug-refractory OCD symptoms. In the second
study (Arumugham et al., 2018), patients were less severe, includ-
ing partial responders to antidepressant medications.
In the meta-analysis of Rehn et al. (2018) rTMS was found to
produce overall a modest effect in reducing YBOCS scores and LF-
rTMS of the pre-SMA yielded the greatest reductions relative to
other cortical targets and stimulation frequency. However, accord-
ing to our criteria taking into account conflicting results across
studies on the significance of the differential effect between real
vs. sham stimulation, no recommendation can be made to date
for LF-rTMS of pre-SMA in the context of OCD.
Table 19
Bilateral LF-rTMS of the pre-SMA in obsessive compulsive disorder.
Articles Number
of
patients
Target, coil type Control
condition
Stimulation
frequency
and
intensity
Number of
pulses/session
and number of
sessions
Significant clinical effects of real versus sham
condition
Class
of the
study
Hawken
et al.
(2016)
22 (real:
10,
sham:12)
Pre-SMA (defined as
15% anterior to Cz, on
the nasion-inion line),
F8c
Tilted coil 1 Hz, 110%
RMT
1200 pulses, 25
sessions
Significant reduction of YBOCS score at the end of the
6-week protocol (real: 40%, sham: 5%), with benefit
maintained at 6 weeks after the last rTMS session
III
Pelissolo
et al.
(2016)
34 (real:
19,
sham:
15)
Pre-SMA (defined
using image-guided
navigation system),
F8c
Sham coil 1 Hz, 100%
RMT
1500 pulses, 20
sessions
No difference between real and sham stimulation on
YBOCS score reduction (real: 13%, sham: 11%) and
responder rate (YBOCS reduction > 25%: real: 10%,
sham: 20%) at the end of the 4-week protocol
II
Arumugham
et al.
(2018)
36 (real:
19,
sham:
17)
Pre-SMA (defined as
15% anterior to Cz, on
the nasion-inion line),
F8c
Sham coil 1 Hz, 100%
RMT
1200 pulses, 18
sessions
No difference between real and sham stimulation on
YBOCS reduction
III
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rTMS in OCD, using different approaches. In one study (Kang et al.,
2009b), LF-rTMS was sequentially delivered over the right DLPFC
and SMA (1200 pulses per site and per session at 100–110% of
RMT) in 20 patients equally randomized to receive 10 sessions of
either real or sham stimulation. No significant effect of the real
procedure was observed on YBOCS and depression scores com-
pared to sham control (tilted coil).
Finally, in a naturalistic open-label study, Singh et al. (2019) tar-
geted either the bilateral SMA (46 patients) or the left OFC (33
patients) using 1 Hz-rTMS in medication-resistant OCD. A majority
of patients (57%) met criteria for partial clinical response (reduc-
tion of YBOCS score > 25%) and 40% were ’complete’ responders
(reduction of YBOCS score > 35%). However, there was no signifi-
cant difference between patients receiving LF-rTMS over bilateral
SMA or left OFC. The presence of comorbid depression and higher
baseline YBOCS score was associated with lower response to rTMS.
13.4. Autism spectrum disorders
A PubMed search (keywords: (rTMS OR theta burst stimulation)
AND autism) identified 29 papers, including only one original
sham-controlled study with at least 10 patients receiving real
stimulation for several daily sessions (Enticott et al., 2014). In this
sham-controlled study, 28 adults with Asperger’s disorder (15 real,
13 sham) underwent 10 daily sessions of deep 5 Hz-rTMS (1500
pulses/session) using a HAUT-coil (H3-coil), which was designed
to stimulate the dmPFC bilaterally. A significant reduction in social
relating symptoms (especially self-oriented anxiety during difficult
and emotional social situations) was found after real stimulation
and not in the sham group.
Another study compared the effect of 1 Hz-rTMS of the left
DLPFC (F3 site, 20 daily sessions, 1500 pulses/session, 90% of
RMT) and anodal tDCS over the same target in 24 children with
autism spectrum disorder (Gomez et al., 2017). In this open-label
study (Class IV), children < 10 years received tDCS, whereas chil-
dren > 11 years received rTMS. A significant improvement of symp-
tom severity in autism-related scores was observed in the rTMS
group with no difference between rTMS- and tDCS-induced
changes.
To our knowledge, all other rTMS/TBS studies performed in the
context of autism had an open-label desing or were based on single
sessions and did not meet our study requirements. For example,
one randomized, sham-controlled, crossover trial assessed the
value of single sessions of iTBS applied bilaterally over the DLPFC
or the posterior superior temporal sulcus (pSTS) in 19 adults with
autism spectrum disorder (Ni et al., 2017). Compared to an active
sham control (real stimulation over the inion), the reaction timein the Conners’ Continuous Performance Test was reduced after
the iTBS session delivered over the bilateral DLPFC, but not the
pSTS. An open-label pilot study also showed that 15 sessions of
iTBS delivered over the right DLPFC under neuronavigation guid-
ance could improve executive functions, YBOCS score, and repeti-
tive behaviors in 10 patients with autism spectrum disorder
(Abujadi et al., 2018).
Overall, the existing evidence concerning the use of rTMS to
treat various aspects of autism spectrum disorders is relatively
weak taken into consideration the small sample sizes, the hetero-
geneity in clinical presentation and measures, and the variety of
rTMS protocols and targets among the studies (Barahona-Corrêa
et al., 2018; Cole et al., 2019).
13.5. Attention deficit hyperactivity disorder
A PubMed search (keywords: (rTMS OR theta burst stimulation)
AND attention deficit hyperactivity disorder) identified 11 papers,
but no original sham-controlled studies with at least 10 patients
receiving real stimulation for several daily sessions. Only one orig-
inal sham-controlled study deserves to be mentioned, which is the
study of Paz et al. (2018). In this study, deep HF-rTMS was per-
formed over bilateral DLPFC areas using an H5-coil (20 sessions
of 1980 pulses/session delivered at 18 Hz) in 22 adults with atten-
tion deficit hyperactivity disorder (9 real, 13 sham), but did not
result in any clinical benefit.
13.6. Mental retardation
A single Class IV study performed on 45 right-handed children
with mental retardation of various aetiologies is worth mentioning
(Qiu et al., 2016). In 24 children aged 2–3 years, a 10-day protocol
of non-navigated HF-rTMS of the left IFG (Broca’s area) was per-
formed coupled with traditional language training, whereas 21
age-matched children received language training only. The com-
bined procedure (HF-rTMS + language training) produced better
clinical improvement than laguage training performed alone, in
terms of movement ability and linguistic competence. This result
is in line with those above described for the rehabilitation of
aphasia.
13.7. Functional neurological disorders
One sham-controlled, crossover Class III study was conducted to
verify whether rTMS, without other concomitant therapies, may
improve functional flaccid paresis (Broersma et al., 2015). This
study enrolled 12 patients with unilateral or asymmetric paresis
lasting from 4 weeks to 25 years, but only 8 of these 12 patients
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consisted of neuronavigated 15 Hz-rTMS delivered over the hand
M1 area contralateral to the paretic limb(s) once daily over 10 con-
secutive weekdays (9000 pulses/session at 80% of RMT). An objec-
tive increase in muscle strength of the paretic hand (measured by a
dynamometer) was found after real stimulation (+24% on average)
but not after realistic sham procedure (+6%). However, subjective
ratings showed that patients did not perceive this objectively mea-
sured motor improvement. In addition, no long-term follow-up
was included in this study, and therefore it remains to be demon-
strated that rTMS can have a real therapeutic benefit in patients
with functional paresis.
14. Summary of recommendations
This work updates the evidence-based recommendations that
were previously established by a group of European experts
regarding the potential therapeutic applications of rTMS in the
neurological, ENT, and psychiatric domains (Lefaucheur et al.,
2014). New recommendations are summarized in Table 20.
Level A evidence (definite efficacy) is still proposed for HF-rTMS
of M1 contralateral to pain side in neuropathic pain and for HF-
rTMS of the left DLPFC in MDD using a figure-of-8 coil, but also a
H1-coil. The same recommendation is now proposed for LF-rTMS
of contralesional M1 in hand motor recovery at the postacute stage
of stroke.
Level B evidence (probable efficacy) is still proposed for: (i) LF-
rTMS of the right DLPFC in MDD; (ii) HF-rTMS of the left DLPFC forTable 20
Summary of recommendations on rTMS efficacy according to clinical indication.
Neuropathic pain Definite analgesic efficacy of HF-rTMS of M1 contrala
CRPS type I Possible analgesic efficacy of HF-rTMS of M1 contral
Fibromyalgia Probable efficacy of HF-rTMS of the left M1 in imp
Fibromyalgia Probable analgesic efficacy of HF-rTMS of the left
Parkinson’s disease Probable efficacy of HF-rTMS of bilateral M1 regio
Parkinson’s disease Probable antidepressant efficacy of HF-rTMS of the le
Motor stroke Definite efficacy of LF-rTMS of contralesional M1 i
Motor stroke Probable efficacy of HF-rTMS of ipsilesional M1 in
Motor stroke Possible efficacy of LF-rTMS of contralesional M1 i
Post-stroke aphasia Probable efficacy of LF-rTMS of right IFG in nonflu
Hemispatial neglect Possible efficacy of cTBS of the contralesional left par
C)
Multiple sclerosis Probable efficacy of iTBS of the leg area of M1 contr
B)
Epilepsy Possible antiepileptic efficacy of LF-rTMS of the epile
Alzheimer’s disease Possible efficacy of multisite rTMS-COG to improve
mild/early stage of the disease (Level C)
Tinnitus Possible efficacy of LF rTMS of the auditory cortex of t
C)
Depression Definite antidepressant efficacy of HF-rTMS of the le
Depression Definite antidepressant efficacy of deep HF-rTMS o
Depression Probable antidepressant efficacy of LF-rTMS of the ri
Depression Probable antidepressant efficacy of bilateral right-s
B)
Depression Probable antidepressant efficacy of bilateral right-
(Level B), while unilateral right-sided cTBS is possi
Depression Possibly no differential antidepressant efficacy bet
DLPFC, and rTMS performed alone vs. combined w
Post-traumatic stress
disorder
Probable efficacy of HF-rTMS of the right DLPFC in
Obsessive compulsive
disorder
Possible efficacy of LF-rTMS of the right DLPFC in
Schizophrenia:auditory
hallucinations
Possible efficacy of LF-rTMS of the left TPC in audito
Schizophrenia: negative
symptoms
Possible efficacy of HF-rTMS of the left DLPFC on n
Addiction and craving Possible efficacy of HF-rTMS of the left DLPFC on cig
In all other conditions, there is ‘‘no recommendation”, which means the absence of suffic
Recommendations that change from our previous work (Lefaucheur et al., 2014) are shotreating depression in PD patients. The same recommendation is
now proposed in 9 new condtions: (i) HF-rTMS of the left M1 in
improving quality of life of patients with fibromyalgia; (ii) HF-
rTMS of the left DLPFC in relieving pain in patients with fibromyal-
gia; (iii) HF-rTMS of bilateral M1 regions in improving motor
symptoms of PD patients; (iv) HF-rTMS of ipsilesional M1 in pro-
moting hand motor recovery at the postacute stage of stroke; (v)
iTBS of the leg motor cortex in relieving lower limb spasticity in
MS; (vi) LF-rTMS of right IFG in promoting nonfluent aphasia
recovery at the chronic stage of stroke; (vii) bilateral right-sided
LF-rTMS and left-sided HF-rTMS of the DLPFC in MDD; (viii) bilat-
eral right-sided cTBS and left-sided iTBS of the DLPFC in major
unipolar depression; (ix) HF-rTMS of the right DLPFC in PTSD.
Level C evidence (possible efficacy) is still proposed for: (i) HF-
rTMS of M1 contralateral to pain side in CRPS type I; (ii) cTBS of the
contralesional left PPC in visuospatial hemineglect recovery at the
post-acute stage of stroke; (iii) LF-rTMS of the epileptic focus to
treat chronic epilepsy; (iv) LF-rTMS of the auditory cortex of the
left hemisphere (or contralateral to the affected ear) in chronic tin-
nitus; (v) of LF-rTMS of the left TPC in auditory hallucinations in
schizophrenia; (vi) HF-rTMS of the left DLPFC on cigarette craving
and consumption. From our previous work, the level of evidence
decreased from B to C in three conditions that were: (i) LF-rTMS
of the contralesional M1 in hand motor recovery at the chronic
stage of stroke; (ii) the differential antidepressant efficacy
between: right LF-rTMS vs. left HF-rTMS, bilateral vs. unilateral
rTMS of the DLPFC, and rTMS performed alone vs. combined with
antidepressants; (iii) HF-rTMS of the left DLPFC on negative symp-teral to pain side (Level A), while LF-rTMS is probably ineffective (Level B)
ateral to pain side (Level C)
roving quality of life of patients with fibromyalgia (Level B)
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to C in two other conditions, namely: (i) multisite rTMS-COG to
improve cognitive function, memory and language level of AD
patients, especially at a mild/early stage of the disease; (ii) LF-
rTMS of the right DLPFC in OCD.
For conditions in which no recommendation has been proposed,
this does not mean that no effect can be obtained in selected
responders, taking into account the high interindividual response
to rTMS protocols. On the other hand, the current recommenda-
tions are based on the differences reached in therapeutic efficacy
of real vs. sham rTMS protocols, replicated in a sufficient number
of independent studies. This does not mean that the benefit pro-
duced by rTMS inevitably reaches a level of clinical relevance.
Compared to meta-analyses, several limitations of the present
systematic review must be acknowledged. For instance, in the
meta-analyses published in the Cochrane Library (Li et al.,
2014b; Pollock et al., 2014; Dougall et al., 2015; Chen et al.,
2016; Bath et al., 2018; O’Connell et al., 2018), two important cri-
teria are taken into account in the assessment of the risk of bias
that are sample size and study duration. Regarding sample size,
Cochrane reviews attribute a high risk of bias for studies with
fewer than 50 participants per arm, an unclear risk of bias for stud-
ies with between 50 and 199 participants per arm, and a low risk of
bias only for studies with 200 or more participants per arm. How-
ever, such sample sizes are rarely achieved in rTMS studies and in
the present work, we only differentiated the studies according to
whether they had more or fewer than 25 or 10 patients in the real
stimulation arm (Class I vs. II-III studies).
Regarding study duration, Cochrane reviews attribute a low risk
of bias for studies with follow-up of 8 weeks or longer, an unclear
risk of bias for studies with follow-up of 2–7 weeks, and a high risk
of bias for studies with follow-up of less than 2 weeks. The dura-
tion of the follow-up was not taken into account in the present
work, but it must be admitted that the vast majority of studies
involved a follow-up not exceeding a few weeks during or beyond
the stimulation time.
A highly structured evaluation of the quality of the evidence
provided by studies in controversial literature, such as for rTMS,
can also provide answers regarding the therapeutic value of this
intervention. The Grading of Recommendations Assessment,
Development, and Evaluation (GRADE) system (Balshem et al.,
2011; Guyatt et al., 2011; Schünemann et al., 2011) integrates mul-
tiple aspects of the published studies into a critical rating of the
quality of the evidence. In the GRADE system, evidence of the out-
come of a study is categorized as high, moderate, low, or very low
based on experts’ confidence in the estimate of the effect. This
assessment takes into account 5 factors that can downgrade the
quality level of a set of evidence: (i) limitations in the design and
execution of the studies (risk of bias in patients’ selection, group
allocation, blinding, selective reporting. . .), (ii) inconsistency
(unexplained heterogeneity of results across studies), (iii) indirect-
ness (according to differences in population definition, interven-
tions, outcome measures or comparisons), (iv) imprecision (small
sample size, wide confidence intervals), and (v) publication bias
(overestimation of the effect because positive results are most
likely to be reported than negative or null findings).
Whether to rate up or down the quality of the body of evidence
for each outcome is a matter of judgment. In the present work, the
risk of bias related to study limitations was taken into account to
downgrade from Class I to Class II the studies including 25 or more
patients in the real stimulation arm or from Class II to Class III the
studies with a smaller sample. Inconsistency and indirectness were
also considered, e.g., regarding the influence of the heterogeneity
of rTMS protocol patterns, clinical profiles of patients, types of
symptoms treated or outcome measures. On the other hand, we
did not estimate the size of the treatment effect, which is usuallydone by calculating the standardized mean difference (SMD) in
the results provided by the active treatment (real rTMS) and pla-
cebo comparator (sham rTMS) across studies. This calculation
makes it possible to standardize the results and to obtain a pooled
effect size regardless of the variability of the intervention effect
between the studies combined for the analyses.
We did not perform this quantified evaluation and we focused
instead on the fact that results were replicated by independent
teams. Indeed, most meta-analyses do not take care that large sam-
ples can come from a single team or research network with redun-
dancies in terms of the origin of the published data. In addition,
one must always keep in mind that very large studies are more
likely to find a statistically significant difference for a trivial effect
that does not really make clinical sense (Ioannidis, 2005). There-
fore, beyond sample sizes, focusing on the replication of results
plays an important role in improving the reliability of research out-
comes (Ioannidis, 2014). In our work, for studies based on the same
methodology applied to patients with the same clinical profile,
only one study was selected per research group at most. The fact
that the results were reproduced by independent teams in differ-
ent articles clearly had more impact in our study than a multicen-
ter study based on a very large sample. This explains why a similar
level of evidence could be attributed in this work to the effects of
rTMS on pain, stroke and MDD, although sample sizes were largely
greater in the latter condition.
In conclusion, differences in the methodology of data analysis
lead to differences in the level of evidence across systematic
reviews and meta-analyses. As an example, in other systematic
reviews based on the GRADE system, the level of evidence of rTMS
efficacy was lower than in our work. For example, HF-rTMS of the
motor cortex reached a ’weak for’ recommendation in neuropathic
pain and fibromyalgia (Cruccu et al., 2016) with a low quality evi-
dence for short-term effects on chronic pain and quality of life, due
to issues of blinding and precision (O’Connell et al., 2018). Con-
versely, other meta-analyses reported a significant analgesic effi-
cacy of active rTMS compared to sham rTMS according to effect
size measurement based on SMD (Jin et al., 2015) or odds ratios
(ORs) up to 4 (Goudra et al., 2017). Regarding therapeutic effects
on depression, one meta-analysis reported higher ORs for various
rTMS procedures (ranging between 1.7 and 7.4) (Mutz et al.,
2018) than what has been shown for most antidepressant drugs
(ranging between 1.4 and 2.1) (Cipriani et al., 2018).
Although rTMS was approved or cleared for ‘‘safety and effi-
cacy” in various therapeutic indications by regulatory agencies,
such as the FDA, there is still a need for substantially larger, rigor-
ously designed studies, particularly including longer courses of
stimulation sessions. As emphasized in our previous article, future
rTMS studies must gain in rigor and power on the following ele-
ments: randomized parallel-group design, sufficient sample size,
accurate targeting, especially using neuronavigation and robotic
arm systems, realistic sham procedure (Rossi et al., 2007;
Mennemeier et al., 2009), double-blinding, and clinically relevant
outcome measures.
On the other hand, technical developments include new forms
of coils and magnetic field geometry (Deng et al., 2013, 2014;
Tendler et al., 2016; Goetz and Deng, 2017; Koponen et al.,
2017), and tailored strategies, based on neuroimaging methods
(e.g., fMRI or diffusion tensor MRI tractography) (Grefkes and
Fink, 2014; Bergmann et al., 2016; Diekhoff-Krebs et al., 2017),
on neurophysiological methods (e.g., high-resolution EEG)
(Bergmann et al., 2016), on concurrent TMS-EEG method
(Tremblay et al., 2019), or on clinical response to single test ses-
sions (Kreuzer et al., 2017). All these data can serve to adapt the
rTMS protocol to a personalized medicine approach.
Even personalized, therapeutic applications of rTMS were
always performed with an open-loop design to date, while one of
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loop configuration (Gharabaghi et al., 2014; Karabanov et al.,
2016; Zrenner et al., 2016, 2018; Mansouri et al., 2018). A
closed-loop configuration means that all TMS pulses are delivered
at a well-defined time, generally according to EEG activity recorded
and analyzed in real-time. Using such a strategy, rTMS could be
coupled with neuronal activities for brain-state dependent and
adaptive stimulation procedure. New coil design could be devel-
oped to offer the possibility to stimulate online at multiple sites
of the brain according to the occurrence of specific neural triggers
in a feedback-controlled stimulation procedure (Koponen et al.,
2018).
Finally, beyond statistical levels of evidence or estimates of
effect size and our confidence in these estimates, the clinical
importance of the proposed therapeutic efficacy must be consid-
ered. The present work only provides arguments to be confident
that some rTMS protocols do something that is different from a
placebo in some indications, but not that the results obtained are
clinically relevant. Clinical relevance in routine practice also
requires that rTMS therapy provides beneficial effects in the long
term. The optimal time window for applying rTMS treatment
should also be specified, i.e. its place in the therapeutic decision
tree, especially in the management of MDD and chronic pain. It
is probably better defined in other clinical conditions, such as
motor stroke, for which the requirements to use rTMS in the posta-
cute or chronic stages are different. However, given the relatively
coarse and therefore debatable definitions of the acute, postacute
and chronic post-stroke phase, which do not represent uniform
periods with sharp boundaries but rather a continuum with differ-
ent time-sensitive processes, a more systematic assessment of the
optimal time window to treat patients with rTMS is needed, ideally
based on individual markers of the responsiveness to rTMS. Fur-
thermore, the objective of rTMS as an add-on or priming technique
in combination with a rehabilitation therapy for a limited period of
time must be differentiated from performing rTMS alone to control
a chronic disease. In the former condition, the timing of rTMS
application in the combined strategy must be considered in the
foreground to promote functional recovery. In the latter condition,
the rhythm of the maintenance sessions is a critical factor for the
usefulness of the procedure in the long term. Actually, among the
patients with chronic, long-lasting disease, some of them can be
considered good or excellent responders and really benefit from
rTMS protocols in the dailylife management of their illness. In con-
trast, the average clinical response to rTMS remains rather modest,
short-lasting, and not clincally meaningful and relevant in most of
the stimulated patients, although the improvement can be statisti-
cally significant on group level. Nevertheless, in spite of present
shortcomings, we are convinced that there is a future for rTMS as
a therapeutic tool (Terranova et al., 2019). All recent studies have
confirmed the good tolerance of this technique, since no severe
complication has been reported. It would be interesting if observa-
tional studies carried out over long periods (5–10 years of follow-
up) could confirm this good tolerance. In addition, all efforts should
be made towards a precision medicine, which aims at reducing the
large interindividual variability in the therapeutic efficacy of rTMS.
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